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Abstract  
 
Genetic variants influence the risk to develop certain diseases or give rise to differences in 
drug response. Recent progresses in cost-effective, high-throughput genome-wide techniques, 
such as microarrays measuring Single Nucleotide Polymorphisms (SNPs), have facilitated 
genotyping of large clinical and population cohorts. Combining the massive genotypic data 
with measurements of phenotypic traits allows for the determination of genetic differences 
that explain, at least in part, the phenotypic variations within a population. So far, models 
combining the most significant variants can only explain a small fraction of the variance, 
indicating the limitations of current models. In particular, researchers have only begun to 
address the possibility of interactions between genotypes and the environment. Elucidating 
the contributions of such interactions is a difficult task because of the large number of genetic 
as well as possible environmental factors. 
 
In this thesis, I worked on several projects within this context. My first and main project was 
the identification of possible SNP-environment interactions, where the phenotypes were 
serum lipid levels of patients from the Swiss HIV Cohort Study (SHCS) treated with 
antiretroviral therapy. Here the genotypes consisted of a limited set of SNPs in candidate 
genes relevant for lipid transport and metabolism. The environmental variables were the 
specific combinations of drugs given to each patient over the treatment period. My work 
explored bioinformatic and statistical approaches to relate patients' lipid responses to these 
SNPs, drugs and, importantly, their interactions. The goal of this project was to improve our 
understanding and to explore the possibility of predicting dyslipidemia, a well-known adverse 
drug reaction of antiretroviral therapy. Specifically, I quantified how much of the variance in 
lipid profiles could be explained by the host genetic variants, the administered drugs and 
SNP-drug interactions and assessed the predictive power of these features on lipid responses. 
Using cross-validation stratified by patients, we could not validate our hypothesis that models 
that select a subset of SNP-drug interactions in a principled way have better predictive power 
than the control models using "random" subsets. Nevertheless, all models tested containing 
SNP and/or drug terms, exhibited significant predictive power (as compared to a random 
predictor) and explained a sizable proportion of variance, in the patient stratified cross-
validation context. Importantly, the model containing stepwise selected SNP terms showed 
higher capacity to predict triglyceride levels than a model containing randomly selected 
SNPs. Dyslipidemia is a complex trait for which many factors remain to be discovered, thus 
missing from the data, and possibly explaining the limitations of our analysis. In particular, 
the interactions of drugs with SNPs selected from the set of candidate genes likely have small 
effect sizes which we were unable to detect in a sample of the present size (<800 patients). 
 
In the second part of my thesis, I performed genome-wide association studies within the 
Cohorte Lausannoise (CoLaus). I have been involved in several international projects to 
identify SNPs that are associated with various traits, such as serum calcium, body mass index, 
two-hour glucose levels, as well as metabolic syndrome and its components. These 
phenotypes are all related to major human health issues, such as cardiovascular disease. I 
applied statistical methods to detect new variants associated with these phenotypes, 
contributing to the identification of new genetic loci that may lead to new insights into the 
genetic basis of these traits. This kind of research will lead to a better understanding of the 
mechanisms underlying these pathologies, a better evaluation of disease risk, the 
identification of new therapeutic leads and may ultimately lead to the realization of 
"personalized" medicine. 
Résumé 
 
La recherche en génétique est en pleine expansion. L'analyse de grandes quantités de données 
génétiques, comme les "Single Nucleotide Polymorsphisms" (SNPs), combinées aux mesures 
phénotypiques au sein d'une population permet de détecter des marqueurs associés à des 
variations phénotypiques, telles que le risque de développer une maladie ou la différence de 
réponse à un traitement. Ces variants génétiques n'expliquent cependant qu'une infime partie 
des variations phénotypiques, suggérant que d'autres facteurs sont aussi à prendre en 
considération, tels que les interactions possibles entre variants génétiques et environnement. 
 
Au cours de ma thèse, j'ai exploré les bases génétiques de certains phénotypes multifactoriels 
chez l'humain. Mon projet principal s'est articulé autour de la détection d'interactions 
éventuelles SNPs-environnement, susceptibles d'expliquer les variations quantitatives de 
lipides chez des patients de la Cohorte Suisse du VIH, les SNPs étudiés étant dans des gènes 
impliqués dans le métabolisme et le transport des lipides, et les facteurs environnementaux, 
les antirétroviraux prescrits à ces patients. Des approches statistiques de régression linéaire 
ont permis de modéliser les niveaux de lipides chez ces patients en fonction des SNPs, des 
médicaments et des interactions entre ces deux derniers. Dans le but de mieux cerner leur 
implication éventuelle dans l'apparition de dyslipidémie, réaction délétère sévère suite à la 
prise de traitements antirétroviraux, j'ai estimé le pouvoir prédictif de ces facteurs sur la 
réponse lipidique. Une validation croisée stratifiée par patient, n'a pas permis de valider 
l'hypothèse qu'une sélection "intelligente" de certaines interactions puisse avoir un meilleur 
pouvoir prédictif des niveaux de triglycérides qu'une sélection aléatoire d'interactions  
SNP-médicament. Néanmoins, tous les modèles linéaires testés, contenant les SNPs et/ou les 
médicaments, ont démontré un pouvoir prédictif sur la réponse lipidique, expliquant une 
fraction des variations des niveaux de lipides. Plus particulièrement, les SNPs sélectionnés 
lors de la validation croisée, ont permis de prédire en partie les niveaux de triglycérides. La 
dyslipidémie est un trait complexe dans lequel interviennent également d'autres facteurs non 
pris en compte lors de nos analyses. Les interactions étudiées n'ayant qu'un faible effet sur la 
réponse lipidique, les approches statistiques utilisées n'ont pas permis leur détection. 
 
Les autres projets de ma thèse ont été réalisés dans le domaine des analyses d'association  
pan-génomique d'individus appartenant à la Cohorte de Lausanne. J'ai été impliquée à travers 
des collaborations internationales dans la recherche et la détection de SNPs associées à des 
variations phénotypiques de certains traits, tels que les niveaux de calcium dans le sérum, 
l'indice de masse corporelle, les niveaux de glucose après glycémie provoquée, le syndrome 
métabolique et ses composantes. J'ai mis en pratique des méthodes de régression linéaire afin 
quantifier l'effet des SNPs. L'identification de variants génétiques, associés aux variations 
observées dans ces phénotypes pourra donner des perspectives d'applications cliniques 
majeures, telle que la prévention du risque et la médecine "personnalisée", sachant que ces 
phénotypes sont rattachés à un risque cardiovasculaire majeur chez l'humain.  
 
Résumé grand public 
 
Les variations de séquence au niveau de l'ADN humain peuvent influencer le risque de 
développer une maladie ou la réponse à un traitement.  La recherche en génétique est en 
pleine expansion, générant une grande quantité de données génétiques qui combinées à des 
mesures phénotypiques tels que la taille, l'indice de masse corporelle, peuvent permettre de 
détecter des marqueurs génétiques, tels que les "Single Nucleotide Polymorsphisms" (SNPs), 
qui sont associés aux variations phénotypiques. Ces variants génétiques n'expliquent qu'une 
infime partie des variations phénotypiques, suggérant l'existence d'autres facteurs, tels que les 
interactions possibles entre variants génétiques et environnement. 
 
Dans ce contexte là, je me suis intéressée aux variants génétiques au sein de gènes impliqués 
dans le métabolisme et transport des lipides (triglycérides, cholestérol) dans une population 
infectée par le virus du SIDA (la Cohorte Suisse du VIH). En effet, ces patients, suite au 
traitement par des médicaments antirétroviraux, peuvent développer des effets secondaires 
tels que des dyslipidémies, qui sont des variations anormales du taux de lipides dans le sérum. 
A l'aide de modèles statistiques basés sur la régression linéaire, j'ai évalué l'influence des 
variants génétiques, des médicaments, et plus particulièrement des interactions entre variants 
génétiques et médicaments sur la réponse lipidique. J'ai ainsi construit plusieurs modèles 
mettant en jeu ces différents facteurs et estimé le pouvoir prédictif de ces derniers sur les 
niveaux de triglycérides. Ces approches statistiques s'inscrivent dans une optique de médecine 
personnalisée où les patients pourraient dans le futur bénéficier de traitements antirétroviraux 
efficaces et engendrant le moins d'effets secondaires possibles. 
J'ai également participé au travers de collaborations internationales impliquant de grandes 
cohortes d'individus, à l'analyse à grande échelle de données génétiques afin de révéler de 
potentielles associations entre des variations dans l'ADN et certaines maladies ou variations 
phénotypiques telles que les niveaux de calcium dans le sérum, les variations dans l'indice de 
masse corporelle, celles des niveaux de glucose après une glycémie provoquée, le syndrome 
métabolique et ses composantes. A l'aide d'outils informatiques et statistiques, j'ai analysé ces 
données et mis en évidence l'existence de variants génétiques associés à certains traits. A 
terme, ces études mèneront à une meilleure compréhension des bases génétiques de 
l'apparition de certaines maladies, et donc à une meilleure prise en charge des patients 
concernés. 
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1 General context 
1.1 Computational genomics 
Computational genomics refers to the use of computational analysis to decipher biological 
insights from genome sequences and related data, including both DNA and RNA sequences as 
well as other "post-genomic" data (i.e. experimental data obtained with technologies that 
require the genome sequence, such as genomic DNA microarrays [1, 2]). As such, 
computational genomics may be regarded as a branch of bioinformatics, but with a focus on 
using whole genomes (rather than individual genes) to understand the principles of how the 
DNA of a species controls its life cycle and response to the environment at the molecular 
level. With the current abundance of massive biological datasets, computational studies have 
become a very important means to biological discovery. 
Genomic techniques have firmly established themselves as a standard tool in biological and 
biomedical research. Together with the rapid advancement of genome sequencing projects, 
microarrays and related high-throughput technologies have been key factors in the study of 
the more global aspects of cellular systems biology. While genomic sequence provides an 
inventory of parts, a proper organization and eventual understanding of these parts and their 
functions requires comprehensive views also of the regulatory relations between them. 
Genome-wide expression data offer such a global view by providing a simultaneous read-out 
of the mRNA levels of all (or many) genes of the genome.  
The (human) post-genomic era began after the release of a rough draft of the human genome 
completed by the Human Genome Project in early 2001 [3, 4]. By 2007, the human sequence 
was declared "complete" (less than one error in 20,000 bases and all chromosomes 
assembled). The ensuing "genomic revolution" in biology has had a fundamental impact on 
the improvement of diagnosis, prevention and treatment of disease. Yet, while researchers 
have already started to use genomic data for predictive purposes in cancer research and 
clinical practice [5-8] , the next challenge lies in integrating the massive amount of data 
produced by different high-throughput technologies.  
 
It has long been known that genetic variants influence the risk of developing certain diseases 
or determine certain traits. The recent generation of massive genotypic data using SNP arrays 
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[9, 10] for individuals with well-characterized phenotypic traits opened the field of genome-
wide association studies (GWAS). These studies employ large cohorts of hundreds if not 
thousands of individuals to search for genetic differences (usually SNPs, but also copy 
number variations (CNVs)) that are correlated with phenotypes. Yet, for the large majority of 
traits the most significant genetic variants only explain a small fraction of the phenotypic 
variance, leaving room for other missing factors. In particular, the existence of  
SNP–environment interactions and their impact remains a difficult task within the context of 
large scale data analysis. 
 
1.2 Pharmacogenectics and pharmacogenomics 
The terms pharmacogenetics and pharmacogenomics tend to be used interchangeably, yet we 
would like to follow the common distinction that pharmacogenetics [11] is generally regarded 
as the study of genetically inherited variations in drug metabolism and response, while 
pharmacogenomics [12] is the general study of all of the many different genes that influence 
drug response. It is the broader application of genomic technologies to drug discovery and 
extended characterization of existing drugs. Pharmacogenetics usually considers one or at 
most a few genes of interest, while pharmacogenomics considers the entire genome or a large 
portion of it.  
 
Nowadays, one of the main goals of pharmacogenetics is to optimize drug therapies by taking 
into account the patients' genotype (genetic makeup) and environment features (like diet or 
lifestyle) [13, 14]. Optimization means to aim for maximum efficacy of the treatment while  
minimizing adverse effects [15].  
 
The promise of pharmacogenetics is to give rise to so-called personalized medicine [16, 17], 
where drugs will be administrated not only based on the phenotype, but also on the genotype 
of a patient. This should give rise to more powerful and safer medications, more accurate 
methods of determining appropriate drug dosages as well as advanced prophylactic screening 
for disease, all of which could potentially result in a decrease in the overall cost of health care.  
 
The introduction of the microarray technologies [1, 2, 18], which enable scientists to gather 
genome-wide data on gene expression [19] or on single nucleotide polymorphisms (SNPs)  
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[9, 10] from many individuals, will play a major role in the future of both pharmacogenomics 
and pharmacogenetics [20, 21]. The explosion in both SNP and microarray data necessitated 
the development of a new means for cataloging and annotating these data (dbSNP, GEO) so 
that scientists can more easily access and use it for their research. 
 
Yet, the analysis of the large datasets produced by these technologies still faces significant 
challenges. In particular, classical methods that were developed to analyze the effect of a 
single or a few SNPs cannot be easily extended to cope with large amounts of genomic data. 
Thus, new approaches are needed to efficiently and adequately deal with the large amounts of 
highly complex data generated by pharmacogenetic studies. Analysis and interpretation of 
these data will allow scientists to not only determine drug responses but also to study disease 
susceptibility and conduct basic research in population genetics. 
 
1.3 Linear regression modeling and features selection 
Linear regression is a well-established statistical tool used in genetics and epidemiological 
studies. It is a form of regression analysis in which observational data y are modeled by a 
linear function of the explanatory variable(s). While in simple regression y depends only on a 
single explanatory variable x, in multi-linear regression y is modeled as a linear combination 
of the explanatory variables X = (x1,x2, …,xn) [22]. Thus, the most general linear model can be 
written as 
 
y = β0 + β1 x1 + β2 x2 + …+ βn xn , 
 
where β0 is referred to as the intercept and βi (i=1,…,n) are the regression coefficients or 
effect sizes. 
  
Linear regression was the first type of regression analysis to be studied rigorously, and 
continues to be used extensively in practical applications. This is because linear models are 
easier to fit than models with non-linear terms and because the statistical properties of the 
resulting estimators are easier to determine. 
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Linear regression has many practical uses. Most applications of linear regression fall into one 
of the following three broad categories: 
• Fitting: Linear regression allows for accessing which fraction of the data for y can be 
explained in terms of a given set of explanatory variables X = (x1,x2, …,xn)  and what 
effect size can be attributed to each component xi.  
• Prediction: If the goal is forecasting, linear regression can be used to fit a predictive 
model to a set of observed data for y and X values. The fitted model can be used to 
make a prediction of the value of y for additionally collected data for X only. 
• Model selection: Given a variable y and a number of features X = (x1,x2, …,xn) that 
may or may not be related to y, linear regression analysis can be applied to quantify 
the strength of the relationship between y and the xj, and to assess which subsets of X 
contain the least redundant information about y. 
The "least-squares method" is the standard fitting method used in linear regression. Here the 
best fit is characterized by parameters which minimize the sum of squared residuals, leading 
to unbiased and consistent estimators for β if the errors have zero mean, finite variance and 
are uncorrelated with the explanatory variables. The least-squares method corresponds to the 
maximum likelihood criterion if the experimental errors are normally distributed. Linear 
models may also be fitted in other ways, such as by minimizing a penalized version of the 
least squares loss function as in ridge regression [23]. Conversely, the least-squares approach 
can be used to fit models that are not linear models. Thus, while the terms "least-squares" and 
linear model are closely linked, they are not synonymous. 
The linear modeling framework has various advantages: its mathematical formalisms and 
computational implementations are very well developed. Furthermore, its interpretation is 
straightforward. It directly models the mathematical relationship between parameters (such as 
SNPs, drug, patients' characteristics) and the phenotype of interest by examining the 
regression coefficients (effect sizes).  
 
However, linear regression also suffers from various limitations: first, linear modeling makes 
assumptions about the nature of the data being modeled. In particular, it assumes a linear 
relationship, which is often not realistic. Second, tests of model parameters assume that the 
errors are normally distributed (linear regression is always unbiased). Finally, linear models 
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can suffer from overfitting depending on the complexity of the model and the amount of data 
[22]. 
 
Once a regression model has been constructed, it is important to confirm the goodness of fit 
of the model and the statistical significance of the estimated parameters. Commonly used 
checks of goodness of fit include the fraction of explained variance R², analyses of the pattern 
of residuals to test for heteroskedasticity (non-constant variance of the errors) and hypothesis 
testing. Statistical significance of the overall fit can be assessed by an F-test; t-tests evaluate 
the significance of individual parameters. 
The generalized linear model (GLM) is a flexible generalization of ordinary least squares 
regression [24]. It generalizes linear regression by allowing non-normal responses (via a link 
function). Generalized linear models were formulated by John Nelder and Robert Wedderburn 
as a way of unifying various other statistical models, including linear regression, logistic 
regression and Poisson regression. They proposed an iteratively re-weighted least squares 
method for maximum likelihood estimation of the model parameters. Maximum-likelihood 
estimation remains popular and is the default method for many statistical computing 
packages. Other approaches, including Bayesian approaches and least squares fits to variance 
stabilized responses, have been developed. Logistic regression (sometimes called the logistic 
model or logit model) is used for prediction of the probability of occurrence of an event by 
fitting data to a logit function (or "logistic curve"). It is a generalized linear model used for 
binomial regression. Like many forms of regression analysis, it makes use of several predictor 
variables that may be either numerical or categorical. 
Model selection [22] is the task of selecting a mathematical model from a set of potential 
models, given the observed data. In the case of regression, it is also known as feature 
selection and it is the technique of selecting a subset of relevant features for building robust 
models. Feature selection algorithms typically fall into two categories: feature ranking and 
subset selection. Feature ranking ranks the features by a metric and eliminates all features that 
do not achieve an adequate score. Subset selection searches the set of possible features for the 
optimal subset. The most popular form of feature selection is stepwise regression. It is a 
greedy algorithm that adds the best feature (or deletes the worst feature) at each round. The 
main control issue is deciding when to stop the algorithm. In statistics, there are a variety of 
optimality criteria that can be used for controlling feature selection. The oldest are Mallows' 
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Cp statistic and Akaike Information Criterion (AIC). Other criteria are Bayesian Information 
Criterion (BIC) which uses, minimum description length (MDL), Bonferroni / Risk Inflation, 
Criterion (RIC), and a variety of new criteria that are motivated by false discovery rate (FDR) 
[25]. 
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2 HIV project 
2.1 HIV/AIDS 
The Human Immunodeficiency Virus (HIV) is the virus that for the large majority of infected 
individuals leads to Acquired Immune Deficiency Syndrome (AIDS) [26, 27]. HIV belongs to 
a subset of retroviruses called lentiviruses (or slow viruses), which means that there is a rather 
long interval (sometimes years) between the initial infection and the onset of symptoms. Upon 
entering the bloodstream, HIV infects the CD4+ T cells and begins to replicate rapidly.  
Scientists believe that when the virus enters the body, HIV begins to disable the body's 
immune system by taking advantage of its aggressive immune response to the virus to infect, 
replicate and kill immune system cells, such as helper T-cells, macrophages and dendritic 
cells. This process is facilitated by the recognition of the glycoprotein CD4 expressed on the 
surface of these cells. The immune system starts to fail when its cell levels (in particular of 
the CD4+ T-cells) fall below a critical threshold (~ 200 cells / mm3). Gradual deterioration of 
immune function and eventual destruction of lymphoid and immunologic organs is central to 
triggering the immunosuppression that leads to AIDS and to giving rise to opportunistic 
infections (Fig. 1).  
The term AIDS applies to the most advanced stages of HIV infection. There are four main 
stages in the progression of an HIV infected person developing AIDS. The period following 
the initial HIV infection is called the window period, during which HIV antibodies develop in 
the bloodstream. Seroconversion refers to the period of time during which the body is busy 
producing HIV antibodies, trying to protect itself against the virus. This is a highly infectious 
stage. The most common symptoms include fever, lymphadenopathy, pharyngitis, rash, 
myalgia, malaise, mouth and esophageal sores, and, less commonly, headache, nausea and 
vomiting, enlarged liver/spleen, weight loss, thrush, and neurological symptoms. After 
seroconversion, most people experience an asymptomatic period. This stage can last 
anywhere from six months to over ten years, varying from person to person. Although the 
person with HIV is experiencing no symptoms, the virus is still replicating inside the body 
and weakening the immune system. After this period, severe CD4+ T-cells loss leads to the 
symptomatic period, in which the body experiences the symptoms associated with HIV. This 
is the final stage before developing AIDS. 
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Most incidents of HIV infections occur through sexual contact. However, the virus can also 
be spread through blood transmission (e.g. by blood transfusions involving unscreened 
blood). It can also be transmitted from an HIV-infected mother to her child during pregnancy, 
birth or breastfeeding. There are a number of tests that are used to find out whether a person is 
infected with HIV. These include the HIV antibody test, P24 antigen test and polymerase 
chain reaction (PCR) test. Early detection offers more options for treatment and preventative 
care.  
AIDS is pandemic and has killed more than 25 million people worldwide since 1981 (when 
the epidemic was first discovered). In 2005 alone, there were an estimated 4 million new HIV 
infections and 3 million deaths caused by AIDS (of which a third occurred in sub-Saharan 
Africa and more than 570 000 victims were children). Today, an estimated 40 million people 
(~0.6% of the world's population) are living with HIV [28], sub-Saharan Africa being the 
most seriously affected region with a prevalence of HIV infection of about 5%. AIDS ranks 
with malaria and tuberculosis as one of three most deadly infectious diseases among adults. 
HIV has orphaned more than 15 million children. 
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Figure 1: Normal immune system vs. HIV-infected immune system.  
In a normal immune system (left side of figure), exposure to environmental antigens continuously activates naive 
and/or memory T cells, driving their replication and establishing and maintaining a pool of proliferating cells 
(activated pool). Activated cells become effectors and undergo apoptosis or survive to replenish the 'resting pool' 
as memory cells. Naive and memory T cells also die by 'natural' (stochastic) events — this is compensated by 
homeostatic proliferation. Production and maturation of T cells in the bone marrow and thymus also compensate 
for these losses. In patients infected with human immunodeficiency virus (HIV), however, several mechanisms 
perturb T-cell homeostasis (right side of figure). In the immune system of an individual infected with the HIV, 
the 'activated pool' of T cells is targeted by the virus, and this impairs the replenishment of the memory 
compartment. The input of T cells from the bone marrow and thymus is also reduced due to direct and indirect 
effects of HIV infection. But the main force that drives the immune system into collapse and that leads to overt 
immune deficiency in HIV infections is the chronic antigenic stimulation that results from uncontrolled HIV 
replication. As a result, the activated cell pool expands, whereas the pools of naive and the memory T cells 
progressively shrink. 
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2.2 HAART 
There is no known cure for HIV. Only a vaccine is thought to be able to halt the pandemic, 
but HIV remains a difficult target, as there are a number of reasons why the development of 
an HIV vaccine is more challenging than that of other classic vaccines. Not only has HIV 
developed multiple mechanisms to avoid the immune response, but many different subtypes 
of the virus, known as clades, circulate in different regions of the world. Within those clades 
there is considerable variability. Based on the different challenges of an HIV vaccine design, 
it is believed that a candidate vaccine will provide robust protection against HIV infection 
only if it is devised to engage both cell-mediated immunity and antibody-based immune 
responses. For many years, there was no effective treatment for AIDS, but today, a number of 
drugs are available to treat HIV infection. In addition, there is progress with medications for 
better treatment of opportunistic infections and illnesses that affect people with AIDS. Since 
1996, the best care for treating individuals infected with HIV is the so-called Highly Active 
Anti-Retroviral Therapy (HAART) [29]. It is expensive and therefore became the standard of 
care only in developed countries, while the worst affected regions in Africa cannot afford 
HAART for the entire affected population. HAART combines the administration of three or 
more drugs from at least two different classes. These drugs act at different levels of the viral 
replication cycle, preventing HIV from reproducing and destroying the body's immune system 
(Fig.2). 
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Modified from Monini et al., 
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Figure 2: HIV replication cell cycle and HAART mode of action 
Human immunodeficiency virus (HIV) infects several cell types, including CD4+ T cells, monocytes and 
dendritic cells. The infectious cycle begins with the adsorption of viral particles to the receptor CD4, which is 
present at the cell surface. This interaction, which is mediated by the HIV envelope (Env) protein gp120, leads to 
subsequent interaction of the gp120 V3 loop region with a co-receptor, usually a member of the seven-
membrane-spanning chemokine-receptor families, the most important being CCR4 or CXCR5. After virus 
adsorption, the viral and cell membranes fuse together, and the viral 'core' (which includes the diploid viral 
genome) is released into the cytoplasm, where the virion-associated reverse transcriptase is activated and begins 
synthesizing viral cDNA. This is subsequently transported to the cell nucleus, where another virion-associated 
enzyme, the HIV integrase, catalyses the insertion (integration) of the viral cDNA into the host-cell genome. 
Transcription of the integrated viral cDNA leads to the production of genomic (unspliced) and messenger 
(spliced) RNA (mRNA) molecules that are transported to the cell cytoplasm. Translation of HIV mRNAs leads 
to the production of Env proteins and immature precursors of capsid (Gag) and viral polymerase (Pol) proteins. 
Immature Gag and fused Gag–Pol precursors are transported to the cell membrane, where viral progeny begin 
assembling and 'bud' from the infected cells. Viral particles released following budding, however, do not contain 
the characteristic HIV condensed core and are not infectious. Virus infectivity is acquired after particle 
maturation, which is mediated by the virion-associated HIV aspartyl protease. This enzyme cleaves the immature 
Gag and Gag–Pol precursors into functional polypeptides. These crucial steps of the HIV life cycle are targeted 
with nucleoside and non-nucleoside reverse-transcriptase (RT) inhibitors (NRTIs and NNRTIs, respectively), 
and with HIV-protease inhibitors (HIV-PIs). 
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The main classes of molecules used in HAART are:  
 
• Nucleoside (nucleotide) reverse transcriptase inhibitors (N(t)RTI): they are 
incorporated into the viral DNA and prevent reverse transcriptase from adding 
nucleotides to form functional DNA. They include abacavir, didanosine, emtricitabine, 
lamivudine, stavudine, tenofovir, and zidovudine. 
• Non-nucleoside reverse transcriptase inhibitors (NNRTI): they attach themselves to 
reverse transcriptase to prevent HIV from converting RNA into DNA, thus preventing 
the cell from producing new virus. They include delavirdine, efavirinz, etravirine, and 
nevirapine. 
• Protease inhibitors (PI): they attack the HIV enzyme protease and include 
amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, 
ritonavir, and tipranavir. 
• Entry inhibitors: They prevent HIV from entering healthy CD4 cells by targeting the 
CCR5 protein. Maraviroc and Selzentry are Food and Drug administration (FDA)-
approved entry inhibitors. 
• Fusion inhibitors (FI): they stop the virus from entering cells by targeting the gp41 
protein on HIV's surface. Enfuvirtide is a FDA-approved fusion inhibitor. 
• Integrase inhibitor: they block the action of an enzyme produced by HIV that allows it 
to integrate into the DNA. It is effective against HIV that has become resistant to other 
antiretroviral drugs. Raltegravir is the only FDA-approved integrase inhibitor, but 
several other integrase inhibitors are under clinical trials. HIV integrase inhibitors may 
be useful not only for inhibiting HIV but also for treating dyslipidemia induced by 
chronic HIV protease inhibitor therapy. 
These drugs can reduce the amount of HIV in the bloodstream to very low levels and often 
enable the body's immune cells to rise back to normal levels. Indeed a dedicated 
combinatorial treatment under regular and systematic supervision and adjustment has 
considerably improved the life expectancy and quality of HIV infected individuals over recent 
years in the developed world [29, 30]. 
An important factor reducing morbidity due to AIDS has been the emergence of efficient 
drugs for fighting opportunistic diseases (caused by bacterial, viral, fungal or protozoan 
pathogens) in immuno-compromised patients. Specifically, there now exist several drugs that 
help to prevent pneumocystis, carinii pneumonia, toxoplasmosis, cryptococcus, and 
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cytomegalovirus infection. Once opportunistic infections have occurred, the same drugs can 
be used at higher doses to treat these infections. Moreover, AIDS related morbidity has also 
been reduced as a result of improved chemotherapy for treating cancers such as lymphomas or 
Kaposi's sarcoma that have higher incident rates in people suffering from AIDS. 
Ongoing research on anti HIV therapies currently focuses on decreasing side effects of the 
present drugs and on the further improvement of drug regimens. The latter is targeted at better 
adherence, determining the optimal sequence of regimens to manage drug resistance, and 
identifying new targets for anti-HIV medications [31]. There is also ongoing research 
studying ways of restoring immune systems damaged by HIV. 
Adverse effects of antiretroviral drugs are well known and are a major challenge for 
physicians prescribing a particular therapy. They vary by drug, by ethnicity, by individual, 
and by interaction with other medications or the patients' diet, including their alcohol 
consumption [31]. The most common adverse effects experienced by patients taking 
antiretroviral drugs are: diarrhea, nausea, headache, fatigue, dyslipidemia, lipodystrophy, 
abdominal pain, liver and renal failure, kidney diseases, pancreatitis, insulin resistance, 
increase of cardiovascular risks, osteoporosis, anemia, neutropenia, insomnia, peripheral 
neuropathies, and birth defects [32, 33].  
 
2.3 Pharmacogenetics applied to HIV treated  population and 
personalized medicine   
Currently, there is no simple way to determine whether people will respond well, poorly, or 
not at all to medication. Therefore, pharmaceutical companies tend to develop general 
therapeutic strategies based on the average patient response, rather than "customized" 
treatments. Yet, the limitation of this approach is becoming more and more obvious and 
costly in light of the wide range of serious adverse drug reactions (ADRs) mentioned above. 
The detection, assessment, understanding and prevention of ADRs are obviously not only a 
concern for antiviral medications but it is a field of itself known as pharmacovigilance. In a 
study published in 1998 [34], it was estimated that in 1994 more than 2.2 million  hospitalized 
patients had serious ADRs and that an estimated 76,000-137,000 had fatal ADRs. The latter 
implies that ADRs range between the fourth and sixth leading cause of death in the United 
States. Since then, the Research on Adverse Drug events And Reports (RADAR) has been 
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initiated. Its goal is to describe previously unrecognized, serious ADRs and identify new 
patient populations at high risk for previously identified serious ADRs [35].  
 
In addition to their impact on human health, ADRs also have a significant impact on 
healthcare costs [36]. ADRs are common causes of hospitalization and lead to large costs to 
society. The cost of hospitalization is, however, only a part of the total cost, as most ADRs 
never come to clinical attention. There are two main costs associated with ADRs, the cost of 
treating illnesses due to ADRs and the cost of avoiding them [37]. 
 
ADRs can be divided into two broad clinical categories, about 80% are pharmacological (or 
of type A) and 20% are idiosyncratic (type B). ADRs of type A are generally dose-dependent, 
related to the pharmacokinetic properties of a drug (absorption, distribution, metabolism and 
excretion), and resolve when the dose is reduced. The type B ADRs are more enigmatic an 
usually cannot be explained by the known pharmacology of the drug [38]. Factors that 
contribute to type B ADRs of a drug are not yet completely understood, but are likely to 
include environmental factors such as diseases, alcohol, smoking and diet. Genetic factors can 
also affect the susceptibility to both types of ADRs. Genetic polymorphisms are a source of 
variation of drug response in the human body [39]. Most interest has centered on the 
involvement of pharmacokinetic factors and in particular drug metabolism. Several 
polymorphisms were discovered that affect gene-expression encoding in phase I and phase II 
metabolic pathways [40, 41], such as cytochrome P450 enzyme, thiopurine methytransferase, 
UDP-glucuronosyl transferase 1A. Membrane transporters also play an important role in 
terms of drug pharmacokinetics. Variations in the multi-drug resistance gene ABCB1/MDR1 
increase the risk of drug toxicity. In addition to the genetic polymorphisms in the 
pharmacokinetics factors, there are also genetic variations in pharmacodynamic factors (drug 
targets) such as variations in enzyme structures, variations in receptors of a certain drug, 
mutations in ion channels, and variations in immune response genes (HLA types) [39]. 
 
Thus, genotypic profiling of patients has the great potential to allow for more customized 
treatment [42]. In particular, many therapeutically active compounds that never entered the 
market because they failed in clinical trails may find their way back to commercialization if 
their ADRs can be demonstrated to occur only for individuals of a certain genotype. 
Similarly, drugs that were not found to be sufficiently active in the general population, may 
still re-enter the market if they can be proven to be highly active for a significant 
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subpopulation that differs in one or more genetic markers. Clinical trials restricting its 
subjects to those with a favorable genotype could be smaller, faster, and therefore less 
expensive, leading to reduced drug costs. If successful, such genetically stratified medications 
could potentially increase both physicians' and patients' confidence in prescribing and taking a 
drug.  
 
As an example, Warfarin is used clinically as an anticoagulant but requires periodic 
monitoring and is associated with adverse outcomes. Recently, genetic variants in the gene 
encoding Cytochrome P450 enzyme CYP2C9, which metabolizes Warfarin, and the vitamin 
K epoxide reductase gene (VKORC1), a target of coumarins, have led to commercially-
available testing that enables more accurate dosing based on algorithms that take into account 
the age, gender, weight, and genotype of an individual. Targeted therapy is the use of 
medications designed to target aberrant molecular pathways in a subset of patients with a 
given cancer type. For example, Herceptin is used in the treatment of women with breast 
cancer in which HER2 protein is overexpressed [7]. Tyrosine kinase inhibitors such as 
Gleevec have been developed to treat chronic myeloid leukemia (CML), in which the BCR-
ABL fusion gene is present in >95% of cases and produces hyperactivated abelson-driven 
protein signaling [43]. These medications specifically inhibit the Abelson tyrosine kinase 
(ABL) protein and are thus a prime example of "rational drug design" based on knowledge of 
disease pathophysiology. As another example, the aim of the five-year, international drug-
sensitivity study is to find the best combinations of treatments for a wide range of cancer 
types: roughly 1000 cancer cell lines are exposed to 400 anticancer treatments, alone or in 
combination, to determine the most effective drug or combination of drugs in the lab. The 
therapies include known anticancer drugs as well as others in pre-clinical development. The 
first data release confirmed several genes that predict therapeutic response in different cancer 
types. These include sensitivity of melanoma, a deadly form of skin cancer, with activating 
mutations in the gene BRAF to molecular therapeutics targeting this protein, a therapeutic 
strategy that is currently being exploited in the clinical setting. 
 
In the context of an HIV population, pharmacogenomics is the study of the genetic basis for 
abnormal drug reactions of patients under antiretroviral therapies. The introduction of 
HAART and its use has considerably enhanced life expectancy of HIV/AIDS individuals, 
reducing viral replication into the host cells. Nevertheless, being a long-term treatment, 
HAART induces toxicities and drug resistance due to the high viral genetic variability 
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(replication cycle and mutation rate). Drug metabolism and toxicity can vary between 
individuals leading to different degrees of treatment efficacy and toxicity effects. The reason 
for HAART failure is multi-factorial, including drug adherence, virological, immunological 
and pharmacological factors. Yet, it is also likely that genetic variations of HIV infected 
individuals account for a major part of the variability in antiviral drug responses [44]. Genetic 
studies and technologies (such as GWAS) are generating new hypotheses in terms of potential 
links between genotypes and phenotypes giving insights on which host genetic 
polymorphisms could influence the HAART drug response, i.e. pharmacokinetics and 
pharmacodynamics, hypersensitivity reaction syndromes, hepatotoxicity, central nervous 
system side effects, hyperbilirubinemia, peripheral neuropathy, lipodystrophy, 
hyperlipidemia, pancreatitis and renal toxicity [31]. To date, pharmacogenetics studies of 
antiretroviral drugs have identified several genetic polymorphisms in critical metabolizing 
and drug-transporter genes which can influence specific antiretroviral drug pharmacokinetics 
(Table 1). As examples, some polymorphisms in the ABC genes, which encode proteins 
responsible for carrying many types of drugs across the membranes, combined with PIs and 
NRTIs treatment showed associations with respectively increase risk of hyperlipidemia, 
unconjugated hyperbilirubinemia and jaundice, and higher intracellular exposure of the 
triphosphate metabolite. PIs and NNRTIs drugs in combination with genetic variations in the 
cytochrome P450 enzyme gene, responsible for oxidative metabolism of the majority of the 
drugs, show respectively higher drug exposure, faster oral clearance, and greater plasma 
exposure [31] (Table 1).  
 
The ultimate goal of pharmacogenomics is to transfer the research knowledge into clinical 
use. The promise is that eventually a "personalized HAART" will lead to both a maximization 
of virological efficacy and a minimization of ADRs of the medications in a cost-efficient 
manner. Yet, developing such an individual HIV treatment may still take many years. 
Researchers are still at the beginning of developing powerful methods for analyzing the 
massive genetic data, facing issues like minimizing false discoveries, dealing with small study 
size (resulting in inadequate statistical power) as well as sometimes unavoidable selection 
bias or ethnic bias [31].  
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Table 1: Summary of most relevant (established and putative) genetic determinants of antiretroviral drug 
pharmacokinetics and toxicity. From Tozzi V, antiviral research, 2009. 
 
2.4 HAART induced dyslipidemia and cardiovascular risk   
The term dyslipidemia refers to an abnormality in the amount of lipids or lipoproteins (VLDL, 
LDL, HDL, IDL) in the blood. The most common types of dyslipidemia are high cholesterol, 
called "hypercholesterolemia" or "hyperlipoproteinemia"; and high triglycerides named 
"hypertriglyceridemia". When high cholesterol (LDL) and triglycerides occur together, the 
condition is called "combined hyperlipidemia", which is the most common form of 
dyslipidemia in societies of developed countries. Low levels of cholesterol may also occur, 
called "hypocholesterolemia" or "hypolipoproteinemia", usually for genetic reasons. The 
prolonged elevation of insulin levels can lead to dyslipidemia.  The increased levels of  
O-GlcNAc transferase (OGT) are known to cause dyslipidemia [15]. The treatment for 
dyslipidemia depends on the condition, but usually involves maintaining a healthy diet, 
exercise and taking medications, with lipid lowering agents (LLA), usually statins or fibrates. 
For HIV patients, dyslipidemia is often a result of their antiviral therapies [45]. HAART can 
lead to elevations in serum levels of total cholesterol and triglycerides, reduction in HDL 
cholesterol, alterations in the distribution of body fat (lipodystrophy), as well as increase in 
insulin resistance and diabetes, which are major risk factors for cardiovascular diseases 
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(CVDs) [46, 47]. PIs and NRTI appear to be involved, through direct metabolic effects and an 
indirect effect of PIs and NRTI-related lipodystrophy [47]. Dyslipidemia occurs in up  
70%-80% of HIV-infected individuals receiving HAART and can be associated with all 
available PIs, although hypertriglyceridemia appears to be more frequent in patients treated 
with ritonavir, saquinavir/ritonavir or lopinavir/ritonavir [48]. HIV protease inhibitor therapy 
induces endoplasmic reticulum (ER) stress, activating the unfolded protein response, which is 
an important signaling pathway in HIV protease inhibitor-induced metabolic syndromes. In 
addition, HAART itself causes metabolic syndrome in a high proportion of patients, 
characterized by lipodystrophy/lipoatrophy, dyslipidemia and insulin resistance that may be 
associated with an increase risk for coronary artery disease and stroke [48, 49]. In order to 
reduce the incidence of adverse metabolic effects, many studies have tried to assess the risk 
for CVDs by evaluating dyslipidemia in HIV treated patients, trying to establish the best 
combinations of drugs [48].  Other options for the treatment of lipid disorders include 
rosuvastatin, ezetimibe and fish oil and the use of HIV integrase inhibitors because the lipid 
goals of patients are not always achieved by the therapy recommended in the current lipid 
guidelines [50]. 
 
More specifically, host genetic variants (SNPs) were reported in the literature to be associated 
with plasma lipid level variations in response to drug therapy [31]. Polymorphisms in 
apolipoproteins (APO) are associated with hyperlipidemia and cardiovascular events in the 
general population. APO polymorphisms have been extensively studied regarding  
PI-associated metabolic and morphological abnormalities[51]. In the general population, 
polymorphisms in APOC3 and APOE are associated with hyperlipidemia and several research 
groups showed the association of APOC3, APOE, APOA1, APOA5 and TNF-alpha 
polymorphisms with the development of dyslipidemia and lipodystrophy. In addition, SNPs 
of ABCA1, APOA5, APOC3, APOE, and CETP  genes contributed to plasma triglyceride and 
LDL–cholesterol levels during HAART [31, 52] (Table 1). Hyperlipidemia has been 
associated not only with PIs but also with an NNRTI drug, Efavirenz. EFV plasma levels are 
influenced by a polymorphism in the ABCB1/MDR1 gene, causing an increase in HDL-
cholesterol [53].  Finally, the contribution of 42 SNPs, most of them associated with lipid 
disorders in the general population, has been validated in the Swiss HIV Cohort Study 
(SHCS). The study also includes environmental factors, in particular the therapy regimens and 
estimates their impact on lipid disorders. As a result, the SNPs and drugs cumulative 
influence has been highlighted to contribute to dyslipidemia in HIV treated individuals [54]. 
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Even if the HAART associated metabolic and morphological abnormalities are multi-
factorial, next-generation HAART could increasingly benefit from genotype-guided drug 
choice, towards the ultimate goal of a personalized therapy (Fig. 3). 
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Figure 3: Goals of pharmacogenetics in the context of the Swiss HIV cohort data.  
Different types of data (the patients' characteristics, the genotypic information, the therapies and the phenotype 
of interest (in this case the lipid levels) are represented in this schematic view. The goal is to combine these data 
into a computer model able to explain the variations we observe in the phenotypes. Ultimately such a model 
should allow for predicting the drug response of a new patient suffering from AIDS according to his or her 
features, which could be beneficial in terms of drug prescription. 
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2.5 Goals of the project  
The main goals of my HIV project were the following: 
 
1. Better understanding of the structure of the genetic and phenotypic datasets generated 
by the Swiss HIV cohort study (see http://www.shcs.ch/ and description below). 
2. Exploration of the relationship between patients' drug responses, patients' features 
(including SNPs), and therapy characteristics. We were particularly interested in the 
potential implications of SNP-drug interactions in the understanding of variations 
observed in HIV patients lipid levels. 
3. Evaluation of the predictive performances of different lipid models using genotypes, 
treatment features and their interactions. 
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2.6 Data, Methods and Results 
2.6.1 The Swiss HIV Cohort Study  
2.6.1.1 General description   
Three datasets (Lipogen 2a, Lipogen 2b, and Lipogen 3) were provided by the Infectious 
Diseases Service of the Centre Hospitalier Universitaire Vaudois (CHUV). The data were 
gathered within the framework of the Swiss HIV cohort study. All three Lipogen datasets 
focus on longitudinal lipid measurements from HIV treated patients as phenotypes. Lipogen 
2b extended Lipogen 2a mainly by a significantly longer follow-up period, while Lipogen 3 
also included more individuals and a much larger set of candidate genes. 
 
All patients were monitored during their treatment for phenotypes indicating obesity, 
metabolic syndrome and diabetes, including anthropometric variations (changes in hip and 
waist circumference, weight). To assess the presence of dyslipidemia, lipid determinations 
included the routine assessments of total cholesterol triglycerides (Chol), triglycerides (TG) 
and high density lipoprotein (HDL). The fasting state (defined as more than eight hours 
without caloric intake) was recorded for all blood draws [52]. Although fasting was requested, 
the compliance was only ~20%. Additional information includes the records of the antiviral 
drug combination, and patients' characteristics, including genotypes for candidate genes 
involved in lipid metabolism. Thus, conceptually, each dataset can be divided into the 
response variables (i.e. the lipid measurements) and the explanatory variables, where the latter 
is assumed to be causal with regard to the former. Specifically the explanatory variables can 
be subdivided as follows:   
 
-  Patients' characteristics: many of these features (like sex, height, ethnicity and presumed 
mode of HIV transmission) are fixed, but some (like age, body mass index (BMI), weight, 
and fasting state) may vary longitudinally from one measurement to the other. 
- Genotypic data: Single Nucleotide Polymorphisms (SNPs) in candidate or validated genes 
involved in lipid transport and metabolism were genotyped for each patient.  
- Treatment data: several drugs were used in highly active antiretroviral therapy (HAART) 
based on viremia and CD4+ T-cells count (see sections 2.1 & 2.2 for details). In general, the 
treatment varied longitudinally (meaning that each patient's treatment varied over time). We 
only considered the treatment regimen immediately prior to a measurement as causal 
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(ignoring the long-term history of treatments, which is usually assumed to be negligible for 
HIV patients). 
As for the response data we considered not only the directly measured Chol, TG and HDL, 
but also non-HDL cholesterol (NHC) that was calculated as NHC = Chol – HDL. Indeed, as 
we mentioned in section 2.4, antiretroviral drugs can elevate the level of lipids in the blood, 
especially triglycerides and total cholesterol. This type of variation may cause dyslipidemia 
which has been associated with many illnesses, most notably cardiovascular diseases.  
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Figure 4: Structure of the Swiss HIV cohort data. 
The dataset can be subdivided in four subsets: the patients' characteristics, the genotypic information, the 
therapies and the phenotype of interest (in this case the lipid levels). The dimensions of the measurements 
changed over time (longer follow up and new dataset). Np: number of patients; Ns: number of SNPs; Nd: number 
of drugs; Nl: number of lipids; Nm: number of measurements 
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2.6.1.2 Specificities of each dataset 
The dataset that was originally used included 4717 lipid measurements from 438 treated HIV 
patients, out of which ~75% were male. On average, each patient had been examined about 10 
times over a follow-up period of four years. 20 SNPs from 12 candidate genes were 
genotyped. Patients were treated with a subset of a total of 18 antiviral drugs. Also many 
patient characteristics were recorded or computed for each patient such as age, sex, fasting 
state, diabetes status, body mass index (BMI), waist circumference, lipid lowering agents 
(LLA), smoking, CD4+ cell count, viral RNA levels, ethnicity, as well as risk behavior that 
may have led to the HIV infection. Hereafter, I will refer to this dataset as Lipogen 2a. I 
mainly used this dataset for my initial analyses described in sections 2.6.2.1 and 2.6.2.2. 
 
Subsequently a further 1466 new lipid measures were included in the Lipogen 2 study. 
Altogether, the extended dataset contains a total of 6183 measurement from the same 438 
patients, recorded during a follow up of six years. We removed four out of 20 SNPs  
(adrb2-27e, tnfa-238a, tnfa-308a and mtp-493t) because they had a high rate of missing 
genotype calls (20% on average). We also discarded three out of the 18 drugs from the dataset 
(emtricitabine (ETC), tipranavir (TPV), enfuvirtide (T20)) because they were very rarely 
given to any of the patients. Hereafter I will refer to this extended dataset as Lipogen 2b. 
Work described in sections 2.6.2.3-5 focused on this dataset. 
 
Most of our analyses (sections 2.6.2.6-8) were performed on a significantly extended dataset 
from the Lipogen 3 study. It contains 12,170 lipid measures from 752 HIV patients. These 
752 subjects include: 418 individuals from Lipogen 2 [52], 123 subjects who developed 
Diabetes Mellitus Type 2 (DM2) [30] and 211 additional subjects selected from the SHCS 
with similar characteristics as Lipogen 2 patients. The main patients' characteristics are shown 
in Table 2. 
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Characteristic Study Participants (n =752) 
Age (years)  47.36 +/- 10.43 
Men/Women (%)  76 / 24 
Fasting state (%)  21.5 
LLA (%)  13.9 
Log10 CD4+ T-cell count  2.66 +/- 0.25 
Log10 viral RNA  1.83 +/- 1.13 
Body Mass Index (BMI)  23.67 +/- 3.8 
Waist circumference (cm)  87.64 +/- 11.54 
Caucasians (%)  85.9 
Diabetes Mellitus type 2 (DM2) (%)  16.8 
Smokers (%)  31.5 
Median number of lipid 
measurements/patient 16 
Median follow-up period (years) (2000-
2008) 7.8 
TG (mmol/L) 2.52 +/- 2.59 
HDL (mmol/L) 1.253 +/- 0.449 
NHC (mmol/L) 4.01 +/- 1.33 
Chol (mmol/L) 5.29 +/- 1.40 
 
Table 2: Characteristics of the Lipogen 3 patients. 
The values are shown in terms of mean +/- standard deviation or in the unit specified in brackets. 
 
The Lipogen 3 dataset included a much larger set of a total of 58 SNPs. Their selection was 
mostly driven by genome-wide association studies on dyslipidemia (HDL: 20 SNPs;  
non-HDL/NHC: 14 SNPs; TG: 22 SNPs), new-onset diabetes mellitus type 2 (12 SNPs), 
metabolic syndrome (42 SNPs), and anthropometric measurements (one SNP) in the 752 HIV 
infected subjects followed in the SHCS. All these SNPs were near or in genes coding proteins 
involved in pathways relevant to beta cell function, or lipid/glucose metabolism/transport 
(Table 3 and Appendix 1).  
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TRIGLYCERIDES               
rs number Nearest Gene 
SNP 
type Alleles Chr HWE MAF 
% 
NaNs 
rs780094 GCKR intronic C/T 2 0,657 0,438 0
rs429358 APOE exonic T/C 19 0,029 0,114 0
rs7412 APOE exonic C/T 19 0,418 0,072 0
rs693 APOB exonic G/A 2 0,767 0,439 0
rs708272 CETP intronic G/A 16 0,878 0,390 0,600
rs328 LPL exonic C/G 8 0,142 0,113 0,386
rs2197089 LPL 3' down A/G 8 0,262 0,425 0,477
rs6586891 LPL intergenic A/C 8 0,179 0,319 0,468
rs4775041 LIPC intergenic G/C 15 0,113 0,243 0,600
rs3135506 APOA5 exonic G/C 11 0,550 0,066 0,600
rs2854117 APOC3 5' up C/T 11 0,794 0,299 0,600
rs2854116 APOC3 5' up T/C 11 0,940 0,402 0
rs5128 APOC3 3' down C/G 11 0,557 0,105 0,468
rs662799 APOA5 5' up A/G 11 0,809 0,082 0
rs16996148 CILP2 3' down G/T 19 0,122 0,092 0,090
rs4846914 GALNT2 intronic A/G 1 0,159 0,444 0,509
rs17145738 TBL2 3' down C/T 7 0,705 0,109 0,477
rs17321515 TRIB1 3' down A/G 8 0,883 0,471 0,337
rs12130333 ANGPTL3,DOCK7,ATG4C intergenic C/T 1 0,471 0,186 0
rs1748195 ANGPTL3,DOCK7 intronic C/G 1 0,038 0,328 0,477
Table 3: List of SNPs in Lipogen 3 previously associated to TG variations. 
The table contains for each SNP, the rs number, the type, the nearest gene, the alleles, the chromosomal location 
(Chr), the Hardy-Weinberg Equilibrium (HWE) test p-value, the minor allele frequency (MAF) and the 
percentage of missing genotypic data (NaNs). 
 
 
Among the 32 drugs of the Lipogen 3 dataset, we only used half of them (16) in our analyses, 
since the remaining drugs were given less than 1% of the time (Table 4). Patients were treated 
with a combination of these drugs, usually including at least one drug from the three major 
classes of medications (NRTI, NtRTI and PI), acting at different levels of the virus life cycle. 
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Drug Full Name  % given Type 
3TC Lamivudine 66,47 NRTI 
ABC Abacavir 26,54 NRTI 
AZT Zidovudine 46,98 NRTI 
D4T Stavudine 16,26 NRTI 
DDI Didanosine 13,67 NRTI 
ETC Emtricitabine 3,87 NRTI 
TNV Tenofovir 16,64 NtRTI 
APV Amprenavir 1,38 PI 
RTV Ritonavir 15 PI 
LPV Lopinavir 12,51 PI 
ATV Atazanavir 7,32 PI 
SQVH Saquinavir hard gel 5,14 PI 
NFV Nelfinavir 16,63 PI 
IDV Indinavir 4,23 PI 
NVP Nevirapine 8,6 NNRTI 
EFV Efavirenz 25,73 NNRTI 
 
Table 4: List of drugs used in HAART in Lipogen 3. 
The table contains the name and full name of each drug, the percentage given within the SHCS and the 
drug type: NRTI (nucleoside reverse transcriptase inhibitor), NtRTI (nucleotide reverse transcriptase 
inhibitor), PI(protease inhibitor), NNRTI (non-nucleoside reverse transcriptase inhibitor). 
 
 
2.6.2 Computational analyses and results 
All analyses were performed in Matlab® under Windows or Linux operating systems. For 
developing my analysis approaches, I focused on TG as the phenotypic response. 
 
2.6.2.1 Structure of the genetic and phenotypic datasets 
Our first goal was to study the structure of the different data subsets and to identify and 
remove potential problems in these data. All lipid levels were log10-transformed (because the 
distributions of the log-values were closer to a normal distribution than those of the 
untransformed values). The SNP values 11 (homozygous for the major allele), 12 
(heterozygous) and 22 (homozygous for the minor allele) were transformed into numerical 
"dosage scale", corresponding to 0, x and 1, respectively, where 0<x<1. We report here 
mainly our results from inspecting the original Lipogen 2a which we studied in detail, but 
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these findings are also representative for the updated datasets Lipogen 2a and Lipogen 3. 
Specifically, we analyzed the Lipogen 2a data as detailed below: 
We first studied the distributions of the drug responses (i.e. four lipid levels) stratified 
according to the patients' characteristics (sex, fasting state, age, BMI and others). We 
computed Pearson correlation between drug responses and patients' features. We subdivided 
drug responses into groups according to sex, age, fasting state variables and quantified the 
proportion of measurements falling in each categories.   
 
Within the Lipogen 2a study consisting of roughly ¾ of men and ¼ of women, we observed a 
sex effect in the TG response. Indeed the distribution of the TG levels corresponding to the 
male individuals was shifted towards higher TG values in comparison with the TG 
distribution of females. This difference between the two distributions has a very high 
statistical significance (t-test p-value=1E-40). TG values also appeared to be correlated with 
age (correlation coefficient r = 0.19), indicating the tendency for higher TG values in older 
patients (Fig. 5). TG was also correlated with BMI (correlation coefficient r = 0.22). 
Furthermore, we investigated the impact of the fasting state on the TG levels. Only about 20% 
of the patients had been fasting when their blood samples were taken and we found a 
statistical difference between the respective lipid levels (t –test: p = 0.028).  
 
 
 
Figure 5: Log10 triglycerides distributions (separated by gender status) and correlation between Log10 
triglycerides and age. 
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On the left plot, the blue histogram corresponds to the female log10(TG)  and the red histogram to the male 
log10(TG). On the right plot, a scatter plot of the log10(TG) as function of  age is represented. The blue line shows 
the slope of the linear regression.   
 
For the genotypic dataset (20 SNPs genotyped in 438 patients), we confirmed that all SNPs 
were in Hardy-Weinberg equilibrium, with one exception (abca1-2962g) which turned out to 
be due to the mixture of sub-populations having different allelic frequencies for this particular 
SNP (the Wahlund effect [55]). We then investigated the significance of the SNP correlations 
(use of controls based on the reshuffling of the SNP information) (Fig. 6). 
 
We analyzed the significance of all pairwise SNP correlations. The aim was to reveal possible 
groups of highly and significantly correlated SNPs. Such correlations can be due either to 
linkage disequilibrium (in particular for SNPs in the same gene) or due to population 
stratification.  
 
To this end, we calculated all pairwise Pearson correlations between the 20 SNPs across all 
patients. We then performed a significance analysis by reshuffling the genotypes for each 
SNP 10,000 times and re-computed the corresponding correlation coefficients. We chose a 
cut-off of significance at 5% (requiring that less than 500 of the correlations after data 
reshuffling had to be higher than the observed one). We observed that SNPs in the same genes 
are usually significantly correlated (for example the SNPs on APOC3, APOE and ABCA1). 
However, we also found a small number of significant correlations between SNPs on different 
genes (mtp-493t and adrb2-16r; apoa5-64g and apoc3-455c), which are probably due to 
population stratification (Fig. 6). 
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Figure 6: Significance of the SNPs correlations. 
The row and column labels refer to the SNP name. Each square shows a distribution of 10 000 Pearson 
correlation coefficients (after data reshuffling). The blue line indicates the observed value of the correlation 
coefficient. The colors indicate the level of significance of the correlations ranging from yellow (p<0.05) to red 
(p<0.0001). 
 
 
For the therapeutic dataset (18 drugs administered in various combinations for 438 patients), 
we studied both the treatment frequency for each drug and correlations between drugs. 
Specifically, we calculated all 324 pairwise Pearson correlations over all treatments. These 
correlations reflect the global "co-administration" indicating which pairs of drugs have been 
given simultaneously and which were most of the time not administered together. Our results 
are shown in Fig. 7 and are consistent with the practice of using combination treatment. By 
definition the drug autocorrelations (along the diagonal) are equal to 1, whereas the remaining 
pairwise correlation values range from -0.58 to 0.58, showing anticorrelation of some pairs 
(DDI-3TC and D4T-AZT) and relatively high correlations of some others (3TC-AZT and 
SQV-RTV).  
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Figure 7: Pairwise drug correlations 
The row and column labels refer to the drug name. Each square shows Pearson correlation coefficient. The 
colors indicate the level of the correlations as indicated in the colorbar on the right. 
 
 
2.6.2.2 Differential response analysis 
To investigate the possible effects of the feature parameters on the lipid levels from Lipogen 
2a, we initially investigated the dependency of each lipid response with respect to one feature 
and then with respect to two features. 
 
Response with respect to single feature 
We first focused on the lipid responses as a function of one single feature, either a drug, a 
SNP or another characteristic of the patients. Discrete features, like the medication (drug 
taken or not taken), SNP genotypes or gender (male or female) divide the measurements into 
subgroups. We then tested the hypothesis that these subgroups have distinct underlying 
response distributions by performing (as an example) a t-test of the responses as a function of 
usage of a single drug (irrespective of the remaining drugs and other features). 
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Response with respect to two features 
Next, the response profiles were investigated as a function of two features. Already for two 
binary features, the data can be subdivided into four subgroups. Generally, we search for 
"interactions" between features. For example, genetic epistasis [56] (the phenomenon where 
the effects of one gene are modified by one or several other genes) could imply an elevated 
(or decreased) response only if both SNPs have a particular allele. Similarly, certain adverse 
drug responses might occur only for a particular combination of drugs. Finally, some drugs 
may give rise to a response only in patients with a certain genotype (which is indeed the 
central point of pharmacogenetics as we outlined in section 2.3).  
In general, epistasis is used to denote the departure from 'independence' of the effects of 
different genetic loci. Statistical models can be used for detection of epistasis in humans. 
Epistasis in the Fisher sense is closer to the usual concept of statistical interaction: departure 
from a specific linear model describing the relationship between predictive factors (here 
assumed to be alleles at different genetic loci). Statistical tests of interaction are limited to 
testing specific hypotheses concerning precisely defined quantities. For statistical testing, we 
can only focus on mathematical models of epistasis rather than those encoded by a rather 
abstract and vague notion of 'independence' or 'masking' of unspecified 'effects'. Therefore, 
statistical interaction does not necessarily imply interaction on the biological or mechanistic 
level. We should like to perform a statistical test and interpret the outcome biologically, but 
this is in general not permissible. The degree to which statistical modeling can elucidate the 
underlying biological mechanisms is likely to be limited, and may require prior knowledge of 
the underlying aetiology [57]. 
In the following, we will refer to 'interaction' in the statistical sense rather than the biological 
one and it will be mainly in the context of SNP-drug interactions. 
 
In order to analyze the differential response we used one feature to define a baseline. For 
example, the lipid measurements of patients with a certain genotype who did not take a 
particular drug can be used to rescale all measurements when this drug was administered. 
Specifically, we defined: 
 
         Δ(LR)g = LRg,t=1 - mean(LRg,t=0)                                             
 
Here, LR refers to the Lipid Response (TG, HDL, NHC, Chol) for patients of genotype g (11, 
12 or 22) at a given SNP, recorded after treatment with (t=1) or without (t=0) a certain drug. 
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The mean over all measurements for a certain genotype was used as a baseline level of the 
lipid responses since, in many cases, there was no response data with and without a given 
drug for the same patient. A disadvantage of this method is that the variation of the 
measurements without treatment is not taken into account. Given the definition of a 
differential response, one may then ask whether subpopulations with a certain SNP genotype 
respond differently to a given drug. To this end, we performed statistical tests (t-test and 
Kolmogorov-Smirnov test) that compared the distributions corresponding to different 
genotypes. In principle, this approach can also be applied to study SNP-SNP or drug-drug 
interactions by selecting first one feature to define the baseline and then the other to define the 
two subpopulations. 
 
The results shown in Fig. 8 illustrate this type of analysis for the TG responses with respect to 
one or two features. The idea was to study the different lipid level distributions for all SNPs, 
all drugs, as well as their combinations. The top row and the rightmost column of Fig. 8 show 
the two distributions of the TG levels for each drug (taken vs. not taken) and SNP (genotype 
11 vs. 12), respectively. The background colors of those plots indicate the significance for the 
difference between the distributions according to a t-test (darker plots correspond to smaller 
p-values). The remainder of the figure shows the four distributions of TG levels 
corresponding to a division of the data both according to all SNP-drug combinations (c.f. 
legend). Again, the background grey scales of the plots indicate the significance of SNP-drug 
interactions according to the t-test of the differential responses Δ(LR)g. 
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Figure 8: TG levels in different drug-SNP conditions. 
The top row and the rightmost column show the two distributions of the TG levels for each drug (taken vs. not 
taken) and SNP (genotype 11 vs. 12), respectively. The remainder of the figure shows the four distributions of 
TG levels corresponding to a division of the data both according to all SNP-drug combinations. The background 
color of the plots indicates the significance level (legend).  
 
 
We observed that some drugs, like ritonavir (RTV), saquinavir (SQV) or lopinavir (LPV), 
alone already have an effect on the TG, irrespective of the SNP genotypes of the patients (top 
row of Fig. 8). Similarly, for some SNPs (most significantly for adrb2-27e and lipg-584t) a 
differential TG response is detectable between the patients being homozygous for the major 
allele (11) and those carrying one minor allele (12)  (rightmost column).  
 
The analysis of SNP-drug interactions revealed several significant pairs (even though the TG 
distributions were usually not strikingly different). For instance, our analysis indicates that the 
carriers of one minor allele for the SNP apoa5-1131 receiving lopinavir (LPV) are more at 
risk for elevated TG levels than those having the 11 genotype. Conversely, the minor allele of 
the SNP cetp-279a appears to be protective for individuals receiving the drug nelfinavir 
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(NFV) (Fig. 8). We noted that this type of analysis is likely to be underpowered, either since 
the drugs were given only rarely (ETC, TPV and T20), or because they were given in 
conjunction with different combinations of others drugs, possibly confounding the lipid 
response.  
 
2.6.2.3 Two-stage model selection  
General purpose and requirements for linear regression 
 
In order to overcome the limitations of our differential response analysis, we explored an 
alternative approach to analyze the response data using linear regression models of the 
following type: 
 
                                  LR g,t = a + bs Gs + cd Td + ds,d Gs Td  + ε                                            (1)                    
 
Here Gs denotes the genotype of the SNP s (usually decoded as the dosage of the minor allele, 
but other models were also tested as detailed below), Td refers to the treatment with drug d (1 
if the drug was given and 0 if not) and the last term allows for modeling a possible SNP-drug 
interaction. The goal is to estimate the different coefficients a, bs , cd and ds,d that best fit the 
data (in the sense that the sum of squared residuals over all data-points is minimal). We were 
particularly interested in SNP-drug interactions affecting the lipid response. These correspond 
to coefficients d whose estimated confidence interval was inconsistent with a vanishing value. 
The likelihood of the interaction is also reflected by a small p-value. All pairwise SNP-drug 
p-values can then be used to identify groups of significantly interacting SNPs and drugs.  
 
In the context of linear regression, it is important to specify how to decode the three possible 
genotypes of a particular SNP. We transformed the genotypes 11 (homozygous for the major 
allele), 12 (heterozygous) and 22 (homozygous for the minor allele) into a numerical scale 
corresponding to different types of genetic models as follows: The additive model assigns 
(0 1 2) to the three genotypes implying that each copy of the minor allele is assumed to assert 
the same effect. In a dominant (0 1 1) or recessive (0 0 1) model the coding is such that it only 
matters whether at least one minor or major allele is present, respectively. The different 
codings were compared in terms of explained variance within simple linear regression 
performed for each SNP. We observed that depending on the SNP, certain codings were more 
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or less favorable. For instance, additive coding for SNPs in CETP gene explained more of the 
TG variations than other codings, whereas dominant coding for SNPs in ADRB2 and SCARB 
genes explained more of the TG variations. We nevertheless decided to use subsequently only 
the simplest additive model for all SNPs because the differences were not large.  
 
Regression analysis is particularly sensitive to missing values and the normalization of the 
data. Therefore, we processed the data as follows: 
 
1. Imputation of missing genotypes and missing phenotypes: As previously mentioned, 
four SNPs (adrb2-27e, tnfa-238a, tnfa-308a and mtp-493t) were removed from the 
genotypic dataset because of their high numbers of missing values. For the remaining 
SNPs the mean value of the patients' genotypes (assuming an additive model) was 
computed and this value was used to substitute for the missing values. A similar 
strategy was applied to variables used as confounding factors when they were not 
recorded.  
2. Normalization of all the data: Drug responses, patients' characteristics, genotypic data, 
treatment data and the SNP-drug interaction terms were normalized with respect to the 
corresponding mean and standard deviation (z-scores). The four log10 normalized lipid 
levels were also adjusted for two major confounding factors (sex and age), using 
multi-linear regression.  
 
 
Two-stage model selection 
 
The general aim was to explore how the lipid responses (LR) depend on the SNP genotypes 
(G), the treatment (T) and, importantly on interactions between a SNP and a drug (GT). To 
this end, we developed a two-stage model selection system using a multiple linear regression 
approach [22] (Fig. 9). 
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Figure 9: Overview of the two-stage analysis  
The methodology used in this analysis was applied to the four lipid responses independently. Importantly,  
SNP-drug interactions included in the regression with multiple terms (2nd stage) were chosen either based on the 
significance of the pairwise interaction coefficients (from 1st stage) or at random among all possible interactions. 
Multiple term models were compared to control models in terms of explained variance (R²) leading to 
hypotheses and response predictions regarding the selected SNP-drug interactions found at the end of the two-
stage analysis. 
 
 
 
 
Stage I 
 
First, 240 independent linear regression analyses were studied to estimate the effect of only 
one SNP (s = 1,…, 16) and one drug (d = 1,…, 15) as well as their interaction using eq. (1). In 
order to assess the likelihood for such an interaction we computed a score for each ds,d 
coefficient to be non-zero. This score is defined as the distance of the estimated value of ds,d 
from zero in units of half of its confidence interval ∆ds,d.: 
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Ss,d = |ds,d| / |∆ds,d|                                                                      (2) 
 
The scores are proportional to the absolute value of the t-statistics from the t-test testing 
whether the coefficients of a linear regression differ significantly from zero.  
 
Stage II 
 
In the second stage, we performed a multi-linear regression, using all the 16 SNPs, the 15 
drugs and a subset of the most significant SNP-drug interactions (s,d) for which the 
significance score Ss,d (computed in the first stage)  is above a chosen threshold Smin:     
 
                         (3) 
 
Note that this single global regression model has many more parameters (between 32 if no 
interaction terms are considered, up to 272 if all of them are included). In general, it is not 
required that the values for parameters of this model (a', b's, c'd and d's,d. ) coincide with the 
corresponding values estimated in the first stage. 
 
To study how many interactions were likely to influence the response, we used the entire 
Lipogen 2b study (6183 measurements) to train models containing linear terms for all SNPs, 
and all drugs, but only certain number of bi-linear SNP-drug interaction terms. For each 
model, the estimated coefficients a', b', c' and d' (minimizing ε² in equation 3) were used to 
compute "fitted" lipid responses: 
 
                        (4) 
 
We then checked the modeling hypothesis by comparing the fitted lipid responses to the 
actual responses and computing the residual values of the regression, which reflect the part of 
the phenotype not explained by the model. 
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The challenging question we had to address was how to evaluate models containing different 
numbers of interactions. To this end, we computed the proportion of variance in the data 
(including n lipid measurements) that is explained by the final model (R²) for different 
selected values of Smin:  
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where LRi,computed correspond to either the fitted or the predicted lipid responses. 
 
We also computed the scores of the final interactions terms, with the estimated coefficients 
d's,d similar as in (2): 
 
S 's,d = |d 's,d| / |∆d 's,d|   
                                        (6) 
 
 
Comparing the two-stage model against control models 
 
To measure the performance of our two-stage method we compared each global model with a 
number of pre-selected interactions with a collection of 1000 control models: These control 
models also included all linear terms (for SNPs and drugs), as well as a randomly selected set 
of interaction terms containing the same number of terms as the two-stage model. 
 
R² values were then computed for each of the 1000 control models, and their distribution was 
compared with the R² value of the two-stage model. This procedure was repeated for different 
numbers of interaction terms corresponding to different chosen values of Smin. In order to find 
the "best" model we computed the difference in R² between each model for a given number of 
interactions and the mean of the corresponding control models (in units of their standard 
deviation):             
                         (7) 
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This R² distance can provide the number of interactions where the difference between the R² 
of the model and the controls is the highest:   
 
The two-stage model selection procedure was developed in order to identify the most 
essential features in the dataset, while excluding non-significant or redundant terms. It 
allowed for reducing the complexity of the data, especially in the large SNP-drug interaction 
space. Figures 10 to 13 show our results from running the two-stage analysis.  
 
Increasing the number N of interaction terms in the model by steps of 20, we observed that 
the R² increases from around 0.15 (N=0) to 0.34 (N=240). In order to assess the significance 
of the increase in R² of the two-stage model selection method, we asked for which N the two-
stage model gives R² values that are significantly higher than that of corresponding control 
models with the same N. We performed 1000 random tests. The R² mean of the ensemble of 
controls at each threshold or number of interaction terms was always below (or equal if no or 
all terms were included) the R² value computed in the two-stage model selection (Fig. 10). 
The difference in units of standard deviation from the random tests was relatively large for 
models containing between 20 and 160 interaction terms. For models including more 
interaction terms, the R² line passed below the upper "whisker" of the boxplot (which 
represents the largest observed value that is less than 1.5 of the interquartile range (the 
distance between the 25th percentile and the 75th percentile)). Thus, only the two-stage models 
that included less than three quarters of all possible interactions fitted the data significantly 
better than models that used the same number of randomly picked interactions (Fig. 10).  
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Figure 10: R² as a function of the number of interaction terms. 
The red line shows R² as a function of the number of interaction terms using the two-stage model selection. The 
blue line corresponds to the mean R² of the 1000 control models with the indicated number of randomly chosen 
interactions. The green line shows the mean +/- the standard deviation of R² within the random model. The box 
plots show the median value as a line and the first (25th percentile) and third quartiles (75th percentile) of the 
distribution as the lower and upper parts of the box. The crosses represent outlying R² values. 
 
To study in more detail which of the two-stage models (or essentially how many SNP-drug 
interactions) achieved the most improvement with respect to the controls, we computed the 
difference between the R² value for each model and the corresponding mean R² value, in units 
of standard deviation from the 1000 control models with randomly selected interactions 
(Fig. 11). 
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Figure 11: R² distance as a function of the number of interaction terms. 
Each square represents the R² distance at each threshold Smin (from a model containing one interaction to a model 
having 239 interactions). 
 
The R² distance is not defined for models with no or all interaction terms because all control 
models in this case are equal and thus have a vanishing standard deviation. Trivially when 
including or excluding only one interaction term the R² distance is small, because the control 
models are still very similar to the reference model (and to each other). We observed that the 
R² distance was also very small when using a large number of interaction terms (200 or 220), 
while it increased rapidly as function of interactions and peaked at 40 with a value of ~6. 
Adding 10 interactions also led to a R² distance peak (data not shown), corresponding to 
another local optima. When adding more than 40 terms, the R² distance decreased in a roughly 
linear fashion between 60 and 220 interactions. We concluded that allowing only ~1/6 of the 
possible SNP-drugs interactions in our two-stage model gave the most significant 
improvement with respect to the randomized controls. The R² value of the optimal model 
together with a histogram of those of the randomized controls is shown in Fig. 12.  
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Figure 12: Distribution of the R² values from 1000 control models with 40 randomly picked interactions 
The green circle represents the R² value (~0.16) when no interaction terms are included in the model. The red 
triangle shows the R² value (~0.22) when a 2-stage model selection is used. The p-value for obtaining this result 
by chance is below 1/1000 (<0.001). 
 
To further assess the fit of the linear model, we compared the fitted triglyceride responses 
versus the actual responses (Fig. 13). The data were represented as a cloud of points, with 
each point corresponding to one measurement. We observed that the dynamic range of the 
fitted values was smaller than that of the actual values. Clearly while our model tends to 
capture the trend of the triglycerides, it cannot fully reproduce the measured variation. This is 
not surprising given that our linear model by definition cannot account for non-linear effects. 
Moreover, it is likely to miss out on many important explanatory variables (e.g. SNPs or 
environmental variables that were not measured but affect the responses). We also checked 
the distribution of the residuals as a function of the fitted triglyceride values, where we 
observed that they were approximately normally distributed, centered around zero and did not 
show any particular trend (data not shown). 
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y = 1*x + 2.5e-16
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Figure 13: Actual TG values as a function of the fitted TG values 
A comparison of the measured triglyceride levels with our model containing 40 interaction terms. Each blue 
point within the cloud of data points corresponds to a single data point. The red line has a slope of one and an 
intercept of zero. 
 
A list of the ten most significant interactions (based on the scores sd' of our two-stage model 
with 40 interactions) is presented in Table 5. For each of these interactions we also showed 
the corresponding rank obtained in the first stage and the associated score sd. We note that the 
rank obtained in the first stage was not very predictive of the rank in the second stage. A plot 
of the ranks of the scores at the second stage versus the ones at the first stage did not show 
any particular correlation (r=0.02) (data not shown). For example, the most significant 
interaction involving the SNP named abca1-969a and the drug SQV was ranked only at 
position 12 in the first stage. The exception is the interaction APV/apoc3-3238g which was 
among the top 10 in both the first and second stages.  
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Interaction names Rank 2nd stage Score 2nd stage Rank 1st stage Score 1st stage 
SQV/abca1-969a 1 -3.48 12 -2.36 
NVP/apoa5-64g 2 -2.84 36 -1.79 
ABC/apoa5-64g 3 2.64 22 2.01 
ATV/apoe-2060c 4 -2.30 15 -2.23 
ABC/cetp-629a 5 2.27 24 1.96 
ABC/adrb2-16r 6 2.22 23 1.97 
NVP/apoc3-455c 7 -2.11 38 -1.75 
D4T/abca1-969a 8 2.08 11 2.37 
EFV/cetp-279a 9 1.98 29 1.87 
APV/apoc3-3238g 10 1.95 10 2.41 
 
Table 5: The ten most significant SNP-drug interaction terms. 
The name of the SNP-drug interaction is shown in the first column. The rank of these interactions after the two-
stage analysis in a model with 40 interactions is given in ascending order in the second column with the 
corresponding scores in the third column. The rank of the same interactions but after the first stage (where all the 
possible interactions were tested) is given in the fourth column and the corresponding score after the first stage is 
shown in the last column. The significance scores (which are positive by definition) have been multiplied by the 
sign of the regression coefficients to indicate the direction of the effect due to the interaction. 
 
The signs in front of the significance scores are those of the regression coefficient associated 
with the corresponding interactions. We observed that the sign of the coefficients for each 
interaction is consistent between the first stage and the second stage, which was not 
necessarily expected since the two steps are independent. These coefficients can be 
interpreted as follows: a negative score decreases the risk of having elevated triglycerides and 
a positive score increases the chance of having elevated triglycerides. For example, patients 
who carry one or two copies of the minor allele of the SNP abca1-969 and were treated with 
SQV have (on average) a lower triglyceride level than patients who are homozygous for the 
major allele and were treated with the same drug. Thus, in this case the rare allele is 
"protective" against high TG under treatment with SQV. In contrast, patients carrying the 
minor allele of the SNP apoa5-64g and under the ABC treatment had, on average, higher 
triglyceride levels than patients homozygous for the common allele. In this case, the major 
allele can be seen as a "protective" allele against high TG under treatment with ABC. 
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Comparison with the other phenotypes 
 
The two-stage model selection was applied in a systematic and independent manner to each of 
the three other phenotypes: NHC, HDL and total cholesterol (data not shown). For the TG and 
NHC analyses, about 40 significant SNP-drug interaction terms maximized the R² distance 
while for HDL and total cholesterol less (20) interaction terms appear to maximize this 
measure. 
 
We observed only mild consistency for the selected SNP-drug interaction terms across the 
different lipid responses (see Table 6), except between cholesterol and NHC, where 17 out of 
20 interactions are the same. With respect to the proportion of variance explained by the 
model (R²), the three other lipids received lower R² values than TG, regardless of the number 
of selected interactions. Yet, the behavior of R² increase from a model without interaction to a 
model with many (selected) was comparable between the responses, with a slightly better 
improvement for the NHC and TG responses.  
 
# common SNP-
drug interactions TG (40) NHC (40) HDL (20) Chol (20) 
TG (40) 40 13 4 7 
NHC (40) 13 40 5 17 
HDL (20)  4 5 20 4 
Chol (20) 7 17 4 20 
 
Table 6: Number of common SNP-drug interaction terms between the phenotypes.  
The numbers correspond to the fraction of common SNP-drug interaction terms between two lipid responses for 
which the two-stage analysis has been run. This table can be seen as symmetric matrix. The diagonal is the total 
number of significant SNP-drug interactions retained at the end of the analysis. This number is also shown in 
parentheses next to each phenotype name. 
 
 
2.6.2.4 Assessment of predictive power of the two-stage approach 
So far our analyses focused on the question of how much of the lipid variability can be 
explained by linear models in terms of genotypic (SNPs) and environmental (drug treatment) 
variables, as well as possible interactions between them. Yet, it is important to realize that 
models that explain a certain fraction of the data variability do not necessarily have predictive 
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power. To establish the latter one has to demonstrate that a model that was established based 
only on a subset of the entire dataset also explains some of the variance of the remaining data. 
Within the context of the HIV data this corresponds to demonstrating that a model trained on 
the available data could accurately predict the expected lipid responses of new patients based 
on their genotypes for different possible treatments. 
 
Cross-validation is the standard technique for assessing how the results of a statistical 
analysis will generalize to an independent data set. Its goal is to estimate how accurately a 
predictive model will perform on out-of-sample data that was not used for training. In general 
cross-validation involves partitioning a sample of data into complementary subsets, 
performing the analysis on one subset (called the training set), and validating the analysis on 
the other subset (called the test set). To reduce variability, multiple rounds of cross-validation 
are performed using different partitions, and the validation results are averaged over the 
rounds [22, 58]. In k-fold cross-validation, the original sample is randomly partitioned into k 
subsamples (or folds). Of the k subsamples, a single subsample is retained as the validation 
data for testing the model, and the remaining k-1 subsamples are used as training data. The 
cross-validation process is then repeated k times, with each of the k subsamples used exactly 
once as the validation data. The k results from the folds then can be averaged (or otherwise 
combined) to produce a single estimation. The advantage of this method over repeated 
random sub-sampling is that all observations are used for both training and validation, and 
each observation is used for validation exactly once. 
 
There are several ways to evaluate the predictive power of a model once a cross-validation 
has produced out-of sample predictions. First, one can evaluate R2 as defined in eq. 5 using 
the predicted responses as computed data (rather than the fitted values as we did when 
evaluating the explanatory power). We note that in this case R2 can assume negative values 
indicating that the mean distance between predicted and measured values is larger than that 
between the measured values and their mean value. So actually always using the mean-value 
for predictions would have better predictive power than a model producing negative R2. To 
avoid such negative values in the cross-validation context one often uses the so-called 
coefficient of determination, which is simply the square of the correlation r between observed 
and predicted values. This coefficient is positive by definition and a somewhat less 
conservative estimate of predictive power, since it tests how well the ranking of the 
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observations are preserved, rather than the actual values. In case of in-sample (fitting) 
evaluation r2 is equal to R2 as defined in eq. 5. 
 
Both r2 and R2 only provide a global assessment of predictive power. These measures do not 
allow for dissecting whether the model performs well only for extreme values or if it tends to 
predict the correct trend for the bulk of the data. For such a more stratified analysis, it is 
customary to quantify the so-called Receiver Operating Characteristics (ROC). This 
technique requires a binary classification in which the individuals' measurements are 
classified into two groups. For example, in the context of our lipid-measurements each 
individual could be assigned to have either "high" or "low" lipid levels after a given treatment 
by applying some (arbitrary, yet fixed) threshold on the corresponding measurement. As a 
threshold, one could use the median value or some recommended clinical cut-off that is used 
to define dyslipidemia. Then to assess the predictive power of a given model one uses the 
predicted values to classify all measurements as "high" or "low". Importantly the 
dichotomization is done in a quasi-continuous manner by varying the classification threshold. 
This is equivalent to sorting all predicted values and then dividing the sorted list of values at 
all positions, starting from the beginning where all measurements are declared to be negative 
all the way to the end where all measurements are declared positive. At each division of the 
list, one can then compute the sensitivity and specificity which are statistical measures of the 
performance of a binary classification test. Sensitivity is the fraction of all measurements 
classified as positive (P) that were indeed high. This is equivalent to the true positive (TP) 
rate: TPR = TP/P). Conversely, specificity measures the proportion of all measurements 
classified as negative (N) that were indeed low. This is equivalent to the true negative rate 
TNR = TN/N). The relationship between sensitivity and specificity, as well as the 
performance of the classifier, is usually visualized in terms of the ROC curve by plotting the 
true positive rate (TPR) against the false positive rate (FPR), where FPR = 1 - TNR [59]. This 
curve allows for comparing the predictive power of all possible compromises between 
sensitivity and specificity. The area under the ROC curve (AUC) (also known as the ROC 
index) provides a single measure of accuracy (predictive power) for a given model. A perfect 
model has an AUC of one, whereas random classifiers give an AUC close to 0.5 [59, 60]. 
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In-sample analysis 
 
While ROC analysis is designed to evaluate predictive performance, it can also be used to 
characterize the explanatory power of a model. To this end we simply used the fitted (rather 
than predicted) values for classifying lipid measurements as positive or negative. Specifically 
we used the entire dataset to compare the two-stage model versus the control models in terms 
of ROC. For this end, after performing the two-stage model selection on the entire dataset, the 
fitted values were re-converted into their original scale (mmol / l). A clinical threshold of 2.26 
mmol/l (200mg/dl) for TG was applied to divide the continuous actual lipid responses into 
two categories (negative or "low risk" and positive and "high risk"). This threshold was based 
on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment Of High Blood Cholesterol in Adults recommendations [61], that 
are also used as guidelines for the HIV population [52, 62].  
  
Using ROC analysis on fitted data allowed for an alternative evaluation of the significance of 
the selected SNP-drug interactions. We compared the sensitivity and specificity performance 
of the two-stage model versus the control model (see Fig. 14 for the TG responses of the 438 
patients from Lipogen 2b with a fixed number of 40 interaction terms). We observed that the 
ROC curve from the two-stage model selection was above the ROC curve from the 10 control 
models, showing that for most of the FP rates, the TP rate of the two-stage model was higher. 
Consequently, the AUC of the two-stage model (0.728) was significantly higher than the 
mean controls (0.706+/-5.3E-3). Thus, our ROC/AUC analysis supports our claim that the 
selection of the 40 interaction terms using our two-stage approach had better explanatory 
power than a random picking of the same number of interactions. 
 
However, we also noticed that the mean ROC curve for control models was significantly 
above the diagonal, indicating that the linear terms (for SNPs and drugs) already explain a 
fraction of the data and that this fraction also increases when adding randomly picked 
interactions. A possible explanation is that each control model may include some relevant 
interactions by chance.  
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Out-of-sample analysis 
 
As we mentioned above, in order to evaluate the predictive power, we performed ROC 
analysis of models considering their out-of-sample estimates from various cross-validation 
schemes.  
 
We made the following observation: While our in-sample ROC curve for the two-stage model 
had been consistently above those of the control curves generated from models with the same 
number of randomly chosen interactions we were not able to receive such a result for our out-
of-sample predictions. Rather we observed that the corresponding ROC curves were 
significantly below the control curves (see Fig. 14) (AUC= 0.575 vs. AUC=0.633 +/-5.6E-3). 
This is a surprising result, because for instance the training sets of a leave-one-out cross-
validation are almost identical to the entire dataset (only 1 out of 438 patients is removed at a 
time), but nevertheless this small difference seemed to produce a strong bias for improving 
prediction power with pre-selected interactions according to our two-stage approach. 
Nevertheless, it should be emphasized that we could still demonstrate significant  
out-of-sample prediction power using SNP-drug interactions, only that choosing them at 
random is at least as good, if not better, as picking interactions that appeared significant in a 
model that consider only a single SNP and a single drug at a time. One possibility might be 
that many of the selected SNP-drug pairs might contain redundant information explaining 
why random sampling of SNP-drug pairs performs better. 
 
64 64
 
Figure 14: ROC curves illustrating performance of two-stage SNP-drug interactions model for the 
triglycerides response. 
Shown above are the four ROC curves for fitting (blue curve) and prediction (green curve) of the the log10 TG, 
using 40 SNP-drug interaction terms. The corresponding control models are shown as mean +/- standard 
deviation respectively, in red and black. A 438-fold cross-validation (leave-one-patient-out) has been used for 
out-of-sample predictions. The clinical threshold is equal to 2.26 mmol/l.  
 
2.6.2.5 Further refinements of the two-stage approach 
 
In the following, we describe additional refinements to our analysis, employed to improve the 
predictive power of our model. However, for predicting TG values none of these 
modifications significantly altered our results (Fig. 14). 
 
Correction and normalization of the response data 
 
We applied a quantile-quantile normalization [22] to the phenotypic data before running the 
two-stage analysis. The transformation was applied to the lipid responses such that the 
transformed values had the same rank, but followed exactly a normal distribution, with zero 
mean and unit variance. The advantage of such a transformation is that it guarantees a normal 
response which leads to correct inference of the parameter estimates and often improves the 
performance of regression which is sensitive to outliers. 
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Logistic regression  
 
Logistic regression is a useful way of describing the relationship between one or more 
independent variables with a binary response variable [22] (see also section 1.3). 
Accordingly, we therefore binarized the lipid levels prior to modeling. We then applied the 
same two-stage analysis on the TG measurements (split into two categories based on the 
classical clinical threshold) using two types of link functions (logit and probit). The AUC 
after cross-validation was equal to 0.57 compared to the AUC of the controls, which was 
equal to 0.62 +/-8.4E-3. Using a discrete TG phenotype and applying the two-stage model 
selection did not increase the out-of-sample prediction accuracy, compared to the 
corresponding control model performance. 
 
Two-stage analysis combined with a stepwise approach 
 
One of the limitations of the two-stage regression is that the scoring of the SNP-drug 
interactions at the first stage is based only on one SNP-drug pair while ignoring all other 
pairs, while the second stage usually includes many pairs. Some pairs may be redundant, e.g. 
because the respective SNPs are identical (or in high linkage disequilibrium) and the 
respective drugs may have been given to many patients. In this case only one pair may be 
attributed a significant interaction in the second stage. In principle a multi-stage method (e.g. 
stepwise model selection [22, 63]) may be an efficient means to identify a collection of non 
redundant significant interactions. Stepwise regression includes regression models in which 
the choice of predictive variables is carried out by an automatic procedure (adding and 
removing terms from a multi-linear model based on their statistical significance in a 
regression; see also section 1.3). We implemented a stepwise procedure to refine the two-
stage model in order to remove redundant SNP-drug interaction (while keeping also the linear 
terms). The final number of interactions has also been used for the control models.  
This procedure was applied after the two-stage model selection to tune the final number of 
interactions and potentially remove the redundant ones. The procedure uses the F-statistic or 
the Akaike information criterion for selecting the best interaction terms. We computed the 
AIC criterion for each model based on the number of parameters and the maximized value of 
the likelihood function. We selected the model with the lowest AIC value. However, the 
resulting ROC curves and AUC values did not exhibit better performance in terms of out-of-
sample predictions, compared to the control models. 
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Additional covariates adjustment 
 
The lipid phenotypes may be influenced systematically by confounding factors such as 
gender, age, fasting state, diabetes status, smoking status, use of lipid lowering agents (LLA). 
In order to study the impact of these factors, we performed an analysis of all lipid responses 
on the whole population, as well as on sub-populations stratified by these factors. 
 
We studied only the male population (which represents around 80% of the data) in order to 
see if gender has any effect on our result. 
The triglycerides showed a higher predictive value (AUC = 0.6112) for out-of-sample 
predictions (but still below controls, AUC =0.6251+-8.6E-3) when only investigating the 
male population whereas the other lipid responses were not as sensitive as TG to gender 
difference. Similarly, we explored the impact of age, fasting state, diabetes status, and 
smoking status in our two-stage analysis. We found that none of these covariates helped to 
improve the predictive power of the cross-validation procedure for TG levels. As an example, 
the cross-validation AUC for non-LLA treated people was equal to 0.575 whereas the control 
models for the same patients gave an AUC of 0.638 +/- 8.2E-3. 
 
To adjust the data for effects induced by LLA (which might have contributed to 
misclassifications), we needed to estimate what the lipid responses of patients would have 
been under LLA if they had been without this treatment. A reasonable assumption is this 
"true" lipid level has been higher than the observed one, and we used a simple method [64] 
that imputed "true" lipid level as the mean of all lipid values measured in the non treated 
population that are above a threshold. This correction was applied to roughly 10% of the 
measurements and the two-stage analysis was re-run on the LLA corrected phenotype. 
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Figure 15: Predictive performance of two-stage SNP-drug interactions model for the triglycerides 
response. 
The log10 TG have been corrected for sex, age, LLA variables and quantile-quantile normalized, using 40 SNP-
drug interactions. A 438-fold cross-validation (leave-one-patient-out) has been used for out-of-sample 
predictions. The clinical threshold is equal to 2.26 mmol/l. The four ROC curves are shown on the left side and 
the corresponding AUC values are displayed on the right side. 
 
Figure 15 shows the ROC analysis (438-fold cross-validation) for the two-stage model of 
quantile-quantile normalized TG after correction for sex, age and LLA. As previously 
mentioned, the ROC curve for fitted values was, for all false positive rate (FPR) values, 
significantly above the control curve generated from models with 40 randomly chosen 
interactions (AUC=0.72 vs. AUC=0.7+/-4.5E-3). In contrast, out-of-sample predictions 
generated a ROC curve that was significantly below the control curve (AUC=0.58 vs. 
AUC=0.62+/-7.3E-3). 
 
Two-stage analysis for SNP-SNP interactions 
  
Our approach can also be applied for studying other types of interactions, like SNP-SNP or 
drug-drug interactions. We tested this on the triglyceride phenotypes corrected for sex, age, 
LLA, which was subsequently quantile-quantile normalized. For the SNP interactions, the 
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second stage regression contained all 16 SNPs and a subset of all 136 non-redundant SNP-
SNP interactions.  
 
Using cross-validation, we found increased predictive power of the two-stage model over its 
random controls for most values of the FPR when using 20 SNP-SNP interactions (AUC=0.56 
vs. AUC=0.52 +/-1.4E-2) (Fig. 16).  
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Figure 16: Predictive performance of two-stage SNP-SNP interactions model for the triglycerides 
response. 
The log10 TG have been corrected for sex, age, LLA variables and quantile-quantile normalized, using 20 SNP-
SNP interactions. A 438-fold cross-validation has been used for out-of-sample predictions. The clinical threshold 
is equal to 2.26 mmol/l. The four ROC curves are shown on the left side and the corresponding AUC value is 
shown on the right side. 
 
While this is an encouraging result, we noted that the total explained variance is smaller in 
this case than for models that include linear terms for drugs or SNP-drug interactions. This 
indicates that the effect of the treatment dominates the lipid response, making it difficult to 
extract the potential effects of the SNPs and of the SNP-SNP interactions from this dataset.  
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Two-stage analysis for drug-drug interactions 
 
For the drug interactions, the second stage regression contained all 15 linear drug terms and a 
subset of interaction terms among all 120 bi-linear drug-drug interaction terms. We tried 
interaction term subsets of different sizes using only the most significant terms from the first 
stage. The two-stage model suffered from rank deficiency at the level of the matrix of the 
explanatory variables due to linear combination of interactions terms (only 0 and 1 as possible 
values). The prediction results were not stable and did not show any improvement of the in or 
out-of-sample predictions over the control model predictions.  
 
Two-stage analysis for gene-drug interactions 
 
The high correlation between some of the SNPs (usually within the same gene) prompted us 
to average out these SNPs and re-run the two-stage analysis using only 10 genes, 15 drugs to 
search for relevant gene-drug interactions (among 150). This refinement did not help in 
improving predictive power of the two-stage model over the control models. 
 
2.6.2.6 The two-stage model selection versus a forward model selection 
The data analyses of this section were performed on the latest SHCS dataset, Lipogen 3. For a 
more comprehensive analysis of the predictive power of different models (detailed below), we 
focused on a single response to antiretroviral treatment. Specially, we focused on the log10 
transformed triglycerides, adjusted for sex, age, LLA and then quantile-quantile normalized. 
We compared the following procedures which aimed at selecting a subset of the 384 (24 
SNPs*16 drugs) possible interactions:  
• Two–stage regression analysis: This procedure was described in detail before (see 
also section 2.6.2.3); each interaction term was first evaluated independently and then 
the N terms with the highest scores were included together in the full model (for 
different choices of N).  
• Forward stepwise procedure: Here interaction terms are added one at a time in a 
greedy manner. Specifically, we used a systematic method for adding terms from a 
multi-linear model based on their regression coefficient statistical significance. The 
method started with an initial model and then compared the explanatory power of 
incrementally larger models. At each step, the p-value of an F-statistic (or adjusted R², 
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Akaike information criterion, Bayesian information criterion, or false discovery rate) 
was computed to test models with and without a potential term.  
• Control models: These models (c.f. 2.6.2.3) provided the reference to evaluate the two 
other procedures. They include the same number of interactions as the reference 
models, but used a random selection. This procedure was repeated at least 10 times for 
each number of interactions. 
 
To assess and compare the performance of the different models for predicting the lipid levels 
we used the explained variance R² (and other related metrics) as well as ROC analysis. R² and 
the area under the curse (AUC) were compared for different N, both for in-sample fitting and 
for out-of-sample predictions (cross-validation). For the latter, we tried different k-fold cross-
validation settings: k=3, k=752 (leave-one-patient-out) and k=12170 (leave-one-measurement-
out). In addition, we investigated the dependence of the cross-validation on whether 
measurements of the same patient were distributed among the different folds (random 
partitioning vs. stratified partitioning). The underlying rationale for comparing these two 
types of partitioning was to test whether having some data of a particular patient in the 
training set would have an impact on the predictive performance. This is important since in a 
realistic setting obviously no lipid measurements are available for new patients. 
 
We first investigated the predictive power for random partitioning of the measurements using 
three-fold cross-validation. We found that a linear model containing only SNPs and the drugs 
but no interactions already explained a significant fraction of the observed lipid levels 
(R²~15%). Using the predicted values for classification gave an AUC of 66.5% seemingly 
indicating significant predictive power of our model. When adding SNP-drug interactions 
using the step-forward procedure the R² further increased by ~3% to 18% (for 25 interaction 
terms) and the AUC also increased by ~1.5% to 68%. For the two-stage model, the 
improvements for R² values and AUC were below the ones from the forward model but the 
trend was similar (R² = 17% and AUC = 67.5%), see Fig. 17, upper part). In contrast adding 
the same number of randomly selected interactions only marginally increased the R² and AUC 
values. However, when trying to predict the lipid responses using a 3-fold stratified cross-
validation (where data from a single patient are not distributed across different folds), the 
models showed instable behavior and actually performed worse than the control models. The 
R² and AUC curves decreased as a function of the number of interactions for both two-stage 
and forward models as well as for the control models (Fig. 17, lower part).  
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Figure 17: SNP-drug interactions R² and AUC of the two growing models for the triglycerides response. 
The log10 TG were corrected for sex, age, LLA variables, using 25 SNP-drug interactions. We used a 3-fold 
cross-validation for out-of-sample predictions. On the upper part of the figure we represent the R² curve and 
AUC curve after random partitioning of the lipid responses across the folds. On the lower part of the figure we 
represent the R² curve and AUC curve after stratified partitioning of the lipid responses across the folds. The red 
color corresponds to the forward model selection, the blue to the two-stage model selection and the green to the 
control models. 
 
We also observed that for 25 SNP-drug interactions, the AUC was lower than the one for the 
control models. The higher predictive power of the control models could be explained by the 
fact that in a stratified partitioning, each fold contains no information about the patients' 
measurements of the other folds, therefore, making each patient very different from the others 
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in terms of features present into the model. A likely explanation is that this study is 
underpowered to pick up interaction terms (if any) resulting in overfitting of the data. As a 
result, the selected interactions seem to be very specific to each patient (fold), indicating why 
randomly picked interaction terms showed better predictive power when the lipid 
measurements are distributed across the folds. The decreasing R² curve could be explained by 
the fact that cross-validation scheme can lead to negative R² values. In addition, for both  
two-stage and forward models, by definition, they were built only by inclusion (and no 
exclusion) of interaction terms, allowing for redundant terms and thus overfitting of the data. 
 
2.6.2.7 In-silico data testing 
We were concerned by the fact that neither our two-stage nor the forward stepwise approach 
for including SNP-drug interactions into predictive models had better predictive power under 
cross-validation than the control models containing randomly selected SNP-drug interaction 
terms. We thus decided to test our methods with in-silico data in order to rule out the 
possibility that there is a fundamental problem or programming error in our algorithms. Using 
artificial data we know which interaction terms are present and what their effect sizes are. 
Thus, we can test the functioning and the sensitivity of the various approaches. Moreover, we 
can compare whether the different cross-validation approaches give rise to different results as 
we observed for the real data.   
   
We generated an in-silico dataset as follows: We first used random numbers drawn from an 
exponential distribution that were multiplied by random numbers drawn from a binomial 
distribution to define the effect sizes (and their sign) of the SNPs, drugs and SNP-drug 
interactions. Once such a model was established, we generated in-silico lipid signals using 
exactly the same feature variables as in 12170 measurements of the Lipogen 3 study. Finally, 
we added random numbers drawn from a normal distribution to simulate noise. 
 
The data were analyzed using the two cross-validation scheme we had employed previously 
for the real data with either random partitioning or the stratified partitioning.  
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Figure 18:  In-silico testing: SNP-drug interactions R² and AUC of the two growing models for the 
triglycerides response. 
The log10 TG were corrected for sex, age, LLA variables, using 25 SNP-drug interactions. We use a 3-fold cross-
validation for out-of-sample predictions. On the upper part of the figure we represent the R² curve and AUC 
curve after random partitioning of the lipid responses across the folds. On the lower part of the figure are 
represented the R² curve and AUC curve after stratified partitioning of the lipid responses across the folds. The 
red color corresponds to the forward model selection, the blue to the two-stage model selection and the green to 
the control models. 
 
We observed that when assigning the measurements randomly to the three folds, the R² 
increased from 86.5% (no interaction) to 91% (25 interaction terms) and the AUC increased 
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from 95.6% (no interaction) to 97% (25 interaction terms) for the forward model. For the two-
stage model, the R² values and AUC were lower than those from the forward model but the 
trend was similar. R² went from 86.5% to 89% and AUC from 95.6% to 96.4% (Fig. 18, upper 
part). Furthermore, when trying to predict the lipid responses using a 3-fold stratified cross-
validation (keeping all measurements of a patient in a single fold) both models exhibited R² 
and AUC curves above the control models curves (Fig. 18, lower part). Similar observations 
were made when using different number of folds (k = 10, or k = 752 corresponding to leave-
one-patient-out) or when changing the level of the noise. 
We make the following conclusions: 
1. The implementations of our algorithms for our two-stage and the forward stepwise 
approach for including SNP-drug interactions are able to identify SNP-drug 
interactions and give rise to predictive models that outperform the random control 
models for data that indeed contains signals for these interactions.  
2. As expected the forward model had better performance than the two-stage method. 
3. The patient specific effect is not present in the in-silico data and that could explain 
why the in-silico data results are not aligned with our results when performing the 
stratified cross-validation (Figs. 17-18, lower part). 
 
2.6.2.8 Stepwise model selection of the different features and predictive 
assessment 
To further investigate the contributions of the SNPs, the drugs and the SNP-drug interactions, 
we decided to analyze different models where the features (SNPs, drugs and interactions) 
were selected as before within the cross validation procedure (leave-one(patient)-out) using a 
stepwise approach (which seemed to perform better, see also section 2.6.2.6).   
Stepwise model selection includes a forward selection, which involves starting with a set of 
variables included in an initial model, examining each variable one by one and including 
those which are statistically significant. Stepwise model selection also includes a backward 
elimination step, which given an initial set of starting variables, removes those which are not 
statistically significant. The stepwise approach is a combination of forward and backward 
steps, testing at each stage for variables to be included or excluded, based on the F-statistic 
[22]. 
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The log10 TG responses were adjusted for various confounding factors (patient id, sex, age, 
fasting state, LLA, log CD4+ T cells, log viral RNA, DM2, BMI, smoking status, ethnicity, 
presumed mode of HIV transmission, waist). TG was regressed on each of these covariates. 
The new TG being used for the features selection and assessment of the model performances 
was defined using the residuals from the linear regression. 
 
The following models were tested for TG predictions:  
-Model with only stepwise selected SNPs terms (Fig. 19)  
-Model with only stepwise selected drugs terms (Fig. 20) 
-Model with stepwise SNP and drug terms (Fig. 21) 
-Model with preselected SNP terms, drug terms and stepwise selected SNP-drug interaction 
terms (Fig. 22) 
-Model with preselected SNP terms, drug terms and stepwise selected SNP-SNP interaction 
terms (Fig. 23) 
-Model with preselected SNP terms, drug terms and stepwise selected drug-drug interaction 
terms (Fig. 24) 
 
We reported the results of the ROC analysis (plot of the TPR as a function of the FPR) after 
fitting and cross-validating the Lipogen 3 data. Control models (as described earlier) that 
included the same number of interactions but chosen at random were also run to assess the 
model selection. Table 7 summarizes the different AUC, r², R² for those models. 
We studied a model containing subsets of SNPs that were stepwise selected among the 22 
possible ones. We analyzed the predictive power of this model in terms of in-sample and  
out-of-sample predictions (Fig. 19). The fitting curve is always above its respective controls 
and consequently the AUC value is higher (58.58% vs. 55.65%). The leave-one-(patient)-out 
cross-validation curve (below the fitting one as expected) is on average above its control line 
(AUC=54.8% vs. AUC=52.5%). Figure 19 shows that the SNPs selected by stepwise have 
predictive power and selecting SNPs performs better than picking them at random in both 
situations (fitting and cross-validation). In terms of R², altogether the SNPs explained 1.03% 
of the lipid level variations when cross-validating the data and 4.7% after fitting. 
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 Figure 19:  ROC curves and AUC values for the model containing only selected SNPs. 
On the left side are represented four ROC curves and on the lower right box, the corresponding AUC values. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
 
 
 
The same analysis has been performed using only the treatment data (Fig. 20). The fitting 
curve overlaps with its respective controls with similar AUC values (61 %). Figure 20 shows 
that the drugs selected alone in an in-sample context have a little more predictive power than 
the SNPs selected alone (Fig. 20). The leave-one-(patient)-out cross-validation curve shows 
unstable behavior, lying under its control line (AUC=56.25% vs. AUC=59.9%). Selecting the 
drug performs worse than picking them at random. This observation may be due to the large 
difference of drugs selected in each fold (patient) showing that predicting which drugs affect 
the TG may vary importantly from one patient to another. In terms of R², altogether the drugs 
explained 3.16% of the lipid level variations after cross-validation the data and 7.33% after 
fitting. 
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Figure 20: ROC curves and AUC values for the model containing only selected drugs. 
On the left side are represented four ROC curves and on the right side box, the corresponding AUC values. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
 
 
Next, we similarly investigated a model containing only SNPs and drugs selected via the 
stepwise approach; we analyzed the predictive power of the model in terms of in-sample and 
out-of-sample predictions (Fig. 21). The fitting curve is above its respective controls and 
consequently the AUC value is higher (66% vs. 64.27%). The leave-one-(patient)-out cross-
validation curve is slightly above its control line (AUC=62.37% vs. AUC=61.85%). Figure 21 
shows that the SNPs and drug selected have predictive power but the model is nearly 
equivalent to randomly picking the same number of SNPs and drugs from the dataset. In 
terms of R², altogether the SNPs and the drugs explained 7.63% of the variations in lipid 
levels after cross-validation (and 13.46% after fitting). In comparison to selecting the SNPs 
and the drugs from the whole dataset and fixing them before running the cross-validation, the 
predictive performances are better (figure not shown), revealing that the set of SNPs and 
drugs selected within the cross-validation process vary from one patient to another.  
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 Figure 21: ROC curves and AUC values for the model containing only selected SNPs and drugs. 
On the left side are represented four ROC curves and on the right side box, the corresponding AUC value. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
 
 
We similarly studied a model with SNP-drug interactions selected via the stepwise method. 
We analyzed the predictive power of the model in terms of in-sample and out-of-sample 
predictions (Fig. 22). The fitting curve is above its respective controls and consequently the 
AUC value is higher (68.2% vs. 65.5%). The leave-one-(patient)-out cross-validation curve is 
overlapping with its control line (AUC~62%). Figure 22 shows that a model containing 
selected SNP-drug interactions has predictive power but it is nearly equivalent to randomly 
picking the same number of interactions from the dataset (as it has been shown in previous 
analyses). Altogether the SNPs, the drugs and their interactions explained 4.86% of the lipid 
levels variations after cross-validation (17.17% after fitting). Selecting the SNP- drug terms 
from the whole dataset and fixing them before running the cross-validation, the predictive 
performances are better (figure not shown), revealing that the set of interactions selected 
within the cross validation process vary from one patient to another, which was also the case 
for the linear terms. Adding interactions in a stepwise manner did not significantly improve 
the predictive performance. 
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 Figure 22: ROC curves and AUC values for the model containing selected SNPs, drugs and SNP-drug 
interactions. 
On the left side are represented four ROC curves and on the right side box, the corresponding AUC values. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
 
 
The same analysis has been performed using SNP-SNP interactions (Fig. 23) .The fitting 
curve is above its respective controls with higher AUC values (67.95% vs. 65.58%). The 
leave-one-(patient)-out cross-validation curve is under its control line (AUC=59.11% vs. 
AUC=61.23%) meaning that selecting the SNP-SNP interactions performs worse than picking 
them at random, reflecting the absence of trend or pattern in the SNP-SNP interaction space 
and consequently reflecting their lack of predictive power for the TG response. 
 
 
80 80
 Figure 23: ROC curves and AUC values for the model containing selected SNPs, drugs and SNP-SNP 
interactions. 
On the left side are represented four ROC curves and on the right side box, the corresponding AUC values. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
 
Concerning the model with drug-drug interactions, the same analysis has been performed 
(Fig. 24). The fitting curve is above its respective controls with higher AUC values (66.14 % 
vs. 65.76%). The leave-one-(patient)-out cross-validation curve is under its control line 
(AUC=62.22% vs. AUC=63.02%) meaning that selecting the drug-drug interactions performs 
worse than picking them at random, likely due to the same reasons as the others interactions. 
The different interactions when selected before the cross validation demonstrate predictive 
power in out-of-sample context (figure not shown). The explained variance after cross-
validation reaches the value of 7.15% 
 
81 81
 Figure 24: ROC curves and AUC values for the model containing selected SNPs, drugs and drug-drug 
interactions. 
On the left side are represented four ROC curves and on the right side box, the corresponding AUC values. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
 
 
Based on the performance of the different models evaluated, it seems that the signal is mainly 
driven by the drugs. The different drugs used in HAART are known to affect the lipid 
metabolism and transport. Therefore, we designed a model which takes into account only the 
SNP information (SNPs and non identical SNP-SNP interactions) (Fig. 25). 
The fitting curve is always above its respective controls and consequently the AUC value is 
higher (~63 % vs. ~60%). The leave-one-(patient)-out cross-validation curve is overlapping 
with its control line (AUC~55%). Figure 25 shows that the SNP-SNP interactions combined 
with the SNPs do not help in reaching very high predictive performance.  
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 Figure 25: ROC curves and AUC values for the model containing selected SNPs and SNP-SNP 
interactions. 
On the left side are represented four ROC curves and on the right side box, the corresponding AUC values. The 
blue curve and bar plot refer to the in-sample predictions and AUC. The light blue ones correspond to the 
controls. The red curve and bar plot refer to the out-of-sample predictions and AUC. The light red ones 
correspond to the controls.  
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Fitting Controls 
  AUC r² R² AUC r² R²
SNPs 0.5858 0.0477 0.0476 0.5565+/-9E-3 0.0232+/-8.3E-3 0.0230+/-7.9E-3
Drugs 0.6103 0.0747 0.0733 0.6123+/-9.97E-4 0.0751+/-1.1E-3 0.074+/-1.2E-3
SNPs + Drugs 0.6601 0.1348 0.1346 0.6427+/-6.8E-3 0.1070+/-9.6E-3 0.1066+/-9.2E-7
SNPs + Drugs + SNP*Drug 
Interactions 0.682 0.1718 0.1717 0.6551+/-1.5E-3 0.1328+/-1.3E-3 0.1325+/-1.2E-3
SNPs + Drugs + SNP*SNP 
Interactions 0.6795 0.1806 0.1806 0.6558+/-1.5E-3 0.1365+/-2E-3 0.1364+/-1.9E-3
SNPs + Drugs + Drug*Drug 
Interactions 0.6614 0.1506 0.1503 0.6576+/-1.2E-3 0.1375+/-2.8E-3 0.1372+/-2.6E-3
 
Leave-one-patient-out  
cross-validation Controls 
  AUC r² R² AUC r² R²
SNPs 0.548 0.0178 0.0103 0.5250+/-9.3E-3 0.0066+/-3.2E-3 -4.22E-4+/-7.5E-3
Drugs 0.5625 0.0385 0.0316 0.5999+/-3.6E-3 0.0593+/-4.5E-3 0.0581+/-4.5E-3
SNPs + Drugs 0.6237 0.083 0.0763 0.6185+/-5.1E-3 0.0737+-/7.5E-3 0.0702+/-8.6E-3
SNPs + Drugs + SNP*Drug 
Interactions 0.6254 0.0726 0.0486 0.627+/-1.6E-3 0.0856+/-2E-3 0.0793+/-3E-3
SNPs + Drugs + SNP*SNP 
Interactions 0.5911 0.045 -0.0245 0.6123+/-4.2E-3 0.066+/-4.9E-3 0.0424+/-6.6E-3
SNPs + Drugs + Drug*Drug 
Interactions 0.6222 0.0849 0.0715 0.6302+/-2E-3 0.0908+/-5.5E-3 0.082+/-3E-3
 
Table 7: Summary of AUC, r² and R² values across the models for both in-sample (fitting) and out-of-
sample (leave-one-out cross-validation). 
The upper table shows the AUC, r² and R² values for the different stepwise selected models after fitting and the 
same values for their corresponding control models. The lower table shows the AUC, r² and R² values the 
different stepwise selected models after a leave-one-out cross validation and the same values for the 
corresponding control models. AUC, r² and R² values for control models are indicated as mean+/-standard 
deviation. 
 
 
As the triglyceride response is a complex trait, we tried to model and predict its values in HIV 
treated individuals with the help of their genetic variants and the drugs taken. It seems that 
already the SNP and the drug terms carry most of the predictive power. With the different 
models described above and using a stratified cross-validation approach, we could detect a 
certain predictive power for model containing only SNPs and model with SNPs and drugs 
(compared to models with randomly selected terms). For the other models studied, mainly 
models containing drug terms and interactions terms, we could not detect a significant 
difference with respect to control models probably due to missing factors, the small sample 
size, potential noise of the dataset or simply lack of large interaction effects. 
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2.7 General conclusions and discussion 
In this project, we were interested in explaining and predicting dyslipidemia, a major lipid 
disorder, in treated HIV-infected individuals. We therefore investigated the different features 
from the dataset in order to build statistical models taking into account the genetic factors and 
drug treatment. In particular, we searched for possible interactions between SNPs and drugs 
that could explain some of the variation in lipid levels. Finally, we assessed the predictive 
powers of the different models. 
 
We compared the performance of different approaches for integrating SNP-drug interactions 
into a linear model in a systematic manner. We established a new procedure that first rates 
each interaction individually and then builds a more comprehensive model using only the 
most significant interactions. The more established step-forward (or stepwise) approach is 
computationally more expensive than the two-stage approach, while its gain in R² and AUC 
for our data was not dramatic. The fact that the stepwise procedure gave better predictive 
performances may be because this approach is designed to select the best interaction at each 
step (local optimum), thus avoiding redundant interactions to be part of the model, which 
could have happened in the two-stage approach.  
 
We showed that the procedures for establishing linear models with a biased selection of  
SNP-drug interactions have better explanatory power than the controls with random 
selections. Yet, we could not robustly establish that these procedures also have significantly 
better predictive power in a stratified cross-validation (where data from one patient are kept in 
the same fold). The only model exhibiting better predictive power when comparing to control 
models in terms of cross-validation was the one containing only SNP terms. The predictive 
power in terms of AUC of a model containing only SNPs and drugs is nearly equivalent to 
that of a model having also SNP-drug interactions, irrespective of whether they were selected 
by stepwise model selection or at random. In addition, the explained variance actually 
decreases when adding interaction terms into the model. This result is probably due to data 
overfitting, the small sample size and the potential noise of the dataset. Yet, it is also plausible 
that the data we investigated simply have no effects or that there is too small signal to allow 
detection of SNP-drug interactions. One should not forget that there was poor gene coverage 
and that the statistical methods used assume allelic homogeneity. If multiple rare variants in 
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each gene play a role, these methods may not be able to capture the underlying signal. In this 
project, we only studied interactions with a limited set of candidate SNPs, which may not tag 
variants that mediate the relevant SNP-drug interactions. Some genetic variants in other genes 
or non-recorded confounding factors (such as alcohol intake not recorded in the SHCS) could 
also play a role in the variation of lipid levels. In order to avoid spurious results, we adjusted 
the TG phenotype for various factors present in the data, which could influence the lipid 
levels, such as patient id, sex, age, fasting state, LLA, DM2, BMI, smoking status, ethnicity 
and waist. We also analyzed only the Caucasian individuals (~85%) and did not find 
significant differences. 
 
Concerning the explained variance, we realized that using R² (as defined in eq. 5) is 
problematic for evaluating out-of-sample prediction, because it decreased when adding 
interaction terms and even became sometimes negative. Moreover, when fitting models it also 
is not the ideal measure to indicate the optimal number of interaction terms, because even for 
random interactions R² increases as a function of the number of terms. One could use the 
adjusted R², which takes into account the number of features into the model. Or the Mean 
Squared Error (MSE), measure similar to R² since it is used to refer to residual sum of 
squares, divided by the number of degrees of freedom. However, the main use of the R² was 
to compare R² from given models with respect to R² from control models (both having the 
same number of terms) with the aim of showing that a smart selection of interactions would 
give better predictive performances than a random set of interactions.  
 
In most our analyses, we used cross-validation approaches to reflect the situation where the 
predicted lipid measurement was not used in the training process. We mainly used leave-one-
patient-out cross-validation. Indeed, using cross-validation schemes that distributed the 
measurements of one patient across different folds (random cross-validation) indicated 
significant predictive power. Yet we believe that this result is less interesting, because in a 
realistic scenario one will have to predict lipid responses for new patients for which no 
measurements will be available. The marked difference between our results for stratified and 
random cross-validation are likely due to the fact that the lipid measurements stemming from 
the same patient are often correlated, while our models largely ignore this correlation. We 
could have averaged out measurements from the same individuals when the same drug was 
given, but this would have meant less phenotypic measurements available for the modeling 
86 86
approaches. Another option to improve predictive power would have been to weight 
consistent measurements from the same patients higher.  
 
While some models ignore the inter-dependency of measurements taken on the same patient, 
future work should investigate whether proper modeling of these correlations would improve 
the predictive power. Indeed, there is a class of models that include these types of effects, the 
"random effects" in mixed models [22]. We nevertheless showed that a model containing only 
SNP terms was able to better predict the triglyceride levels than a model built from randomly 
selected SNPs. Since SNP patterns reflect the patient identity, this positive result may be 
simply due to patient correlation rather than a direct effect of the genetic variants on lipid 
metabolism, while this "artificial" predictive signal is diluted when also including drugs and 
interactions in the model. 
 
Further work is needed to address the predictive power of SNP-drug interactions. We cannot 
rule out that more sophisticated model selection procedures (like LASSO [65] or ridge 
regression [23]) would yield better predictive power than the procedures we investigated. It is 
also plausible that going beyond linear modeling is necessary to demonstrate increased 
predictive power when including interactions. This includes methods for classification like 
Neural Networks [16] or Support Vector Machines [66].  
 
We believe that our report of the challenges we encountered in detecting SNP-drug 
interactions in the context of the lipid responses in the Swiss HIV Cohort Study will be useful 
for future work in this field. We hope that our work will provide important lessons also for 
other computational projects directed towards the goal of "personalized" medicine by 
integrating gene-environment interactions in a data-driven analysis. This is particularly 
important since the amount of data generated by new technologies such as sequencing will 
raise new challenges and there will be an increase need of statistical approaches in order to 
reduce the complexity of the data and capture relevant signatures like gene-environment 
interactions. 
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3 Genome-Wide Association Studies projects 
During the second half of my PhD, I was also involved in different projects related to 
genome-wide association studies (GWAS). In contrast to my HIV project, all these projects 
employed genotypic data (usually Single Nucleotide Polymorphisms, generated using SNP 
arrays) across the entire genome.   
3.1 Genome-Wide Association Studies: Benefits and current limitations 
The goal of these studies was to search for correlations between genetic markers and any 
measurable trait in a population of individuals. The motivation is that such associations could 
provide new candidates for causal variants in genes (or their regulatory elements) that play a 
role in the phenotype of interest. In the clinical context, this may eventually lead to a better 
understanding of the genetic components of diseases and their risk factors. 
 
Most of these GWAS usually currently include the following steps:  
• genotype calling from the raw chip-data and basic quality control  
• principle component analysis (PCA) to detect  possible population stratification  
• genotype imputation (using linkage disequilibrium information from HapMap)  
• statistical testing for association between a single genetic marker and continuous or 
categorical phenotypes  
• correction for multiple hypothesis testing  
• data presentation (e.g. using quantile-quantile (p-value inflation) and Manhattan plots 
(p-value values as a function of chromosomal position)) 
• cross-replication and meta-analysis for integration of association data from multiple 
studies. Replication of findings in different studies can strengthen the evidence for a 
real association. By combining the results of different studies, statistical meta-analysis 
can also provide additional power for the discovery of new associations. 
The first wave of large-scale, high-density genome-wide association (GWA) studies has 
improved our understanding of the genetic basis of many complex traits [67]. For several 
diseases, including hypertension [68, 69],  type 1 [70] and type 2 diabetes [71, 72], 
inflammatory bowel disease, prostate cancer [73] and breast cancer [74], there has been a 
rapid increase in the number of loci implicated in these diseases. For others, such as asthma 
88 88
[75], coronary heart disease [76], fewer novel loci have been found, although opportunities 
for mechanistic insights are equally promising. Several common variants influencing 
important continuous traits, such as lipid traits [71, 77-79], height [80], body mass index 
(BMI) [81] , and fat mass [82] have also been found. A recent catalog of GWAS hits lists 779 
published loci for 148 traits (see Fig. 1, http://www.genome.gov/26525384). 
Recent successes in the identification of susceptibility variants that underlie many important 
biomedical phenotypes has increased confidence that this information can be translated into 
clinically beneficial improvements in disease management [83]. 
 
From the many GWAS that were performed in recent years it has become apparent that even 
well-powered (meta-) studies with many thousands (and even ten-thousands) of samples can 
at best identify a few (dozen) candidate loci with highly significant associations. Most 
common variants that have been found to be associated with disease through GWAS typically 
have very small effects on the variability of the trait and explain a rather small portion of the 
heritability. These initial findings suggest that many GWAS may have not been sufficiently 
powered to discover associations with such small effects and therefore stimulated the creation 
of consortia to merge results from several GWAS in order to reach sufficient statistical power 
to identify smaller and smaller genetic effects. Increasing sample size indeed provides the 
required power, but the clinical significance of these findings remains an open question [84]. 
While many of these associations have been replicated in independent studies, each locus 
explains but a tiny (<1%) fraction of the genetic variance of the phenotype (as predicted from 
twin-studies). Remarkably, models that pool all significant loci into a single predictive 
scheme still miss out by at least one order of magnitude in explained variance. Thus, while 
GWAS already today provide new candidates for disease-associated genes and potential drug 
targets, very few of the currently identified (sets of) genotypic markers are of any practical 
use for accessing risk for predisposition to any of the complex diseases that have been 
studied. Many of the greatest challenges to be faced in the years ahead lie not so much in the 
identification of the association signals themselves, but in defining the molecular mechanisms 
through which they influence disease risk and/or phenotypic expression [83]. 
Various solutions to this apparent enigma have been proposed: First, it is important to realize 
that the expected heritabilities usually have been estimated from twin-studies, often several 
decades ago. It has been argued that these estimates entail problems of its own (independently 
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raised twins shared a common prenatal environment and may have undergone intrauterine 
competition, etc.).  
Second, the genotypic information is still incomplete. Most analyses use microarrays probing 
only around half a million of SNPs, which is almost one order of magnitude less than the 
current estimates of about 4 million common variants from the Hapmap CEU panel. While 
many of these SNPs can be imputed accurately using information on linkage disequilibrium, 
there still remains a significant fraction of SNPs which are poorly tagged by the measured 
SNPs. Furthermore, rare variants with a Minor Allele Frequency (MAF) of less than 1% are 
poorly interrogated by these SNP-chips, but may nevertheless be the causal agents for many 
phenotypes. Finally, other genetic variants like Copy Number Variations (CNVs) (or even 
epigenetics) may also play an important role.  
Third, it is important to realize that current analyses usually only employ additive models 
considering one SNP at a time with few, if any, co-variables, like sex, age and principle 
components reflecting population substructures. This obviously only covers a small set of all 
possible interactions between genetic variants and the environment. Even more challenging is 
taking into account purely genetic interactions, since already the number of all possible  
pairwise interactions scales like the number of genetic markers squared.  
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3.2 Overview of my projects 
I was involved in the following five projects: 
 
1. A meta-analysis of serum calcium across different cohorts (meta-analysis), one 
being the Cohorte Lausanne (CoLaus). 
2. A GWAS aimed at studying the interaction between SNPs and body mass index on 
two-hour glucose levels (after an oral glucose test tolerance) within the MAGIC 
consortium. 
3. A project that investigated the impact of three atrial natriuretic peptide (ANP) gene 
variants on HDL-cholesterol and other metabolic syndrome components in 
overweight/obese people. This work has been done in collaboration with the 
INSERM and Paris 7 University.  
4. Within the GIANT consortium, I have worked with a couple of members of my 
group and run different GWAS on the following phenotypes: hip circumference, 
hip circumference controlled for BMI and overweight/obese vs. normal weight 
case-control studies.  
5. Finally, I am involved in the Hypergenes consortium. Its aims at building a model 
to dissect complex genetic traits, using Essential Hypertension (EH) as a disease 
model with the main outcome, to find human genes responsible for EH, using a 
whole genome association approach. I have been doing data processing, genotype 
calling, quality control on the genotypic data and collection of the phenotypic 
measurements. 
 
For projects 1-4, I performed GWAS on the Cohorte Lausanne sample (CoLaus). CoLaus [85] 
is a population-based study, which consists of a sample of individuals of Caucasian origin 
from Lausanne. The study includes 5435 individuals between 35 and 75 years old, of which 
52.5 % are women and 47.5 % are men. Participants were extensively phenotyped (in terms of 
clinical and biological measurements as well as questionnaire responses related to life style 
and history) and were genotyped using Affymetrix Human Mapping 500K Array. The 
CoLaus study was approved by the Institutional Ethic's Committee of the University of 
Lausanne. The last project (5) used data from the Hypergenes consortium. 
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In the following chapters, I will describe the projects, my contribution followed by a detailed 
discussion.   
 
 
NHGRI GWA Catalog 
www.genome.gov/GWAStudies 
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 Figure 1: Published Genome-Wide Associations through March 2010, 779 published GWA at p<5E-8 for 
148 traits. 
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3.3 Genome-wide association for serum calcium  
I have been involved in a project whose aim was to uncover genetic variations influencing 
human serum calcium levels at genome-wide scale. This project has been initiated in 
Lausanne and statistical analyses were led by Dr. Karen Kapur, a post-doc in the 
Computational Biology Group. 
3.3.1 Background 
Calcium levels in blood serum play an important role in many biological processes. As a 
universal cellular signaling molecule [86], calcium is involved in membrane potential, heart 
rate regulation and generation of nerve impulses. It also influences bone metabolism and ion 
transport [87]. Serum calcium levels have been associated with numerous disorders of bone 
and mineral metabolism as well as with cardiovascular mortality. The regulation of serum 
calcium is under strong genetic control, with twin studies showing that the variance in total 
calcium due to genetic effects is between 50% and 78%.  
3.3.2 Scope of this project 
This study presented the first meta-analysis of genome-wide associations from four cohorts 
totaling 12,865 participants of European and Indian Asian descent. It identified common 
polymorphisms at the calcium-sensing receptor (CASR) gene locus that were associated with 
serum calcium concentrations. We showed that CASR variants give rise to the strongest 
signals associated with serum calcium levels in both European and Indian Asian populations, 
while no other locus reaches genome-wide significance, indicating that CASR is a key player 
in genetic regulation of serum calcium in the adult general population.  
Our analysis entitled Genome-wide meta-analysis for serum calcium identifies significantly 
associated SNPs near the calcium-sensing receptor (CASR) gene, was published in PLoS 
Genetics in July 2010. It can be found in Appendix 2 and also online: 
http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1001035. 
3.3.3 My contribution 
Here I describe the data analysis that I performed on serum calcium and calcium-related 
outcomes on the CoLaus study. My main contribution was to replicate the major results found 
by Karen Kapur. In order to provide an independent confirmation of her results obtained 
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using our analysis tool QUICKTEST [88] (that was developed in our group), I used Matlab® 
scripts for my analysis. 
 
I first extracted from the CoLaus data [85] a subset of 5404 individuals for whom serum 
calcium measurements and questionnaire responses to queries about personal histories of 
osteoporosis and osteoarthritis were available. Their genotypes were either measured or  
imputed (prior imputation of allele dosage of SNPs was performed using IMPUTE [89] and 
SNPs typed in the HapMap CEU population) giving a total of ~2.5 million SNPs. 
 
Then, I computed active serum calcium which I estimated from total serum calcium by the 
following formula:  Ca_corrected (mmol/L) = Ca_total (mmol/L) + (40 – albumine [g/L])/40. 
Individuals with outliers for corrected calcium values, i.e. <1.9 or >3.0 mmol/L were 
excluded. I log transformed the phenotype, adjusted for age and pseudosex (pseudosex is a 
variable with three categories: men, premenopausal women and postmenopausal women. I 
defined the new phenotype used for the following association analysis using the residuals 
from the linear regression.  
 
I carried out linear-regression analyses for association using an additive genetic model on the 
new phenotype. I corrected p-values for inflation using genomic control methods [90] for 
genotyped and imputed SNPs. I generated a text file containing my analysis results for all 
SNPs. It included the information in Table 1. 
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Column Description 
name SNP rs number 
chromosome Chromosome number 
position physical position for the reference 
sequence on the Genomic build 35 
strand Strand (+/-) indicating either the 
positive/forward strand or the 
negative/reverse strand 
referenceallele Reference SNP allele (A/C/G/T) 
modeledallele Modeled (or coded) SNP allele 
(A/C/G/T) 
build Genomic build used 
modelledallelefrq modeled (or coded) allele frequency 
n Number of individuals with both 
genotype and phenotype 
measurements within the analyzed 
group 
beta effect of the modeled allele 
sebeta standard error of the effect 
p uncorrected p-value for the additive 
model 
pexhwe exact Hardy-Weinberg test p-value 
call genotyping call rate for the SNP, within 
the analyzed subgroup 
imputed 1/0 coding ; 1 = imputed SNP ; 0 = 
directly typed SNP 
usedforimputation 1/0 coding ;  1 = used for imputation ; 0 
= not used for imputation 
rsqhat or .info statistic  used for imputation quality assessment 
 
Table 1: Genome-wide association results format. 
 
Figures 1 and 2 show the Manhattan plot and quantile-quantile plot of the association results 
for CoLaus.  
 
I also investigated the association of rs1801725, the top hit in the European cohorts, with 
several outcomes postulated to be correlated with serum calcium. I performed the analysis of 
osteoporosis and osteoarthritis status (binary responses) in CoLaus, using logistic regression 
including age and pseudosex as covariates. Table 3 reports the -log10 transformed p-value for 
association, the effect size and its standard error, the odds ratio and its confidence interval. 
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3.3.4 Results 
Confirming Karen's findings, my analysis showed 23 SNPs exceeding the genome-wide 
significance threshold of 5E-8, all located on chromosome 3 (Fig. 1). My quantile-quantile 
plot of the association results is shown in Figure 2. Even though there is no excessive p-value 
inflation, Figure 2 shows deviation from the expected line and most of the signal corresponds 
to SNPs on chromosome 3. The two top hits for association with serum calcium (in terms of 
p-values) are rs17251221 and rs1801725. Their exact location, their coded and non-coded 
alleles, the beta estimates, its standard errors and the p-value for association are reported in 
Table 2. According to the NCBI SNP database, the two SNPs are located in the calcium-
sensing receptor locus (CASR).  
 
 
Figure 1: Manhattan plot for the Genome-wide association results for CoLaus. 
The figure shows the significance of association of all SNPs in the GWAS for CoLaus after applying genomic 
control correction. SNPs are plotted on the x-axis according to their position on each chromosome against 
association with serum calcium concentrations on the y-axis (shown as -log10 p-values).  
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Figure 2: Quantile-Quantile plots of genome-wide association results for CoLaus.   
Shown are observed -log10 p-values on the y-axis plotted against expected -log10 p-values on the x-axis after 
applying genomic control correction (λ = 1.0145). Results are color-coded by chromosome. The top results 
largely derive from the CASR locus on chromosome 3.   
 
 
db SNP Chr Position (Build 35)
Coded 
Allele 
Non-
Coded 
Allele 
Beta Se  GC  P-value 
rs17251221 3  123475937 G A 7.11E-03 1E-03  7.89E-12 
rs1801725 3 123486447 T G 7.11E-03 1E-03 8.01E-12 
 
Table 2: Two top hits genome-wide significant. 
Are reported the two top hits for association. Chr is the Chromosome number. Position is given for NCBI Build 
35. The coded allele is the allele to which the beta (effect) estimate refers. Se stands for standard error of the beta 
coefficient. GC p-value is the p-value after genomic control correction. 
 
I also analyzed the association of the rs1801725 and rs17251221 with two calcium-related 
outcomes: osteoarthritis, osteoporosis. Logistic regression including age and pseudosex as 
covariates showed a significant association between rs1801725 and osteoarthritis (p-value = 
0.0281, not significant after Bonferroni correction) whereas it did not give a significant 
association between rs1801725 and osteoporosis (p-value = 0.213) (Table 3). I observed 
similar results and conclusions between rs17251221 and the two outcomes.  
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Ca-related outcomes beta se beta OR OR CI p-value 
Osteoporosis  0.1732 0.1391 1.18 [0.9054; 1.5618] 0.213 
Osteoarthritis  -0.1466 0.0668 0.8636 [0.7577; 0.9843] 0.0281 
 
Table 3: Logistic regression of two clinical phenotypes on rs1801725.  
Are reported the effect size (beta), its standard error (se beta), the odds ratio (OR), the odds ratio confidence 
interval (OR CI) and the p-value of the rs1801725 T allele from logistic regression of the two phenotypes. 
 
3.3.5 Conclusions 
Independently analyzing the CoLaus data, I also found that the rs1801725 T allele and 
rs17251221 G allele were associated with higher serum calcium in the CoLaus population 
(Table 2); this SNP is located on the CASR locus on chromosome 3. In our meta-analysis (see 
article), we observed that the rs1801725 SNP had the strongest association in individuals of 
European descent, while for individuals of Indian Asian descent the top hit was rs17251221. 
The two SNPs are in strong linkage disequilibrium. 
 
Concerning the calcium-related outcomes within the CoLaus population, the rs1801725 T 
allele and the rs17251221 G allele showed some association with osteoarthritis status, 
although not statistically significant after a Bonferroni correction. There was no association 
with osteoporosis. However, the evidence of association with osteoarthritis was not supported 
by the meta-analysis (see article). 
 
Our analysis suggests that CASR is a key player in the regulation of serum calcium in the 
adult general population. 
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3.4 Two-hour glucose Genome-wide association studies 
3.4.1 Background 
MAGIC (the Meta-Analyses of Glucose and Insulin-related traits Consortium) represents a 
collaborative effort to combine data from multiple GWAS to identify additional loci that 
impact glycemic and metabolic traits. 
 
Two-hour post-load glucose measured during the oral glucose tolerance test (OGTT) defines 
glucose tolerance, reflects insulin resistance and correlates with cardiovascular risk. Yet 
common genetic determinants of two-hour glucose are largely unknown. Identifying such 
variants might lead to better understanding of type 2 diabetes (TD2) pathophysiology and 
cardiovascular complications. T2D is defined as a state of chronic hyperglycemia defined as 
elevated glucose levels measured either when fasting or two-hour after glucose challenge (2-h 
glucose) during an OGTT [91]. 
 
Genome-wide association studies have revealed loci associated with glucose and  
insulin-related traits [92]. A recent meta-analysis of genome-wide association studies of 
fasting glycemic traits in non diabetic individuals conducted by MAGIC reported the 
discovery of nine new loci associated with fasting glucose (FG) (in or near ADCY5, MADD, 
ADRA2A, CRY2, FADS1, PROX1, SLC2A2, GLIS3, and C2CD4B) and one locus associated 
with fasting insulin levels (IGF1). The same study showed effects on FG for seven previously 
published glucose and/or type 2 diabetes loci G6PC2, MTNR1B, GCK, DGKB, GCKR, 
SLC30A8, and TCF7L2. They also demonstrated association of  ADCY5, PROX1, GCK, 
DGKB, GCKR with type T2D [93].  This is a powerful demonstration of how analyses of 
continuous metabolic traits in healthy individuals can lead to the discovery of previously 
unsuspected T2D susceptibility genes. Detailed physiological characterization of each locus 
may help elucidate their role in regulation of glucose levels, insulin secretion and/or action, 
and identify potential pathways involved in T2D pathogenesis [92]. Another recent MAGIC 
meta-analysis, identified two additional novel loci (GIPR and VPS13C) associated with two-
hour glucose after an OGTT [91]. VPS13C is the human homologue of a yeast vacuolar 
sorting protein and GIPR is the glucose-dependent insulinotropic peptide receptor that 
mediates the incretin effect of GIP.  
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3.4.2 
3.4.3 
Scope of this project 
The project aims at dissecting the interaction between SNPs and body mass index (BMI) on 
two-hour glucose levels. Increased BMI is a risk factor for impaired glucose tolerance, and 
may interact with an individual's genetic susceptibility.  
Therefore, the study tries to answer several questions such as: Can SNP*BMI interactions 
identify new variants associated with two-hour glucose not seen in the main effects? Is it 
possible to identify SNP*BMI interactions in known two-hour glucose loci? In order to 
address these questions, MAGIC is meta-analyzing the GWAS results (tests of interaction to 
identify new loci with heterogeneity of effect by BMI) from eight studies, totaling more than 
15,000 non diabetic individuals. The consortium is following up SNPs (to test existing two-
hour loci for interaction with BMI) previously associated with two-hour glucose levels (in or 
near GIPR, VPS13C, ADCY5, GCKR, TCF7L2 genes, and in addition two SNPs in or 
near HS3ST2 and PPP1R3B) in 15 replication samples (~ 40, 000 individuals).  
 
My contribution 
In this context, I have been involved in providing GWAS results on the two-hour glucose 
phenotype within the CoLaus study, which was subsequently meta-analyzed with the results 
of other cohorts by the Consortium. 
Consequently, I extracted a subset of 425 individuals from the CoLaus data [85] for whom 
two-hour glucose measurements were available and performed two types of analyses.  
 
Continuous BMI analyses 
 
I fit models of the following form:  
 
G120 = α + β1(BMI) + β2(SNP) + βc(covariates) + ε       (1.1) 
G120 = α + β1(BMI) + β2(SNP) + β3(BMI *SNP) + βc(covariates) + ε   (1.2) 
 
Here G120 is the untransformed two-hour glucose, BMI is the untransformed Body Mass Index 
(weight/height²) and the SNP is coded additively (i.e. dosage of the minor allele). The 
additional covariates included in the models are: age (untransformed and continuous), sex and 
the ten first principal components. Following the analysis protocol, I previously excluded all 
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individuals with diagnosed T2D (and/or using medication for diabetes), having fasting 
glucose >=7mmol/l and BMI <18.5kg/m2 or missing BMI information. 
 
For model (1.2), I performed linear regression analyses using Matlab®, and I generated a text 
file including (for each SNP) the information in Table 1. 
 
Column Description 
CHR Chromosome 
POS_# Position on NCBI build 35  
SNP rs number of the SNP 
STRAND Strand of the chromosome on HapMap 
(+/-) 
N Sample size for the SNP 
EFFECT_ALLELE Allele for which the effect is reported 
NON_EFFECT_ALLELE Other allele at the SNP 
EFFECT_ALLELE_FREQ Effect allele frequency 
BETA_2 β2 – the coefficient for the SNP 
SE_BETA_2 s.e(β2) – the robust standard error of β2
P_BETA_2 P-value for SNP 
BETA_3 β3 – the coefficient for interaction 
SE_BETA_3 s.e(β3) – the robust standard error of β3
P_BETA_3 P-value for interaction 
COVAR_BETA_2_BETA_3 Cov(β2,β3) – the covariance between β2 
and β3
CALL_RATE The call rate for the SNP 
R2HAT Imputation accuracy measure between 
true and imputed genotypes 
 
Table 1: Genome-wide association results format. 
 
Similarly, for model (1.1) I produced the same information excluding the four terms related to 
the SNP*BMI interaction (i.e. the covariance between β2 and β3 and those related to β3). 
 
 
 
BMI stratified analyses 
 
For these analyses referred to as main effects models, I stratified the CoLaus individuals by 
BMI into three groups: 
Group1: 18.5 <=BMI < 25 (N=200) 
Group2: 25 <=BMI < 30 (N=155) 
Group3: 30 <= BMI < 50 (N= 70) 
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I then considered the following model: 
 
G120 = α + β1(BMI) +  β2(SNP) +  βc(covariates) + ε        (1.3) 
 
where G120 is untransformed two-hour glucose, BMI is untransformed and treated 
continuously and the SNP is coded additively. The additional covariates included in the model 
are: age (untransformed and continuous), sex and the ten first principal components. 
Following the analysis protocol, I excluded all individuals with diagnosed T2D (and/or using 
medication for diabetes), having fasting glucose >=7mmol/l and BMI <18.5kg/m2, BMI 
>=50kg/m2 or missing BMI information. 
 
Then for the model (1.3) I performed linear regression analyses of two-hour glucose levels, 
independently for each BMI group again using an additive genetic model and I provided the 
output  (as described previously) as text files format (one per BMI group).  
 
3.4.4 Results and conclusions 
The first two scans I performed for the two-hour glucose phenotype included BMI as a 
covariate, investigating the main effect of each SNP (model 1.1) and additionally the 
SNP*BMI interaction effect (model 1.2). In the third GWAS, I ran stratified analyses 
according to the BMI of the individuals (three groups) and searched for SNP main effects. My 
analyses did not reveal any genome-wide significant hit. The lack of association might be due 
to the small sample size (N=425). My analysis results are currently being meta-analyzed with 
results from eight other cohorts, aiming at detecting some SNP*BMI interactions influencing 
the two-hour glucose levels in up to 15,000 healthy individuals.  
 
Genetic studies [93] of glycemic traits identified T2D risk loci, as well as loci containing 
genetic variants that are associated with a modest elevation in glucose levels but are not 
associated with overt diabetes. In-depth physiological investigation should help to further 
understand glucose homeostasis in humans and may reveal new pathways for diabetes 
therapeutics. Two-hour glucose level is a heritable quantitative trait known to be associated 
with diabetes. Identification of genetic variation underlying this trait and contribution to T2D 
in non diabetic individuals have been established recently [91]. 
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This and other ongoing meta-analyses conducted by MAGIC may identify common genetic 
variants and potential SNP*BMI interactions that are specifically associated with two-hour 
glucose levels in diabetes free individuals. If successful, those meta-analysis results will 
provide novel insights into the pathogenesis of hyperglycemia, type 2 diabetes, related 
metabolic disorders and cardiovascular diseases. 
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3.5 Study of the impact of atrial natriuretic peptide gene variants on 
HDL-cholesterol and other metabolic syndrome components in 
overweight/obese people, a replication study  
3.5.1 
3.5.2 
3.5.3 
Background 
According to the definition of the International Diabetes Federation (IDF), metabolic 
syndrome is a cluster of the most dangerous heart attack risk factors: diabetes and raised 
fasting plasma glucose, abdominal obesity, high cholesterol and high blood pressure. ANP is 
a vasoactive peptide, involved in the modulation of blood pressure and vascular tone. It seems 
to also play a role in lipid metabolism as it stimulates lipolysis in human adipocytes. The gene 
(NPPA) which codes for ANP therefore is a candidate for cardiovascular risk and 
predisposing metabolic conditions.  
Scope of this project 
This study has been carried out in collaboration with Dr. Ronan Roussel from INSERM 
U695, Xavier Bichat School of Medicine, University Paris Diderot, Hôpital Bichat. His group 
is interested in the genetics of the atrial natriuretic peptide (ANP) gene (natriuretic peptide 
precursor A, NPPA). In contrast to the three GWAS projects described previously, in the 
present analysis, the focus was on three SNPs (rs5063, rs5064, rs5065) in the ANP gene and 
their potential effects on metabolic syndrome (MS). In this context, I provided data analysis 
for the CoLaus cohort on these three SNPs. 
 
Our results were subsequently meta-analyzed with raw data from six studies, totaling more 
than 37,800 overweight/obese individuals. A paper, entitled Impact of atrial natriuretic 
peptide gene variants on HDL-cholesterol and other metabolic syndrome components in 
overweight/obese people describing the discovery analysis performed on the DESIR study 
and the meta-analysis has been submitted to Obesity  and is accessible in Appendix 3. 
 My contribution  
I used the gender-specific IDF metabolic syndrome definition [94] (Table. 1) in order to 
classify CoLaus individuals. From the 5435 individuals, 1416 were considered as metabolic 
syndrome carriers, whereas 4019 were considered not to be carriers.  
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Metabolic syndrome Men Women 
Waist (cm) >=94 >=80 
High Triglycerides (mmol/l) TG>1.7  or lipidic treatment TG>1.7 or lipidic treatment 
Low HDL (mmol/l) hdl<1.03 or lipidic treatment hdl<1.29 or lipidic treatment 
Hypertension (mm Hg) 
sbp>=130 or dbp>=85 or Hyp 
treatment 
sbp>=130 or dbp>=85 or Hyp 
treatment 
Glycemia (mmol/l)  gluc>=5.6 or dm2 gluc>=5.6 or dm2 
 
Table 1: Metabolic syndrome definition in men and women. 
Description of the biological and clinical features defining metabolic syndrome in both male and female 
populations (IDF). HDL: High density lipoprotein; TG: triglycerides; sbp: systolic blood pressure; dbp: diastolic 
blood pressure; Hyp: hypertensive; gluc: glucose; dm2: diabetes mellitus type 2. 
 
In addition, each component of metabolic syndrome (Table 1) was also considered 
individually as a phenotype used for statistical analysis of associations with the ANP gene 
variants. I analyzed metabolic syndrome and its constituents within the entire Caucasian 
CoLaus sample (n=5435) and also within the overweight population (BMI >=25 kg/m²) 
(n=2867) (Table 2). 
 
Characteristics CoLaus (overweight) 
N (Men) 2867 (1619) 
Age (years)  55.0± 10.7 
BMI (kg/m²)  29.1 ±3.9  
Waist circumference (cm) 97.9 ± 10.9 
Triglycerides (mmol/l) 1.66 ± 1.36 
HDL(mmol/l) 1.49 ±0.39  
Metabolic syndrome (%) 44.2 
 
Table 2: Characteristics (Mean ± SD) of overweight/obese (BMI ≥ 25 kg/m²) individuals of CoLaus. 
BMI: Body mass index. HDL: High density lipoprotein. Metabolic Syndrome (MetS) was defined according to 
the International Diabetes Federation criteria. 
 
 
The genotypic information for the three ANP SNPs of interest (rs5063, rs5064 and rs5065) 
had to be retrieved from our imputed CoLaus genotypes [89] since they were not directly 
measured on the Affymetrix 500K SNP arrays. The three SNPs are in linkage disequilibrium. 
Their minor allele frequencies in the overweight population are shown in Table 3.  
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SNP CoLaus (overweight) 
  Minor allelic frequency (%) Genotyping technique 
rs5063  
(G664A) 
3.2 Imputed 
rs5064 
(C708T) 
8.1 Imputed 
rs5065   
(T2238C) 
13.8 Imputed 
 
Table 3: Allelic frequencies and type of genotyping technique in the CoLaus overweight population.  
 
I performed logistic regression association tests of the three genetic variants with metabolic 
syndrome and its categorical components using Matlab®. For associations of the same three 
variants with the continuous metabolic syndrome components, I used the standard linear 
regression. I tested different genetic models: additive, recessive and dominant. I ran the 
analyses on the overweight/obese population, stratifying individuals according to BMI, and 
also on the whole CoLaus population. I adjusted the phenotypes for sex, age and for BMI 
when considering the entire population. All the regression analyses contain an intercept, the 
covariates (sex, age, and possibly BMI) and the SNP of interest. The p-value for association, 
the effect size and its standard error are reported in the following tables. 
 
3.5.4 Results 
Metabolic syndrome in the overweight/obese group of the CoLaus population 
The proportion of individuals having a BMI>= 25kg/m² is 52.75% (n=2867). 
 
Logistic regression (including age and sex as covariates) showed no significant association 
between the variants and the metabolic syndrome phenotype in the overweight population 
under any of the genetic models (data not shown for the dominant model) (Table 4).  
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  additive model beta se p 
Met Syndrome rs5063 0.0103 0.1417 0.9418 
  rs5064 0.0660 0.1009 0.5131 
  rs5065 6.0327e-04 0.0789 0.9939 
 
  recessive model beta se p 
Met Syndrome rs5063  0.9504 1.1733 0.4179 
  rs5064 -0.0156 0.4771 0.9739 
  rs5065 -0.2105 0.2852 0.4605 
 
Table 4: Association of the ANP variants with the metabolic syndrome in the overweight/obese group of 
the CoLaus population, under an additive (upper part) and recessive model (lower  part). 
beta: the regression coefficient indicating the change per allele; se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
 
 
Analysis of the metabolic syndrome components in the overweight/obese group of the 
CoLaus population 
 
 
  additive model beta se p 
Waist rs5063 -0.6317 0.6829 0.3549 
  rs5064 -0.4792 0.4847 0.3229 
  rs5065 -0.3828 0.3784 0.3118 
TG rs5063 -0.0094 0.0918 0.9186 
  rs5064 -0.0284 0.0652 0.6629 
  rs5065 0.0282 0.0509 0.5791 
HDL rs5063 -3.1525e-04 0.0246 0.9898 
  rs5064 -0.0101 0.0174 0.5603 
  rs5065 -0.0134 0.0136 0.3254 
 
Table 5: Association of the ANP variants with the metabolic syndrome components in the 
overweight/obese group of the CoLaus population, under an additive model. 
beta: the regression coefficient indicating the change per allele; se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
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Logistic regression (including age and sex as covariates) failed to demonstrate an association 
between the variants and the metabolic syndrome components in the overweight population 
under an additive genetic model (data not shown for the dominant model) (Table 5). 
 
  recessive model beta se p 
Waist rs5063 0.1209 5.7938 0.9834 
  rs5064  0.4660  2.3087 0.8400 
  rs5065 -0.4760  1.3656 0.7274 
TG rs5063 2.1615 0.7779 0.0055 
  rs5064 -0.0566 0.3104 0.8553 
  rs5065 -0.0706 0.1836 0.7006 
HDL rs5063 -0.2319 0.2083 0.2655 
  rs5064 0.1709 0.0830 0.0393 
  rs5065 0.0418 0.0491 0.3942 
 
Table 6: Association of the ANP variants with the metabolic syndrome components in the 
overweight/obese group of the CoLaus population, under a recessive model. 
beta: the regression coefficient indicating the change per allele;se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
 
Logistic regression (including age and sex as covariates) showed significant associations 
between rs5063 and the triglycerides (p-value = 0.0055) and between rs5064 and HDL  
(p-value=0.0393), in the overweight population under a recessive genetic model (Table 6). 
Under the dominant model, there was no clear signal detected between the variants and the 
different components in the overweight population (data not shown). 
 
Metabolic syndrome in the CoLaus population (N=5435) 
 
Logistic regression (including age, sex and BMI as covariates) did not reveal a significant 
association between the variants and the metabolic syndrome phenotype in the entire 
population under any of the genetic models (data not shown for the dominant model)  
(Table 7). 
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  additive model beta se p 
Met Syndrome rs5063 0.0402 0.1322 0.7610 
  rs5064 0.1760 0.0966 0.0685 
  rs5065 0.0787 0.0755 0.2970 
 
  recessive model beta se p 
Met Syndrome rs5063 0.6405 1.0152 0.5281 
  rs5064 0.6178 0.4441 0.1642 
  rs5065 0.1652 0.2738 0.5464 
 
Table 7: Association of the ANP variants with the metabolic syndrome in the CoLaus population, under 
an additive (upper part) and recessive model (lower part). 
beta: the regression coefficient indicating the change per allele; se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
 
Analysis of the metabolic syndrome components in the CoLaus population (N=5435) 
 
Logistic regression (including age, sex and BMI as covariates) failed to identify significant 
association between the variants and the metabolic syndrome components in CoLaus 
population under an additive genetic model (data not shown for the dominant model)  
(Table 8). 
 
  additive model beta se p 
Waist rs5063 -0.1173 0.2915 0.6873 
  rs5064 -0.0391 0.2081 0.8511 
  rs5065 0.1053 0.1626 0.5172 
TG rs5063 -0.0139 0.0560 0.8033 
  rs5064 -0.0407 0.0400 0.3089 
  rs5065 -0.0012 0.0312 0.9682 
HDL rs5063 0.0115 0.0185 0.5347 
  rs5064 -0.0249 0.0132 0.0601 
  rs5065 -0.0148 0.0103 0.1518 
 
Table 8: Association of the ANP variants with the metabolic syndrome components in the CoLaus 
population, under an additive model. 
beta: the regression coefficient indicating the change per allele; se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
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Logistic regression (including age, sex and BMI as covariates) demonstrated significant 
associations between rs5063 and the triglycerides (p-value = 0.0189) and between rs5063 and 
waist (p-value=0.0428), in the entire population under a recessive genetic model (Table 9). 
However, no association has been found between the variants and the different components in 
CoLaus under the dominant model with the exception for rs5064 with HDL (negative effect 
size) (Table 10). 
 
  recessive model beta se p 
Waist rs5063 5.3091 2.6207 0.0428 
  rs5064 1.1216 0.9415 0.2335 
  rs5065 0.5897 0.5828 0.3116 
TG rs5063 1.1814 0.5033 0.0189 
  rs5064 -0.0334 0.1809 0.8534 
  rs5065 -0.0115 0.1120 0.9184 
HDL rs5063 0.0898 0.1668 0.5904 
  rs5064 0.0549 0.0599 0.3597 
  rs5065 0.0125 0.0371 0.7357 
 
Table 9: Association of the ANP variants with the metabolic syndrome components in the CoLaus 
population, under a recessive model. 
beta: the regression coefficient indicating the change per allele; se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
 
 
  dominant model beta se p 
HDL rs5063 0.0108 0.0189 0.5679 
  rs5064 -0.0318 0.0142  0.0253 
  rs5065 -0.0196 0.0115 0.0886 
 
Table 10: Association of the ANP variants with HDL in the CoLaus population, under a dominant model. 
beta: the regression coefficient indicating the change per allele; se: the standard error of the corresponding beta; 
p: the two sided p-value for association. 
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3.5.5 Conclusions 
From the CoLaus analysis (which served as a replication for the meta-analysis), no significant 
association was detected between the metabolic syndrome incidence/prevalence and the SNPs 
under any genetic model. This observation might be due to the way we classified the CoLaus 
individuals as metabolic syndrome carriers. The classification was based on the IDF 
definition, and not from a clinical diagnostic, which would be more reliable. However, few 
associations were detected under a recessive model, positively associated with TG and HDL 
in the overweight CoLaus population (respectively rs5063 and rs5064) (Table 6) and rs 5063 
associated with increased waist and TG in CoLaus (Table 9). One significant negative 
association (decrease) was detected between the HDL levels and the variant rs5064 under the 
dominant model in the whole population, suggesting an adverse effect of this variant.  
 
In the meta-analysis, our collaborators tested whether the metabolic syndrome and its lipid 
components were associated with these polymorphisms in overweight/obese participants of 
six cross-sectional cohorts around the world (40,000 individuals). Neither the metabolic 
syndrome nor waist circumference was associated with any of the three selected SNPs. 
However, the HDL levels were strongly positively associated with rs5065 (p-value=3E-6 and 
more marginally with rs5063 (p-value=0.05) and rs5064 (p-value=0.04). Triglyceride levels 
were negatively associated with the rare allele of rs5064, but not with the two other SNPs. 
Neither the meta-analysis, nor CoLaus alone replicated or confirmed the findings of the 
discovery analysis performed on 5212 (2248 overweight/obese) individuals from the DESIR 
study. 
 
Moreover, several studies found the ANP plasmatic levels to be associated with blood lipid 
levels; namely, they were positively correlated with HDL and negatively with triglyceride 
levels. Here, our collaborators hypothesized a plausible causal link between the genetic 
variation rs5065 with the HDL increase, via the increase in ANP circulating levels (not 
directly measured in the study), in overweight populations (based on the assumption that the 
more the fat depot is present, the more the ANPs play they lipolytic role). HDL is in addition 
affected by a number of factors, including physical activity and alcohol, for which no 
adjustment has been made.  
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Another limitation of this study was that population stratification in the meta-analyses was not 
dealt with analytically. Several ethnic groups are represented among the cohorts. Population 
principal components could have been used to take this issue into account. Waist 
circumference could have also been used rather than BMI as a cut off to define the overweight 
population, since it is the main criteria of metabolic syndrome carriers. Other suggestions 
could be to analyze men and women separately on the different phenotypes and only combine 
them if there is no sex interaction. Or investigate a more direct relationship, one between 
plasma levels of ANP and the SNPs. 
 
 
The present findings remain hypothetical and should trigger further clinical investigations to 
understand how ANP gene variants may affect the lipid metabolism and to test whether these 
effects may be relevant to diseases processes, especially in the metabolic, cardiovascular and 
renal fields. 
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3.6 Genome-wide association studies for anthropometric measures  
3.6.1 Background 
The GIANT (Genome-wide Investigation of ANThropometric measures) consortium is an 
international assembly of statisticians and genetic epidemiologists, which was established to 
pool genome-wide association (GWA) results on anthropometric parameters used as measures 
of obesity such as adult height, body weight, body mass index (BMI), waist circumference 
(WC) and hip circumference (HC).  
Obesity is a risk factor for developing several diseases, including type 2 diabetes, 
cardiovascular diseases and certain types of cancer. Obesity, defined as a body mass index 
(BMI; in kg/m2) of 30, results from an imbalance in energy intake and energy expenditure 
[95]. However, the underlying mechanisms are largely unknown and are being intensively 
studied. Recently, it has become clear that not only the amount of body fat but also its 
distribution is important in determining disease risk: an increasing WC as a measure of 
abdominal obesity is related to increased chronic disease risk and mortality, independent of 
BMI as a measure of general obesity [96]. 
Although environmental factors play an important role in the development of obesity, multiple 
twin and family studies have indicated that genetic factors also make a significant contribution 
to its etiology [97]. Many genetic loci have been identified as being associated with obesity; 
however, these loci only explain a small part of the genetic variance underlying the 
development of obesity [98, 99]. Recently, GWAS have expanded the number of genetic 
susceptibility loci for obesity by identifying several new single nucleotide polymorphisms 
(SNPs) consistently associated with both BMI and weight, and thus, contributing to obesity 
risk [81, 100]. The loci identified are located in or near the genes FTO, MC4R, TMEM18, 
GNPDA2, SH2B1, KCTD15, MTCH2, NEGR1, BDNF, and ETV5. These loci are likely to be 
involved in many biological pathways because they are expressed in numerous tissues. 
Notably, most of the new obesity genes (except MTCH2, NEGR1, and ETV5) are expressed in 
the hypothalamus, a crucial center for energy balance and regulation of food intake [95]. 
Another meta-analysis searched for genetic loci influencing obesity and fat distribution and 
identified three loci (near TFAP2B, MSRA, LYPLAL1) implicated in the regulation of human 
adiposity , defined by WC and waist–hip ratio (WHR)) [101].
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3.6.2 Scope of this project 
The specific aims of GIANT are (i) integrating the study-specific GWAS via a uniform 
protocol using imputed genotypic data to pool GWA results across studies, (ii) the replication 
of top hits, and (iii) performing the follow-up studies on these replicated hits. This consortium 
was already successful in describing new genetic loci for height [80] and new polymorphisms 
of the MC4R gene [81, 100] having impact on BMI and obesity in general.  
The GIANT consortium aims towards a better understanding of the genetic contribution to 
obesity. This includes meta-analyzing HC, extremes phenotypes (BMI, height, and WHR 
controlled for BMI), as well as case-control studies for overweight/obese vs. normal weight. 
This provides an opportunity to explore whether extreme phenotypes are determined by other 
genetic loci than those associated with traits across the whole distribution. 
A paper, meta-analyzing the GWAS results from various studies, entitled Association 
analyses of 249,796 individuals reveal eighteen new loci associated with body mass index, 
was published in Nature Genetics in October 2010. The manuscript is accessible in Appendix 
4 and also online: http://www.nature.com/ng/journal/v42/n11/full/ng.686.html. 
 
3.6.3 My contribution 
In this context, I have been involved providing GWAS results on the following phenotypes: 
HC, HC controlled for BMI, and overweight/obesity case-control studies within the CoLaus 
study [85], which were subsequently meta-analyzed with other cohorts results by the 
Consortium. For my analyses, I extracted 5404 HC measurements and 5434 BMI 
measurements and performed the following analyses. 
 
HC and HC controlled for BMI 
 
To these data, I first fitted models stratified by gender of the following form:  
 
HC = α + β1(age) + β2(age²) + βi(PCi) + ε         (1.1) 
HC_BMI = α + β1(age) + β2(age²) + β3(BMI) + βi (PCi) + ε                  (1.2) 
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Here HC is the untransformed HC measurement, BMI is the untransformed Body Mass Index 
(weight/height²). The covariates included in the models are: age (untransformed and 
continuous), age² and the ten first principal components (PCi).  
 
I then defined the corrected HC and HC_BMI as the inverse normal transformed residuals 
from linear regressions in eq. (1.1) and (1.2). For the following SNP association analysis, I 
regressed each SNP coded additively ((i.e. dosage of the minor allele) onto the corrected 
phenotypes in men and women separately using Matlab®, and I generated a text file including 
(for each SNP) the information in Table 1: 
 
Column Description 
MARKER NAME rs id of the marker analyzed 
STRAND Strand on which the alleles are reported 
(+/-) 
N The effective number of subjects 
analyzed 
EFFECT_ALLELE The allele associated with phenotypic 
traits 
OTHER_ALLELE Indicating the other (non-effect) allele 
EAF Effect allele frequency 
IMPUTATION Imputation posterior probability for 
imputed SNPs, or the integer value 
directly genotyped markers 
R2HAT Imputation accuracy measure between 
true and imputed genotypes 
BETA The regression coefficient indicating 
change per effect_allele 
SE The standard error of beta 
P The two-sided P-value for the 
association 
 
Table 1: Genome-wide association results format. 
 
 
 
Overweight/obese vs. normal weight 
 
For these analyses, I stratified the CoLaus individuals by BMI into four groups (see also 
Table 2): 
 
1. Overweight (BMI≥25 kg/m2 vs. normal-weight [<25 kg/m2]) – sex stratified  
2. Obesity class I (BMI≥30kg/m2 vs. normal-weight [<25 kg/m2]) – sex stratified 
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3. Obesity class II (BMI≥35 kg/m2 vs. normal-weight [<25 kg/m2]) – sex pooled 
4. Obesity class III (BMI≥40 kg/m2 vs. normal-weight [<25 kg/m2]) – sex pooled  
 
N CONTROLS (M/W) CASES (M/W) TOTAL (M/W)
Overweight 2567 (941/1626) 2867 (1619/1248) 5434 (2560/2874)
Obesity class I 2567 (941/1626) 869 (444/425) 3436 (1385/2051)
Obesity class II 2567 224 2791
Obesity class III 2567 56 2623
 
Table 2: CoLaus individuals stratified by BMI. (N: Number of individuals; M: Men; W: Women) 
 
 
I then considered the following model: 
 
Overweight/obesity vs. normal weight = α + β1(age) +  β2(age²) +  βi(PCi) + β3(SNP) + ε         (1.3) 
 
Here the phenotype is a binary variable and the SNP is coded additively (i.e. dosage of the 
minor allele). The covariates included in the models are: age (untransformed and continuous), 
age² and the ten first principal components.  
 
I then performed for the model (1.3) logistic regression estimating the risk of being a case 
predicted by SNP (additive model), independently for each BMI group and I provided the 
output (as described previously) and additional information (see below) as text files format. 
 
OR: The odds ratio per effect_allele 
CI_lower: The lower 95% confidence limit of OR 
CI_upper: The upper 95% confidence limit of OR 
P: The two-sided p-value for the association 
 
3.6.4 Results and conclusions 
My GWAS results were meta-analyzed with those from 45 other cohorts (more than 240,000 
individuals). Specifically, our collaborators examined associations between BMI and ~2.8 
million SNPs in 123,865 individuals, with targeted follow-up of 42 SNPs in 125,931 
117 117
additional individuals. From the 32 significant loci, they confirmed 14 known obesity-
susceptibility loci and identified 18 new loci associated with BMI (p<5E-8), one of which 
includes a copy number variant near GPRC5. Some loci map near key hypothalamic 
regulators of energy balance, or near GIPR, an incretin receptor. 
 
The 32 confirmed associations found by GIANT, included 19 loci with p < 5E-8, 12 
additional novel loci near RBJ/ADCY3/POMC, QPCTL/GIPR, FANCL, SLC39A8, TMEM160, 
CADM2, LRP1B, MTIF3/GTF3A, ZNF608, PTBP2, RPL27A/TUB, NUDT3/HMGA1, and one 
locus (NRXN3) previously associated with waist circumference. These 19 loci included all ten 
loci from previous GWA studies [81, 100] of BMI, two loci previously associated with body 
weight (FAIM2 and SEC16B) and one locus previously associated with waist circumference 
(near TFAP2B). The remaining six loci, near GPRC5B, MAP2K5/LBXCOR1, TNNI3K, 
LRRN6C, FLJ35779/HMGCR, and PRKD1, have not previously been associated with BMI or 
other obesity-related traits. 
 
Our study increased the number of loci robustly associated with BMI from 10 to 32. Together, 
the 32 confirmed BMI loci explained 1.45% of the inter-individual variation in BMI 
(estimated heritability of 40-70%), with the FTO SNP accounting for the largest proportion of 
the variance (0.34%). This suggests the existence of other genetic markers influencing BMI 
and obesity and/or interactions of these markers with other loci or environmental variables. 
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3.7 The Hypergenes Project 
3.7.1 Background 
Hypergenes is an EU-funded collaborative project. It includes research activities in the areas 
of population genetics, molecular epidemiology, clinical sciences, bioinformatics and health 
information technology, with predicted outcomes in the fields of prevention, early and clinical 
diagnosis and treatment, in addition to increasing the knowledge about the etiology of 
Essential Hypertension (EH) and Target Organ Damages (TOD).  
 
Essential hypertension (also called primary or idiopathic hypertension) is the form of 
hypertension that by definition has no identifiable cause. It is the most common type of 
hypertension, affecting 95% of hypertensive patients [102]. EH refers to a persisting elevated 
blood pressure (BP) with heterogeneous genetic and environmental causes. Prevalence 
increases with age. In developed and developing countries alike, EH affects 25–35% of the 
entire adult population and up to 50% of those beyond the sixth decade of life. EH is a 
powerful risk factor for cardiovascular disease (CVD), the most common cause of morbidity 
and mortality in Europe [103]. Besides being a major risk factor for coronary heart disease 
and renal failure, EH is causally involved in nearly 70% of all strokes, the third commonest 
cause of death worldwide after ischemic heart disease and all types of cancer combined. By 
2020, stroke mortality will have almost doubled. EH contributes pathogenetically to the 
development of both systolic and diastolic heart failure. EH has a strong genetic component 
(from 30% to up to 70% depending to the assumed mode of inheritance [68, 104]), which is 
modulated by several, even though not fully understood [105] environmental influences. It is 
likely that both genetic and non-genetic determinants of hypertension interact differently in 
different populations. 
 
To date, 12 GWAS on blood pressure and hypertension have been published, mostly on 
participants of European origin. Only two of the published studies on blood pressure traits 
(CHARGE BP and Global BP Gen) have identified an association withstanding correction for 
multiple testing genome-wide significance. In total, 14 independent loci have been identified 
so far for blood pressure traits that reached genome-wide significance, including replication in 
independent cohorts [69, 106]. Global BP Gen (n = 34,433) identified association between 
systolic (SBP) or diastolic blood pressure (DBP) and common variants in eight regions near 
the CYP17A1 (p = 7E-24), CYP1A2 (p = 1E-23), FGF5 (p = 1E-21), SH2B3 (p = 3E-18), 
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MTHFR (p = 2E-13), c10orf107 (p = 1E-9), ZNF652 (p = 5E-9) and PLCD3 (p  = 1E-8) 
genes. The CHARGE Consortium (n = 29,136) identified 13 SNPs for SBP, 20 for DBP and 
10 for hypertension at P < 4E-7. The top ten loci for SBP and DBP were incorporated into a 
risk score; mean BP and prevalence of hypertension increased in relation to the number of 
risk alleles carried. When ten CHARGE SNPs for each trait were included in a joint meta-
analysis with the Global BP Gen Consortium (n = 34,433), four CHARGE loci attained 
genome-wide significance (p  < 5E-8) for SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), six 
for DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4) and one for 
hypertension (ATP2B1). 
 
The common variants associated with blood pressure phenotypes have a very small effect 
size. The significant variants so far explain only a very small fraction of the heritability of 
blood pressure traits. The effect sizes of the variants identified are small and currently explain 
about 1% of the phenotypic variability (after correcting for major confounders such as sex, 
age, and body mass index). Rare variants may explain more of the phenotypic variability, it is 
also possible that gene-environment interactions play an important role, but it is currently not 
possible to quantify them [68].  
 
3.7.2 Scope of this project 
The project is focused on the definition of a comprehensive genetic epidemiological model of 
complex traits like Essential Hypertension (EH) and intermediate phenotypes of hypertension 
dependent/associated Target Organ Damages (TOD). To identify the common genetic 
variants relevant for the pathogenesis of EH and TODs, Hypergenes performed a Genome-
Wide Association Study (GWAS) of 4,000 subjects recruited from historical well-
characterized European cohorts. Genotyping was done with the Illumina Human 1M 
BeadChip. Well-established multivariate techniques and innovative genomic analyses through 
machine learning techniques have been used for the GWAS investigations. Using a machine 
learning approach, they aim at developing a disease model of EH integrating the available 
information on EH and TOD with relevant validated pathways and genetic/environmental 
information to mimic the clinician's recognition pattern of EH /TOD and their causes in an 
individual patient. The experimental design included the distinct data generation for two 
datasets in parallel, each with around 1,000 cases and 1,000 controls, followed by a reciprocal 
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replication andjoint analysis. This design is more powerful than replication alone and allows 
also a formal testing of the potential heterogeneity of findings compared to a single step (one 
large sample) design. Association results will be used to build a customized and inexpensive 
genetic diagnostic chip that can be validated in existing cohorts (n=12,000 subjects). 
Designing a comprehensive genetic epidemiological model of complex traits will also help to 
translate the genetic findings into improved diagnostic accuracy and new strategies for early 
detection, prevention and eventually personalized treatment of a complex trait.  
Hypergenes's Scientific and Technological Objectives and expected outcomes are (i) finding 
genes responsible for EH and TOD, using a whole genome association/entropy-based 
approach, (ii) developing an integrated disease model, considering the environment, using an 
advanced bioinformatics approach and (iii) testing the predictive ability of the model to 
identify individuals at risk. 
 
3.7.3 My contribution and results 
In contrast to the four other GWAS collaborations, in this project I was involved in one of the 
first step of a GWAS, which is the genotype calling from the raw chip-data and basic quality 
control (see also section 3.1). For Hypergenes, there were two genotyping centers, one in 
Milan, the other in Geneva. I performed the genotype calling corresponding roughly to half of 
the total sample size, including almost 2000 samples hybridized on Human 1M-Duo v2.0 
BeadChips and scanned with the Illumina iScan® at the Plateforme génomique-NCCR 
Frontiers in Genetics, at the University of Geneva. 
 
These chips interrogate more than 1,100,000 evenly distributed SNPs per sample. The 
Human1M-Duo BeadChip focuses on tag SNPs produced by the International HapMap 
Project, on SNPs in functional gene regions, on SNPs and non-polymorphic markers in 
known and novel copy number regions (CNV), on SNPs mapping in Absorption, Distribution, 
Metabolism and Excretion (ADME) related genes as well as Major Histocompatibility 
Complex (MHC) regions. SNPs in 1M BeadChip have 1.5kb median marker spacing. 
After whole genome amplification, fragmentation of samples genomic DNA, and locus-
specifically hybridized to each individual target on the beads, each SNP was characterized 
through a single-base enzymatic extension assay using two colors labeled nucleotides. After 
the extension, the labels were visualized by staining with a sandwich-based 
immunohistochemistry assay that increases the overall sensitivity of the assay. 
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The protocol ended with the chip scanning process and storage of fluorescence intensities and 
other related scan files. Fluorescence intensities were then extracted and normalized using a 
proprietary normalization method from Illumina's software, Genome Studio, and a Genome 
Studio Project (.bsc file) wad created. Clusters were created for each SNP against a cluster 
reference file (created using a diverse set of over 100 samples from different HapMap 
populations) and genotypes were attributed. Genome Studio calculated sample and SNP 
statistics. Genome Studio calculated the Call Rate/individual and allowed to evaluate sex 
mismatch. The call rate/individual is the percentage of SNPs correctly called over the total 
number of SNPs genotyped. We set a call rate threshold at 0.95 and only samples with call 
above this threshold were used for further analysis of association.  
 
My genotyping activity is summarized in Table 1, where the number of samples genotyped 
divided by cohort and the number of samples with call rate above or below 0.95 are reported. 
 
 
 
Table 1: Overview of the subjects genotyped with call rate <0.95 and call rate >0.95. 
 
Genome Studio allows to estimate the sex of the genotyped subjects, based on the SNPs 
mapping on sex chromosomes. This was a very useful tool to check the concordance between 
sex estimated on genetic data and sex reported in files sent by the Clinical centers. If sex 
inconsistencies were observed and confirmed after having re-checked with the Clinical 
centers, the DNA sample was removed from further statistical analysis of association. 
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Gender estimation and gender check in the sample genotyped in the Geneva center gave the 
results described in Table 2. 
 
 
 
Table 2: Overview of sex mismatches detected.  
 
For each DNA sample, a final report was generated from the .bsc file. This report is the final 
output of Genome Studio genotyping. It is a .csv file and contains genotyping information as 
follows: 
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Table 3: List of parameters included in the final reports generated by Genome Studio, with a brief 
description of their meaning. 
 Raws 7 (Allele1-Top) and raw 8 (Allele2-Top) are the base (nucleotide) call for allele1 and allele 2 and 
represent the genotype at a specific SNP. The GC score (raw 9) is an additional quality parameter. 
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3.7.4 Conclusions 
95.7% of the samples had a genotyping call rate above 0.95. The same procedure was 
performed for the samples genotyped in Milan. In this case, 96.8% of the samples had a call 
rate above 0.95. In total, all genotyping data of the 4061 individuals genotyped were uploaded 
successfully into Hypergenes servers.  
 
The main goal of Hypergenes project is to detect new loci involved in the blood pressure 
traits. Genome-wide association study was therefore carried out using logistic regression 
analysis. The normotensive were healthy subjects above 55 years of age who had been 
followed for a long period with no hypertension detected and the hypertensive were subjects 
with hypertension detected before age of 50 or under hypertensive treatment. From the 
discovery phase, no genome-wide significant association signal has been found within 
Hypergenes. A second stage has been initiated, where 15,000 SNPs have been carried forward 
to replication in around 12,000 individuals. Genotyping should be finished in few weeks. At 
the same time, chromosome Y and mitochondrial haplogroup clustering from the discovery 
phase are investigated in order to identify male/female migration patterns in Europe. 
 
Hypergenes data have also been involved in different ongoing GWAS projects. Hypergenes 
served as a replication cohort in GIANT consortium for height and BMI phenotypes. The 
latter has been described in section 3.6. Hypergenes is also among the discovery cohorts for 
sleeping and resting hearth rate meta-analysis. The replication phase is in progress.  
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Appendix 1: Polymorphisms significantly associated with serum lipids, diabetes mellitus type 
2, and/or obesity in recently published genome-wide analyses. 
 
Appendix 2: Genome-wide meta-analysis for serum calcium identifies significantly 
associated SNPs near the calcium-sensing receptor (CASR) gene. 
 
Appendix 3: Impact of atrial natriuretic peptide gene variants on HDL-cholesterol and other 
metabolic syndrome components in overweight/obese people. (Not available on the online 
version) 
 
Appendix 4: Association analyses of 249,796 individuals reveal eighteen new loci associated 
with body mass index. 
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Polymorphisms significantly associated with serum lipids, diabetes mellitus type 2, 
and/or obesity in recently published genome-wide analyses. 
Note: The rs numbers of the 10 DM2 SNPs that are confirmed in 3 genome-wide analyses that studied genome 
variation using SNPs are highlighted bold. All participants in these genome-wide analyses were of Northern 
European ancestry. While all SNPs are located in genes involved in lipid and/or glucose metabolism, none of the 
indicated SNPs necessarily represents the causal variant – they may, rather, be in LD with or regulate the 
putative causal, functionally relevant variant(s). Most cited studies used gene “chips” covering at least 300K or 
500K SNPs - A study using an array with reduced genome coverage (Affymetrix 100K GeneChip) failed to 
identify any gene-lipid associations.  
 
No. of SNPs that will be included in 
the analysis of the following 
endpoints:  
rs number Gene or 
closest gene 
Phenotyp
e 
predomi-
nantly 
affected 
by 
variant 
allele(s) 
Ref. 
HDL-
C 
Non-
HDL-
C 
TG Glucos
e/DM2 
Met Sy Anthr
opome
tric 
chang
es 
Comments 
rs780094  
 
GCKR TG [1-3]   1  1  glucokinase regulatory protein: regulates 
glucokinase 
rs429358 
rs7412 
 
rs4420638***  
 
rs10402271 
APOE/C1/C4 LDL-C [1-3]  3     Apolipoprotein E, APOE cluster 
 
*** rs4420638 is in strong linkage disequilibrium 
with rs429358 and rs7412 and will therefore not be 
genotyped. 
 
rs708272 and rs7412 were interrogated in Lipogen 
2 [4] 
rs693  
 
rs562338 
rs754523 
 
APOB LDL-C, TG [1-3]  3 3  3  rs693 = APOB C7673T 
 
Only LDL-associated SNP that was not enriched 
in patients with coronary artery disease vs controls 
in [3] 
rs1800775  
 
rs3764261 
rs1864163 
rs9989419 
rs12596776 
rs1566439 
rs708272 
CETP HDL-C 
 
 
 
 
 
 
TG 
[1, 2] 
 
 
 
 
 
 
[4] 
6   
 
 
 
 
 
 
1 
 6  Cholesteryl Ester Transfer Protein 
 
rs1800775 (-629C>A) and rs708272 (279G>A) 
were interrogated in Lipogen 2 [4] 
 
 
 
rs328  
 
rs2197089 
rs6586891 
LPL HDL-C, TG [1-3] 3  3  3  Lipoprotein Lipase, LPL S447X 
 
rs328 was interrogated in Lipogen 2 [4] 
Another SNP is: rs10503669, which is in perfect 
LD with rs328 
 
rs1800588  
rs4775041 
 
LIPC  HDL-C, TG [1-3] 2  2  2  Hepatic Lipase, LIPC C-514T 
 
Another SNP is rs261332, which is in strong LD 
with rs1800588 
rs2266788  
rs12286037 
rs28927680 
rs3135506 
 
rs2854117 
rs45537037rs51
28 
rs662799 
 
APOA5/A4/C3/
A1  
ZNF259, 
BUD13 
HDL-C, TG [2, 3] 
 
 
 
 
 
 
 
[4] 
4  4 
 
 
 
3 
1 
 4  rs2266788 = APOA5 T1259C 
 
rs662799 (APOA5 -1131T>C) and rs3135506 
(APOA5 64C>G) were interrogated in Lipogen 2 
[4] 
 
rs2854117 (APOC3 -482C>T), 
rs45537037 (APOC3 -455T>C), and rs5128 
(APOC3 +3238C>G) were interrogated in Lipogen 
2 [4] 
 11
rs11591147 
 
rs11206510 
 
PCSK9 LDL-C [1, 3]  2      
Another SNP: rs505151 was associated with LDL-
C and stroke in non-genome-wide analyses [5-7]. 
LDL-C association not confirmed in [8] 
 
Proprotein convertase subtilisin/kexin type 9 
 
rs11591147 = E670G = 23968A>G 
rs646776 
 
CELSR2, 
PSRC1, SORT1 
LDL-C [1] 
 
 1     2 additional SNPs contribute to LDL-C; they are in 
strong LD with rs646776: 
rs599838 [1] 
rs599839 [3] 
rs16996148 NCAN, CILP2, 
PBX4 
LDL-C, TG [1, 3] 
 
 1 1  1   
rs4846914 
 
 
GALNT2 HDL-C, TG  
[1, 3] 
1  1  1  Another SNP is rs2144300, which is in perfect LD 
with rs4846914  
rs17145738 BCL7B, TBL2, 
MLXIPL 
TG [1, 3] 
 
  1  1   
rs17321515 TRIB1 TG [1, 3] 
 
  1  1   
rs12130333 
 
rs1748195 
ANGPTL3, 
DOCK7, 
ATG4C 
TG [1, 3] 
 
  2  2   
rs12654264 HMGCR LDL-C [1] 
 
 1      
rs6511720 LDLR LDL-C [1, 3] 
 
 1      
rs3890182 
rs4149268 
 
rs4149313 
ABCA1 HDL-C 
 
 
TG 
[1, 3] 
 
 
[4] 
2   
 
 
 
1 
 2   
 
rs4149313 (2962A>G) was interrogated in 
Lipogen 2 [4] 
rs2156552 
 
rs2000813 
 
 
LIPG, ACAA2 HDL-C 
 
Non-HDL-C 
[1, 3] 
 
[4] 
1  
 
1 
  1   
rs2000813 (584C>T) was interrogated in Lipogen 
2 [4] 
rs2338104 MVK/MMAB HDL-C [3] 1    1   
rs8050136  
 
 
FTO DM2, 
obesity 
[9-11]    1 1 1 risk allele=A, non-risk=C 
 
Fat mass and obesity associated, FTO: a gene of 
unknown function [9] 
 
rs8050136 associated with BMI in DM2 and 
controls, and with waist circumference in cases 
only. DM2 association of rs8050136 disappears 
when adjusted for BMI and waist circumference 
[11] 
 
rs9939609 used in  for all analyses since all other 
SNPs highly correlated and because of 100% 
genotyping success rate. rs9939609 is highly 
correlated with 45 SNPs in the first FTO intron [9] 
 
Hapmap population frequency of risk allele was 
0.45 in Europeans, 0.14 in Japanese and Chinese 
[9] 
rs4430796 
 
TCF2 DM2 [12]    1 1  No anthropometric information  
 
rs7903146  
 
 
TCF7L2 DM2 [2, 10, 
11, 13] 
   1 1  risk allele= T, non-risk=C.  
 
Transcription factor 7-like 2 
 
Variant with the highest odds ratio for DM2 
(1.37), substantially higher than the other “DM2 
variants”. 
 
A second SNP in strong LD with rs7903146 is: 
rs7901695 [11] 
 22
rs13266634  
 
SLC30A8 DM2 [2, 10, 
11, 13, 
14] 
   1 1  risk allele=C, non-risk=T 
 
Solute carrier family 30, member 8 
 
SLC30A8 R325W 
rs1111875 
 
 
IDE-KIF11-
HHEX 
DM2 [2, 10, 
11, 13] 
   1 1  risk allele=C, non-risk=T 
 
Contained in an LD block containing insulin 
degrading enzyme (IDE), the homeodomain 
protein HHEX, and the kinesin-interacting factor 
KIF11 
 
Additional risk alleles in this LD block are: 
rs5015480 
rs7923837 
 
rs9300039  
 
EXT2-ALX4-
LOC387761 
DM2 [10, 13]    1 1  Contained in an LD block containing genes 
potentially involved in beta cell function or 
development 
 
rs9300039 is located in an intergenic region on 
chromosome 11; in zero LD with rs7480010 [10]; 
in LD with 58 SNPs [10] (risk allele=C, non-
risk=A) 
 
Additional risk alleles in this LD block are: 
 
3 SNPs located in introns of exostosin 2 (EXT2) 
(rs3740878, rs11037909 and rs1113132); 
rs7480010 (in/near a hypothetical gene 
LOC387761) [13]; NB: DM2 association of 
rs7480010 not replicated in [10]; DM2 association 
of the 3 intronic variants of EXT2 not replicated in 
[13] 
rs10811661  
 
CDKN2A/B DM2 [2, 10, 
11] 
   1 1  risk allele=T, non-risk=C 
 
Cyclin dependent kinase inhibitor 2A/B 
 
A second SNP in strong LD with rs 10811661 is: 
rs564398  
rs4402960  
  
IGF2BP2 DM2 [2, 10, 
11] 
 
[2] for 
rs14705
79 
   1 1  risk allele=T, non-risk=G 
 
insulin-like growth factor 2 mRNA-binding 
protein 2 
 
A second SNP in strong LD with rs4402960  
is: rs1470579 
rs7754840  
 
CDKAL1 DM2 [2, 10, 
11, 14] 
    1  risk allele=C, non-risk=G 
 
CDK5 regulatory subunit-associated protein 1-like 
1 
 
associated with waist circumference in DM2 cases 
but not controls  [11] 
 
Two additional SNPs in strong LD with rs7754840 
are: rs10946398, rs7756992 
Rs5219  
 
KCNJ11 DM2 [2, 10, 
11, 15] 
   1 1  risk allele=T, non-risk=C (=KCNJ11 E23K) 
 
Potassium Channel, Inwardly Rectifying, 
Subfamily J, Member 11 
 
A second SNP in strong LD with rs5219 is rs5215 
[2] 
rs1801282 PPARG DM2 [2, 10, 
11, 16] 
 
   1 1  risk allele=C, non-risk=G = PPARG P12A 
 
Peroxisome proliferative activated receptor, 
gamma, PPARG 
 
[16]: not a genome-wide analysis 
 33
rs10010131 
rs6446482  
 
WFS1 DM2 [17]    2 2  not a genome-wide analysis 
 
Wolframin, mutations of which are associated with 
Wolfram syndrome, characterized by DM and 
diabetes insipidus 
 
P-values for DM2 association of the two SNPs are, 
respectively, 1.4 x10-7 and 3.4 x10-7 
Total Number of SNPs genotyped for 
each metabolic endpoint 
20 13 25 12 42 1  
 
 44
References 
 
1. Kathiresan, S., et al., Six new loci associated with blood low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat 
Genet, 2008. 40(2): p. 189-97. 
2. Saxena, R., et al., Genome-wide association analysis identifies loci for type 2 diabetes 
and triglyceride levels. Science, 2007. 316(5829): p. 1331-6. 
3. Willer, C.J., et al., Newly identified loci that influence lipid concentrations and risk of 
coronary artery disease. Nat Genet, 2008. 40(2): p. 161-9. 
4. Arnedo, M., et al., Contribution of 20 single nucleotide polymorphisms of 13 genes to 
dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics, 2007. 
17(9): p. 755-64. 
5. Abboud, S., et al., Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a 
risk factor of large-vessel atherosclerosis stroke. PLoS One, 2007. 2(10): p. e1043. 
6. Chen, S.N., et al., A common PCSK9 haplotype, encompassing the E670G coding 
single nucleotide polymorphism, is a novel genetic marker for plasma low-density 
lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll 
Cardiol, 2005. 45(10): p. 1611-9. 
7. Evans, D. and F.U. Beil, The E670G SNP in the PCSK9 gene is associated with 
polygenic hypercholesterolemia in men but not in women. BMC Med Genet, 2006. 7: 
p. 66. 
8. Kotowski, I.K., et al., A spectrum of PCSK9 alleles contributes to plasma levels of 
low-density lipoprotein cholesterol. Am J Hum Genet, 2006. 78(3): p. 410-22. 
9. Frayling, T.M., et al., A common variant in the FTO gene is associated with body 
mass index and predisposes to childhood and adult obesity. Science, 2007. 316(5826): 
p. 889-94. 
10. Scott, L.J., et al., A genome-wide association study of type 2 diabetes in Finns detects 
multiple susceptibility variants. Science, 2007. 316(5829): p. 1341-5. 
11. Zeggini, E., et al., Replication of genome-wide association signals in UK samples 
reveals risk loci for type 2 diabetes. Science, 2007. 316(5829): p. 1336-41. 
12. Gudmundsson, J., et al., Two variants on chromosome 17 confer prostate cancer risk, 
and the one in TCF2 protects against type 2 diabetes. Nat Genet, 2007. 39(8): p. 977-
83. 
13. Sladek, R., et al., A genome-wide association study identifies novel risk loci for type 2 
diabetes. Nature, 2007. 445(7130): p. 881-5. 
14. Steinthorsdottir, V., et al., A variant in CDKAL1 influences insulin response and risk 
of type 2 diabetes. Nat Genet, 2007. 39(6): p. 770-5. 
15. Florez, J.C., et al., Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K 
and ABCC8 A1369S influence progression to diabetes and response to interventions 
in the Diabetes Prevention Program. Diabetes, 2007. 56(2): p. 531-6. 
16. Florez, J.C., et al., Effects of the type 2 diabetes-associated PPARG P12A 
polymorphism on progression to diabetes and response to troglitazone. J Clin 
Endocrinol Metab, 2007. 92(4): p. 1502-9. 
17. Sandhu, M.S., et al., Common variants in WFS1 confer risk of type 2 diabetes. Nat 
Genet, 2007. 39(8): p. 951-3. 
 
 
 55
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Abstract
Calcium has a pivotal role in biological functions, and serum calcium levels have been associated with numerous disorders
of bone and mineral metabolism, as well as with cardiovascular mortality. Here we report results from a genome-wide
association study of serum calcium, integrating data from four independent cohorts including a total of 12,865 individuals
of European and Indian Asian descent. Our meta-analysis shows that serum calcium is associated with SNPs in or near the
calcium-sensing receptor (CASR) gene on 3q13. The top hit with a p-value of 6.3610-37 is rs1801725, a missense variant,
explaining 1.26% of the variance in serum calcium. This SNP had the strongest association in individuals of European
descent, while for individuals of Indian Asian descent the top hit was rs17251221 (p = 1.1610-21), a SNP in strong linkage
disequilibrium with rs1801725. The strongest locus in CASR was shown to replicate in an independent Icelandic cohort of
4,126 individuals (p = 1.02610-4). This genome-wide meta-analysis shows that common CASR variants modulate serum
calcium levels in the adult general population, which confirms previous results in some candidate gene studies of the CASR
locus. This study highlights the key role of CASR in calcium regulation.
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Introduction
Calcium is the most abundant mineral in the human body
contributing approximately one kilogram to the average adult
human body mass. Whereas 99% of calcium is stored in the
skeleton and teeth, the remaining 1% circulates in the bloodstream
and is involved in many physiological processes including its
function as a universal cellular signaling molecule [1–2]. Calcium
plays a key role in membrane potential, which is important for
muscle contraction, heart rate regulation and generation of nerve
impulses. Calcium also influences bone metabolism, ion transport
and many other cellular processes [3]. Approximately 2/5 of
calcium in the extracellular fluid is found in blood serum. The
level of serum calcium is under tight hormonal control with a
normal concentration of 2.15–2.55 mmol/L. Serum calcium is
under strong genetic control, with twin studies showing that the
variance in total calcium due to genetic effects is between 50% and
78% [4–5].
While skeletal calcium is important in numerous clinical
disorders, in particular bone and mineral disorders, the clinical
role of serum calcium is less clear. Several [6–7] (but not all [8])
studies indicated that elevated serum calcium levels are associated
with an increased risk of cardiovascular disease. Patients with
hyperparathyroidism, who suffer from chronic hypercalcemia,
have a high prevalence of hypertension and increased cardiovas-
cular mortality [9–11]. However, the mechanisms underlying the
putative association of serum calcium with increased cardiovascu-
lar morbidity and mortality remain unclear.
Rare monogenic forms of hypo- or hypercalcemia have been
described, including disorders involving the calcium-sensing
receptor (CASR, locus 3q13) gene. Heterozygous and homozy-
gous CASR mutations that inactivate CASR are responsible,
respectively, for familial hypocalciuric hypercalcemia, type 1
(also known as familial benign hypercalcemia) (OMIM
#145980) [12–13] and neonatal severe hyperparathyroidism
(OMIM #239200) [13]. On the other hand, mutations that
result in CASR activation lead to autosomal dominant
hypocalcemia (OMIM #146200) [14]. Mutations in many
other genes have also been found to lead to disturbances of
serum calcium levels (Table 1).
In the present study, we report results obtained from meta-
analysis of genome-wide associations of serum calcium levels from
four cohorts with a total of 12,865 participants. We first describe
the design of the study and its main finding, that variants in CASR
give rise to the strongest signals associated with serum calcium
levels in both European and Indian Asian populations. Our results
confirm previous studies showing that mutations in CASR
are associated with serum calcium levels in young healthy women
[15–16] and extend this observation to men and women across a
large spectrum of age. We show that CASR is a key player in the
genetic regulation of serum calcium in men and women from the
general adult population.
Results
We performed a meta-analysis for genome-wide associations of
serum calcium, determined by subtracting the estimated amount
of calcium bound to albumin from the total serum calcium, to infer
the amount of ionized calcium (see Materials and Methods). Our
study included four cohorts: (i) 5404 European individuals from
the Cohorte Lausanne (CoLaus) [17–18], (ii) 5548 European and
Indian Asian individuals from the London Life Sciences
Population (LOLIPOP) Study from West London UK [19–20],
(iii) 1196 European individuals from the InCHIANTI Study
(Tuscany, Italy) [21], and (iv) 717 individuals of European descent
from the Baltimore Longitudinal Study of Aging (BLSA) study
based in the Baltimore-Washington DC area [22], totaling 12,865
participants (see Table 2 for more detailed characteristics of each
cohort).
Genome-wide association scans were performed first indepen-
dently for each cohort using linear regression and then the effect
sizes from each cohort were meta-analyzed (see Materials and
Methods). Due to the possibility of population substructure
obscuring effects of genetic variants, meta-analysis was performed
separately for (i) combined European and Indian Asian cohorts
(N= 12,865) and restricted to cohorts of (ii) European
(N= 8,919), and (iii) Indian Asian descent (N= 3,947). The
meta-analyses yielded 100 SNPs from the combined cohorts, 70
SNPs when restricting to European cohorts and 22 SNPs
restricting to Indian Asian cohorts that exceeded the genome-
wide significance threshold of 5610-8 (Figure 1A–1C) (the full list
is provided in Table S2A, S2B, S2C). All SNPs reaching statistical
significance clustered around the CASR locus at 3q13. The most
significant SNP in the (i) combined and (ii) European meta-
analyses was rs1801725 (p = 6.29610-37, p = 2.58610-18, respec-
tively) and in the (iii) Indian Asian meta-analysis was rs17251221
(p = 1.07610-21). These two SNPs are less than 11 kb apart and
are in high linkage disequilibrium with each other (r2 = 0.946,
0.494, 1.0, 1.0 in HapMap CEU, CHB, JPT, YRI, respectively),
and therefore most likely derive from the same association signal.
We find that rs1801725 explains 1.26% of the variance in serum
calcium, with the effect sizes and standard errors of the serum
calcium increasing T allele in individual cohorts shown in Figure 2
and Table S3. According to our additive model, each rs1801725
T allele increases log10 serum calcium (in units mmol/L) by
3.61610-3, equivalent to a multiplicative effect of 1.008 on serum
calcium (see also Table S2). At an average serum calcium level of
2.25 mmol/L, each rs1801725 T allele yields an increase of
0.01874 mmol/L, or 21% of one standard deviation of serum
calcium levels in a normal population. The regional pattern of
association of SNPs around the CASR locus, and their linkage
disequilibrium with rs1801725, are shown in Figure 3. Of note,
rs1042636, which has been associated with decreased serum
calcium [23], also achieved genome-wide significance with the G
minor allele associated with decreased serum calcuim
(p= 4.96610-9). However, conditional on the rs1801725 locus,
located 12 bps upstream, the rs1042636 p-value became
3.3261024, indicating that the two loci share contributions to
serum calcium levels.
To confirm the rs1801725 signal, we analyzed the association
pattern with serum calcium in a separate cohort. We used a
subset of 4,126 Icelandic individuals from the deCODE study
[24–25] with serum calcium measurements. We found the
rs1801725 T allele to be strongly associated with increased
serum calcium (p= 1.02610-4), replicating the key meta-analysis
result.
While only the CASR locus reached nominal genome-wide
significance for association with serum calcium, the top regions
with p,10-5 are shown in Table 3. These SNPs cover 12 regions,
the significance of which is displayed across cohorts in Figure S3.
There were no SNPs in other candidate genes (which have
previously been shown to be involved in disorders associated with
disturbed serum calcium levels) that were associated with serum
calcium at genome-wide significance. The most significant SNPs
within 500 kb of the gene transcripts are shown in Table 1.
Considering the set of 18,611 distinct SNPs mapping to the set of
serum calcium candidate genes excluding CASR, we find no
significant association (at significance level 0.05 and applying the
Serum Calcium Meta-Analysis
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Bonferroni correction for multiple testing, giving a cut-off p-value
of 2.69610-6, see also Figure S4). Indeed, fixing the sample size
and genome-wide significance threshold our study is well-powered
($0.80) to detect SNPs explaining at least 0.31% of the variance.
Therefore the common SNPs within the candidate genes
(excluding CASR) likely play at best a small role in serum calcium
regulation.
We analyzed the association of the top SNP with several
calcium-related outcomes (coronary heart disease, myocardial
infarction, hypertension, stroke, osteoarthritis, osteoporosis and
kidney stones). The number of cases and controls for each
outcome and each cohort is given in Table S4. Logistic regression
including age and pseudosex (see Materials and Methods) as
covariates did not find any significant association between
rs1801725 and the calcium-related outcomes, after correcting for
multiple testing (effect sizes and standard errors for the T allele are
listed in Table S5). Power calculations show that given the sample
sizes for the clinical traits above, our study has good power ($0.80)
to detect odds ratios of 1.20, 1.13, 1.77, 1.27, 1.27, 1.24 and 1.75,
respectively. As the smallest p-values from calcium-related traits
were for osteoarthritis and osteoporosis (bonferroni-corrected
p= 0.21, 0.44, respectively), we further investigated bone density
traits. None of deCODE hip bone mineral density or spine bone
mineral density (N= 6657 and 6838, respectively) nor In-
CHIANTI total bone density, trabecular bone density, cortical
bone density, cortical bone thickness or cortical bone area
(N= 1196) bonferroni-adjusted p-values for eight traits were
significant.
Discussion
This genome-wide scan of 12,865 individuals revealed CASR as
the most significant (and only genome-wide significant) locus
influencing serum calcium levels. Specifically, we found evidence
for a strong association of SNPs located in the CASR locus with
serum calcium levels in both Europeans and Indian Asians. The
strongest locus in CASR was further shown to replicate in an
independent Icelandic cohort of 4,126 individuals.
The top signal (rs1801725, 2956G.T) explains 1.26% of the
variance in serum calcium. Indeed, this is similar to results from
other GWAS of human height [26–29], body mass index [30–31],
serum urate [32–34] and serum lipid concentrations [34–36], for
which the genome-wide significant loci uncovered thus far
collectively explain only a small fraction of the phenotypic
variance (usually at least one order of magnitude less than the
total additive genetic variance estimated from heritability studies
[37–38]). The rs1801725 T allele (A986S) was associated with
higher serum calcium, consistent with previous findings (see Table
S6). The rs1801725 polymorphism (with T allele frequencies of
16.76%, 19.98% in European and Indian Asian cohorts,
respectively) affects serum calcium levels of a substantial
proportion of the population.
The rs1801725 polymorphism encodes a missense variant in
exon 7 of the CASR gene, which leads to a non-conservative
amino-acid change (serine substitution for alanine-986, A986S
corresponding to nucleotides 2956G.T) in the cytoplasmic tail of
CASR. In vitro studies showed that mutations within the C-
terminal tail may influence several aspects of CASR function,
such as signal transduction, intracellular trafficking and cell
surface expression [39–41]. However, PolyPhen predicts
rs1801725 to be a benign substitution. It is presently unclear
whether this substitution gives rise to functional variants, as
functional studies have yielded conflicting results [42–43]. Deep
sequencing of this region may help identifying the causal variants.
While it is still not possible to infer a direct causal role, it is of
interest to note that the SNP gives rise to an amino acid change
in the C-terminal tail of CASR, a domain which plays a key role
in the receptor function and may potentially influence intracel-
lular trafficking following CASR activation by extracellular
calcium.
Several studies have reported associations of A986S and
nearby CASR mutations with various phenotypes. The A986S
CASR polymorphism has been associated with variations in
circulating calcium levels in healthy adults in some studies
[15,23,44–45], but not in others [46–47]. The fact that the latter
studies were underpowered (sample size ranging from 148 to
1252) to detect a small effect size likely explains these inconsistent
results. The rs1042636 (R990G) polymorphism has been
associated with the magnitude of parathyroid hormone (PTH)
secretion in patients with primary hyperparathyroidism [48], and
preliminary results suggest that it could influence response to
cinacalcet, a calcimimetic used to treat secondary hyperparathy-
roidism in patients with end-stage renal disease [49]. In a meta-
analysis, 986S was associated with a 49% increased risk
(P = 0.002) of primary hyperparathyroidism [47,50–51]. Among
patients with primary hyperparathyroidism, the AGQ haplotype
(i.e. 986A, 990G, 1011Q, which is associated with lower serum
calcium levels and hypercalciuria [52]) was associated with
increased risk, and the SRQ haplotype with decreased risk, of
kidney stones [50].
CASR has been previously considered as a candidate gene for
osteoporosis [53] and coronary heart disease as well as increased
total and cardiovascular mortality [54]. In our meta-analysis, we
found no significant association of rs1801725 with these calcium-
related phenotypes. A recent meta-analysis focusing on effects of
candidate genes on osteoporosis also reports negative results for
CASR [55]. Furthermore, results on the association of elevated
serum calcium with increased cardiovascular risk in the general
population are controversial [6–8]. It is therefore not clear to
what extent serum calcium might predict cardiovascular risk. The
SNPs identified in this meta-analysis could serve as genetic
instruments in future studies, such as Mendelian randomization
analysis in longitudinal cohorts, to further investigate the causal
effect of serum calcium on osteoporosis and on cardiovascular
disease risk (see Table S5 for rs1801725 effects and standard
errors).
Our meta-analysis suffers from some limitations. First, we used
corrected serum calcium and not directly measured ionized serum
calcium. The correlation between corrected serum calcium and
Author Summary
Calcium levels in blood serum play an important role in
many biological processes. The regulation of serum
calcium is under strong genetic control. This study
describes the first meta-analysis of a genome-wide
association study from four cohorts totaling 12,865
participants of European and Indian Asian descent.
Confirming previous results in some candidate gene
studies, we find that common polymorphisms at the
calcium-sensing receptor (CASR) gene locus are associated
with serum calcium concentrations. We show that CASR
variants give rise to the strongest signals associated with
serum calcium levels in both European and Indian Asian
populations, while no other locus reaches genome-wide
significance. Our results show that CASR is a key player in
genetic regulation of serum calcium in the adult general
population.
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ionized serum calcium varies between 0.66 and 0.87 [56–58]. We
can hypothesize that the association of ionized serum calcium with
CASR variants would be stronger than the one with corrected
serum calcium because ionized calcium is the form physiologically
active on CASR. Second, data on serum phosphate, PTH or
vitamin D are not available, so that we cannot explore further
these relationships. Third, sample sizes for calcium-related clinical
traits were limited, many clinical traits in CoLaus were self-
reported instead of clinically diagnosed, and we incur a multiple
testing penalty due to the number of clinical traits posited to be
associated with serum calcium. However, the major strengths of
the study are the hypothesis-free nature of GWAS studies, the
large sample meta-analysis and the inclusion of multiple
populations.
Materials and Methods
Cohorts
CoLaus is a population-based sample from Lausanne,
Switzerland, consisting of 5435 individuals between 35 and 75
years old (after QC) of which a subset of 5404 had available
serum calcium measurements. The study design and protocols
have been described previously [17–18]. The CoLaus study was
approved by the Institutional Ethic’s Committee of the University
of Lausanne. The London Life Sciences Prospective Population
Study (LOLIPOP) is an ongoing population-based cohort study
of ,30,000 Indian Asian and European white men and women,
aged 35–75 years living in West London, United Kingdom [59].
All study participants gave written consent including for genetic
studies. The LOLIPOP study is approved by the local Research
Ethics Committee. The participants included in the present study
are a subset of 3947 Indian Asians and 1601 Europeans from the
LOLIPOP cohort study. LOLIPOP individuals are separated by
origin as well as the genotyping platform, with IAA, IAI or IAP
denoting Indian Asians genotyped on Affymetrix, Illumina or
Perlegen platforms, respectively, and EWA and EWI denoting
Europeans genotyped on Affymetrix or Illumina platforms,
respectively (see Table S1). The InCHIANTI study is a
population-based epidemiological study aimed at evaluating the
factors that influence mobility in the older population living in
the Chianti region in Tuscany, Italy. The details of the study have
been previously reported [60]. Overnight fasted blood samples
were taken for genomic DNA extraction, and measurement of
serum calcium. For this study, 1196 subjects with serum calcium
and GWAS data were analyzed. The study protocol was
approved by the Italian National Institute of Research and Care
of Aging Institutional Review and Medstar Research Institute
(Baltimore, MD). The Baltimore longitudinal study on Aging
(BLSA) study is a population-based study aimed to evaluate
contributors of healthy aging in the older population residing
predominantly in the Baltimore-Washington DC area [61].
Starting in 1958, participants are examined every one to four
years depending on their age. Blood samples were collected for
DNA extraction. This analysis focused on a subset of the
participants (N= 717) of European ancestry. The BLSA has
continuing approval from the Institutional Review Board (IRB) of
Medstar Research Institute. Approval was obtained from local
ethic committees for all studies and all participants signed
informed written consent. The deCODE study consists of
individuals who visited a private outpatient laboratory, the
Laboratory in Mjodd, Reykjavik, Iceland between 1997 and
2008. The main referral center for this laboratory is a
multispecialty medical clinic in Reykjavik (Laeknasetrid). For
the serum calcium analysis we used information on 4,126
individuals with both genome-wide SNP data and measured
serum calcium and serum albumin. The samples for bone density
analysis have previously been described in detail [24–25]. For this
study 6,657 individuals with total hip bone mineral density
(BMD) and 6,838 individuals with lumbar spine BMD and SNP
data were available for analysis. All participants gave informed
consent and the study was approved by the Data Protection
Commission of Iceland (DPC) and the National Bioethics
Committee of Iceland.
Clinical data
For each CoLaus participant a venous blood sample was
collected under fasting conditions. Measurements were conducted
using a Modular P apparatus (Roche Diagnostics, Switzerland).
Total serum calcium was measured by O-cresolphtalein (2.1% –
1.5% maximum inter and intra-batch CVs); albumin was
Table 2. Characteristics of participants, by study.
CoLaus
LOLIPOP
European Whites
LOLIPOP Indian
Asians InCHIANTI BLSA deCODE
Sample size 5404 1601 3947 1196 717 4126
Gender (males/females) 2542/2862 1397/204 3832/115 533/663 390/327 1313/2813
Age
(years)*
53.43
(34.9,75.4)
54.5
(22.6,75.0)
50.7
(35.0,74.9)
68.22
(21,102)
70.4
(22,98)
60.1
(7,103)
Pre/Post menopause 1210/1652 100/104 56/59 79/584 38/289 872/1836 (105 with pre
and post measurements)
Serum calcium
(mmol/L)*
2.29
(0.094)
2.41
(0.12)
2.37
(0.11)
2.36
(0.10)
2.31
(0.11)
2.38
(0.14)
Corrected serum
Calcium (mmol/L)*
2.18
(0.09)
2.31
(0.09)
2.29
(0.09)
2.30
(0.09)
2.30
(0.1)
2.31
(0.14)
Serum albumin
[g/L]*
44.2
(2.5)
43.7
(2.9)
43.4
(2.9)
42.3
(3.1)
40.4
(3.5)
42.9
(3.9)
Characteristics are shown for CoLaus, LOLIPOP European, LOLIPOP Indian Asian, InCHIANTI, BLSA and deCODE. Corrected serum calcium, designed to estimate the
amount of biologically active serum calcium, is defined as Ca_corrected = total serum calcium [mmol/L] + (40 - albumin [g/L])/40.
*Values represent mean (range) or mean (sd).
doi:10.1371/journal.pgen.1001035.t002
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measured by bromocresol green (2.5% – 0.4%). To further
characterize the identified genetic variants, we analyzed the
association with several outcomes postulated to be correlated with
serum calcium. Within the CoLaus study, we have questionnaire
responses to queries about personal histories of osteoporosis,
osteoarthritis, myocardial infarction and stroke in addition to
clinical data determining hypertension status, defined as previ-
ously described [17]. The assessment of LOLIPOP study
participants was carried out by a trained research nurse, during
a 45 minute appointment according to a standardized protocol
and with regular QC audits. An interviewer-administered
questionnaire was used to collect data on medical history, family
history, current prescribed medication, and cardiovascular risk
factors. Physical assessment included anthropometric measure-
ments (height, weight, waist, hip) and blood pressure. Blood was
collected after an 8 hour fast for biochemical analysis, including
glucose, insulin, total and HDL cholesterol and triglycerides, and
whole blood was taken for DNA extraction [59]. InCHIANTI
serum albumin concentrations were determined as percentage of
total protein using agarose electrophoretic technique (Hydragel
Protein (E) 15/30, Sebia, Issy-les-Moulineaux, France). Serum
calcium was measured using calorimetric assay (Roch Diagnostic,
GmbH, Mannheim, Germany) by a Roche-Hitachi autoanalyzer
(The intra-assay CV and 0.9% and the inter-assay CV was 1.5%).
Measures of bone density, bone dimensions and osteoporosis
diagnosis were assessed by peripheral quantitative computed
tomography (pQCT) using the XCT 2000 device (Stratec
Medizintechnik, Pforzheim, Germany) [62]. BLSA albumin
concentrations were measured by a calorimetric assay using
bromocresol green (Ortho-Clinical Diagnostics). Calcium
concentrations were measured by a calorimetric assay (Vitros
5,1,FS).
Genome-wide genotyping and imputation
CoLaus participants were genotyped using Affymetrix Hu-
man Mapping 500 K Array. For the genome-wide association
stage, genotyping in LOLIPOP participants was carried out
using the Illumina 317 K mapping array, Affymetrix Human
Mapping 500 K array, and Perlegen, 284 K platforms (Table
S1). Participants of the InCHIANTI and BLSA studies were
genotyped using Illumina Infinium HumanHap 550 K SNP
arrays were used for genotyping [21]. Imputation of allele
dosage of SNPs was performed using either MACH [63] or
IMPUTE [64] with parameters and quality control filters as
described in Table S1. All European cohorts imputed SNPs
typed in the HapMap CEU population; LOLIPOP Indian Asian
cohort imputed SNPs using mixed HapMap populations, given
that this showed greater concordance with real genotypes
compared with use of any one HapMap population. SNPs were
excluded if cohort-specific imputation quality as assessed by
r2.hat (MACH) or .info (IMPUTE) metrics were ,0.30. In
total, 2,557,252 genotyped or imputed SNPs had data from one
or more cohorts and were analyzed. Genotypes in deCODE
were measured using either humanHap300, humanHap300-duo
or humanCNV370.
Statistical analysis
Individual genome-wide association analysis. Biologically
active serum calcium is estimated by the correction, Ca_corrected
= total serum calcium [mmol/L] + (40 - albumin [g/L])/40. Indi-
viduals with values,1.9 or.3 were removed as these were extreme
outliers. Linear-regression analyses were carried out using an
additive genetic model on log10-transformed corrected calcium
levels adjusted for age and pseudosex (a factor variable with three
values: males, pre-menopausal females and post-menopausal
females). BLSA also included the first two and LOLIPOP
included the first four ancestry principal components in the
regression, respectively. Regression analyses were performed with
QUICKTEST [65] (CoLaus), MACH2qtl (LOLIPOP) [63] or
MERLIN [66] (InCHIANTI, BLSA).
Meta-analysis. The results from all cohorts were combined
into a fixed-effects meta-analysis using inverse variance
weighting. Tests for heterogeneity were assessed using
Cochran’s Q statistic and the log of the related H statistic [67]
after grouping LOLIPOP subsets into European and Indian
subsets. For rs1801725 and rs1042636 the p-values were
(0.07657, 0.1432) and (0.3450, 0.8876), respectively, indicating
Figure 1. Genome-wide association results. Manhattan plots
showing significance of association of all SNPs in the meta-analysis for
(A) combined European and Indian Asian cohorts, (B) European cohorts
only and (C) Indian Asian cohorts only. SNPs are plotted on the x-axis
according to their position on each chromosome against association
with serum calcium concentrations on the y-axis (shown as 2log10 p-
values).
doi:10.1371/journal.pgen.1001035.g001
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limited between-study variability. The analysis was implemented
in R and run on a quad-core Linux machine. SNPs were reported
provided they had effect size estimates in at least 2 of the 5
European cohorts, in at least 2 of the 3 Indian Asian cohorts, or
in at least 3 of the 8 total cohorts. For the overall meta-analysis,
residual inflation of the test statistic was corrected using genomic
control [68]. The inflation factor was 1.0207 for the all combined
cohorts, 1.0068 for European cohorts and 1.0286 for Indian
Asian cohorts. Where reported, individual study p-values are
corrected for inflation using genomic control methods for
genotyped and imputed SNPs combined (inflation factors for
individual studies were 1.0139 (CoLaus), 0.9891 (LOLIPOP
EWA), 0.9994 (LOLIPOP EWP), 0.9967 (LOLIPOP IAA),
1.0131 (LOLIPOP IAI), 0.9985 (LOLIPOP IAP), 0.9842
(InCHIANTI), 1.0019 (BLSA)). The regional association plot
(Figure 3) was created modifying a publically available R script
[69]. The map of fine-scale recombination rates was downloaded
from the HapMap website http://www.hapmap.org/downloads/
recombination/ using Phase II HapMap data (release 21).
Quantile-quantile plots of the association results are shown in
Figure S1A, S1B, S1C, study-specific quantile-quantile plots are
shown in Figure S2. Associations below p= 561028 were
Figure 2. Comparison of rs1801725 significance across cohorts. The effect size and 95% confidence intervals of the serum calcium
increasing T allele of SNP rs1801725 are shown separately for each cohort (CoLaus, LOLIPOP_EWA, LOLIPOP_EWP, LOLIPOP_IAA, LOLIPOP_IAI,
LOLIPOP_IAP, BLSA, InCHIANTI) and for the replication cohort deCODE. European cohorts are shown in blue and Indian Asian cohorts are drawn
in green. The size of the box is proportional to the precision 1/se2 and the meta-analysis estimate and 95% confidence interval across all cohorts
is given by a diamond.
doi:10.1371/journal.pgen.1001035.g002
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considered genome-wide significant, which corresponds to a
Bonferroni correction for the estimated one million independent
common variant tests in the human genome of European
individuals [70]. The analysis of osteoporosis status in CoLaus
and InCHIANTI was performed using logistic regression
including age and pseudosex as covariates in QUICKTEST
[65]. Linkage disequilibrium was estimated from HapMap CEU
(2007-01, build 35 non-redundant) genotypes. LD r2 statistics
were estimated for SNPs within 500 kb using Haploview [71].
Association of rs1801725 with calcium-related out-
comes. For each related trait (coronary heart disease,
hypertension, kidney stones, myocardial infarction, osteoarthritis,
osteoporosis and stroke) we performed a fixed-effects meta-analysis
of the logistic regression coefficients. We applied the bonferroni
correction to adjust for multiple testing. We performed Wald-
based power calculations using a type I error of 0.05/7 and meta-
analysis coefficient estimates and standard errors to estimate the
sample size for each trait giving power 0.80.
Figure 3. Regional association plot of the CASR locus. Plots show genomic position on the x-axis and 2log10 p-values on the y-axis for
SNPs in the CASR locus on chromosome 3. The sentinel hit is shown as a red square. Patterns of linkage disequilibrium between the sentinel SNP
and all other SNPs are color-coded. Red circles indicate high correlation (r2.0.8), green circles indicate moderate correlation (r2.0.5), blue
circles indicate low correlation (r2.0.2) and black circles indicate no correlation (r2,0.2). The fine-scale recombination rates from [72–73] are
plotted in light blue.
doi:10.1371/journal.pgen.1001035.g003
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Supporting Information
Figure S1 Quantile-Quantile plots of genome-wide association
results. Observed -log10 p-values on the y-axis are plotted against
theoretical -log10 p-values on the x-axis resulting from each meta-
analysis. Results are color-coded by chromosome. The top results
largely derive from the CASR locus on chromosome 3. Results are
shown separately for (A) all cohorts, (B) European cohorts and (C)
Indian Asian cohorts.
Found at: doi:10.1371/journal.pgen.1001035.s001 (6.48 MB TIF)
Figure S2 Study-specific quantile-quantile plots. Shown are
observed -log10 p-values plotted against expected -log10 p-values
resulting from each single study after applying genomic control
correction. The study-specific l-values were l=1.0139 (CoLaus),
l=0.9891 (LOLIPOP_EWA), l=0.9994 (LOLIPOP_EWP),
l=0.9967 (LOLIPOP_IAA), l=1.0131 (LOLIPOP_IAI),
l=0.9985 (LOLIPOP_IAP), l=0.9842 (InCHIANTI),
Table 3. Significance of top SNPs.
Combined European and Indian Asian Cohorts
db SNP Chr
Position
(Build 35)
Coded
Allele
Non-
Coded
Allele
Frequency
Coded Allele Beta Se
Lower 95%
CI
Upper 95%
CI P-value R2
rs1801725 3 123486447 T G 17.75 3.61E-03 2.81E-04 3.06E-03 4.16E-03 6.29E-37 0.0126
rs17120351 8 14731368 T C 96.24 4.03E-03 7.67E-04 2.52E-03 5.53E-03 2.06E-07 0.0021
rs7448017 5 117800594 T G 17.83 -1.73E-03 3.57E-04 -2.43E-03 -1.03E-03 1.65E-06 0.0018
rs742393 1 25271187 G A 78.86 2.11E-03 4.44E-04 1.24E-03 2.98E-03 2.41E-06 0.0018
rs16827695 1 40956147 G A 94.52 3.46E-03 7.41E-04 2.01E-03 4.92E-03 3.74E-06 0.0017
rs1550532 2 234046848 G C 74.24 -1.15E-03 2.48E-04 -1.64E-03 -6.66E-04 4.28E-06 0.0017
rs261503 13 81305121 G A 91.35 2.45E-03 5.29E-04 1.41E-03 3.49E-03 4.60E-06 0.0017
rs10119 19 50098513 G A 73.82 -1.63E-03 3.53E-04 -2.33E-03 -9.41E-04 4.76E-06 0.0017
rs17666460 6 149298132 G A 11.16 1.93E-03 4.18E-04 1.11E-03 2.75E-03 4.81E-06 0.0017
rs16902486 8 129024247 G C 4.26 -2.66E-03 5.75E-04 -3.78E-03 -1.53E-03 4.83E-06 0.0017
rs17005914 2 70721826 T C 21.4 -1.47E-03 3.24E-04 -2.11E-03 -8.38E-04 6.76E-06 0.0016
rs10455097 6 74550153 C A 47.75 -9.58E-04 2.15E-04 -1.38E-03 -5.37E-04 9.94E-06 0.0015
European Cohorts
db SNP Chr
Position
(Build 35)
Coded
Allele
Non-
Coded
Allele
Frequency
Coded
Allele Beta Se
Lower 95%
CI
Upper 95%
CI P-value R2
rs1801725 3 123486447 T G 16.76 3.11E-03 3.55E-04 2.41E-03 3.80E-03 2.58E-18 0.0085
rs17120351 8 14731368 T C 96.24 4.03E-03 7.67E-04 2.52E-03 5.53E-03 1.69E-07 0.0031
rs7448017 5 117800594 T G 17.83 -1.73E-03 3.57E-04 -2.43E-03 -1.03E-03 1.40E-06 0.0026
rs16827695 1 40956147 G A 94.45 3.46E-03 7.41E-04 2.01E-03 4.92E-03 3.20E-06 0.0024
rs261503 13 81305121 G A 91.35 2.45E-03 5.29E-04 1.41E-03 3.49E-03 3.95E-06 0.0024
rs16902486 8 129024247 G C 4.7 -2.92E-03 6.30E-04 -4.15E-03 -1.68E-03 4.04E-06 0.0024
rs17666460 6 149298132 G A 11.16 1.93E-03 4.18E-04 1.11E-03 2.75E-03 4.13E-06 0.0024
rs12325114 16 72861392 T C 76.14 -1.40E-03 3.05E-04 -2.00E-03 -8.01E-04 4.86E-06 0.0024
rs6427310 1 150628843 T C 16.29 -1.65E-03 3.60E-04 -2.35E-03 -9.41E-04 5.09E-06 0.0023
rs17005914 2 70721826 T C 21.4 -1.47E-03 3.24E-04 -2.11E-03 -8.38E-04 5.83E-06 0.0023
rs12416668 10 83645028 T C 94.94 -2.77E-03 6.18E-04 -3.98E-03 -1.56E-03 7.60E-06 0.0023
rs6111021 20 16221853 C A 41.75 1.20E-03 2.67E-04 6.71E-04 1.72E-03 8.36E-06 0.002
Indian Asian Cohorts
db SNP Chr
Position
(Build 35)
Coded
Allele
Non-
Coded
Allele
Frequency
Coded AlleleBeta Se
Lower 95%
CI
Upper 95%
CI P-value R2
rs17251221 3 123475937 G A 19.24 4.72E-03 4.86E-04 3.76E-03 5.67E-03 1.07E-21 0.0233
rs13203335 6 166194438 T C 28.04 -2.91E-03 5.70E-04 -4.03E-03 -1.79E-03 4.70E-07 0.0066
rs4695355 4 48030638 G A 40.26 1.72E-03 3.75E-04 9.89E-04 2.46E-03 5.70E-06 0.0053
rs10846917 12 124568003 T C 59.69 1.74E-03 3.78E-04 9.98E-04 2.48E-03 5.79E-06 0.0053
We report SNPs with p-values ,1E-05 filtered by distinct regions, determined by merging SNPs within 1 Mb of each other. Results are given for different cohort subsets
of combined European and Indian Asian cohorts, European cohorts, and Indian Asian cohorts. The Beta and SE values represent the effect of the coded allele on log10
corrected serum calcium levels; R2 represents the fraction of variation explained by the SNP.
doi:10.1371/journal.pgen.1001035.t003
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l=1.0019 (BLSA). For the combined European and Indian Asian,
European only and Indian Asian only meta-analyses the inflation
factors were 1.0207, 1.0068, and 1.0286, respectively.
Found at: doi:10.1371/journal.pgen.1001035.s002 (4.36 MB TIF)
Figure S3 Comparison of significance across cohorts. The effect
size and 95% confidence intervals of SNPs which do not reach
genome-wide significance in the combined European and Indian
Asian meta-analysis are shown separately for each cohort (CoLaus,
LOLIPOP_EWA, LOLIPOP_EWP, LOLIPOP_IAA, LOLIPO-
P_IAI, LOLIPOP_IAP, BLSA, InCHIANTI). European cohorts
are drawn in blue and Indian Asian cohorts are drawn in green.
The size of the box is proportional to the precision 1/se2 and the
meta-analysis estimate and 95% confidence interval across all
cohorts is given by a diamond.
Found at: doi:10.1371/journal.pgen.1001035.s003 (0.38 MB
TIF)
Figure S4 Candidate gene QQ-plots. For 18611 SNPs mapping
to candidate genes (excluding CASR), we compare observed -log10
p-values to the mean quantiles of the uniform distribution. As a
comparison, we randomly choose a set of genes from which we
select the same number of SNPs. From 1,000 random draws we
calculate the 95th percentile of -log10 p-values (in blue). Results are
shown separately for all cohorts, European only and Indian Asian
only (A–C). CoLaus permuted phenotype results comparing
observed p-values to the 95th percentile of -log10 p-values from
100 permutations are shown in (D).
Found at: doi:10.1371/journal.pgen.1001035.s004 (0.41 MB TIF)
Table S1 Genotyping, imputation, and analysis procedures by
study. The genotyping platforms, quality control (QC) filters applied
before imputation, imputation software, number of SNPs, and
genotype-phenotype association software are shown for each study.
Found at: doi:10.1371/journal.pgen.1001035.s005 (0.05 MB
DOC)
Table S2 Complete list of genome-wide significant SNPs. Below
is the list of all SNPs that exceeded the threshold of genome-wide
significance (p,5610e-8). Position is given for NCBI Build 35.
Meta-analysis is performed by inverse variance weighted fixed
effect regression. The coded allele is the allele to which the beta
(effect) estimate refers. Results are shown separately for (A)
European and Indian Asian cohorts, (B) European cohorts only,
and (C) Indian Asian cohorts only.
Found at: doi:10.1371/journal.pgen.1001035.s006 (0.24 MB
DOC)
Table S3 Significance of top SNPs by cohort. Shown are study-
specific results of the SNPs with genomic control (GC) p-values
,1E-05 filtered by distinct regions, determined by merging SNPs
within 1 Mb of each other. Results are shown separately for (A)
European and Indian Asian cohorts, (B) European cohorts, and
(C) Indian Asian cohorts.
Found at: doi:10.1371/journal.pgen.1001035.s007 (0.08 MB
DOC)
Table S4 Number of cases and controls for calcium-related
outcomes. For several related phenotypes, we test the association
of rs1801725 with these binary responses. Shown here are the
number of cases and controls for each phenotype in each cohort
and the total across cohorts.
Found at: doi:10.1371/journal.pgen.1001035.s008 (0.04 MB
DOC)
Table S5 Logistic regression of clinical phenotypes on rs1801725.
We report the effect size and standard error of the rs1801725 T allele
from logistic regressions of each clinical phenotype.
Found at: doi:10.1371/journal.pgen.1001035.s009 (0.04 MB
DOC)
Table S6 Studies of CASR mutations and serum calcium. A
survey of previous studies which investigate the relationship
between CASR mutations and levels of serum calcium.
Found at: doi:10.1371/journal.pgen.1001035.s010 (0.05 MB
DOC)
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Obesity is globally prevalent and highly heritable, but its underlying genetic factors remain largely elusive. To identify genetic loci 
for obesity susceptibility, we examined associations between body mass index and ~2.8 million SNPs in up to 123,865 individuals 
with targeted follow up of 42 SNPs in up to 125,931 additional individuals. We confirmed 14 known obesity susceptibility loci 
and identified 18 new loci associated with body mass index (P < 5 × 10−8), one of which includes a copy number variant near 
GPRC5B. Some loci (at MC4R, POMC, SH2B1 and BDNF) map near key hypothalamic regulators of energy balance, and one of 
these loci is near GIPR, an incretin receptor. Furthermore, genes in other newly associated loci may provide new insights into 
human body weight regulation.
19 loci associated with BMI at P < 5 × 10−8 (Table 1, Fig. 1a and 
Supplementary Table 1). These 19 loci included all ten loci from 
previous GWAS of BMI6–10, two loci previously associated with body 
weight10 (at FAIM2 and SEC16B) and one locus previously associated 
with waist circumference14 (near TFAP2B). The remaining six loci, 
near GPRC5B, MAP2K5-LBXCOR1, TNNI3K, LRRN6C, FLJ35779-
HMGCR and PRKD1, have not previously been associated with BMI 
or other obesity-related traits.
Stage 2 follow up identifies additional new loci for BMI
To identify additional BMI-associated loci and to validate the loci 
that reached genome-wide significance in the stage 1 analyses, we 
examined SNPs representing 42 independent loci (including the 19 
genome-wide significant loci) having a stage 1 P < 5 × 10−6. Variants 
were considered to be independent if the pair-wise linkage disequi-
librium (LD, r2) was less than 0.1 and if they were separated by at 
least 1 Mb. In stage 2, we examined these 42 SNPs in up to 125,931 
additional individuals (79,561 newly genotyped individuals from 16 
different studies and 46,370 individuals from 18 additional studies 
for which genome-wide association data were available; Table 1, 
Supplementary Note and Online Methods). In a joint analysis of 
stage 1 and stage 2 results, 32 of the 42 SNPs reached P < 5 × 10−8 
(Table 1, Supplementary Table 1 and Supplementary Figs. 1 and 2). 
Even after excluding SNPs within the 32 confirmed BMI loci, we still 
observed an excess of small P values compared to the distribution 
expected under the null hypothesis (Fig. 1b and Supplementary 
Fig. 3), suggesting that more BMI loci remain to be uncovered.
The 32 confirmed associations included all 19 loci with P < 5 × 10−8 
at stage 1, 12 additional new loci near RBJ-ADCY3-POMC, QPCTL-
GIPR, SLC39A8, TMEM160, FANCL, CADM2, LRP1B, PTBP2, MTIF3-
GTF3A, ZNF608, RPL27A-TUB and NUDT3-HMGA1 and one locus 
(in NRXN3) previously associated with waist circumference15 (Table 1, 
Supplementary Table 1 and Supplementary Figs. 1 and 2). In all, 
our study increased the number of loci robustly associated with BMI 
from 10 to 32. Four of the 22 new loci were previously associated 
Association analyses of 249,796 individuals reveal  
18 new loci associated with body mass index
Obesity is a major and increasingly prevalent risk factor for multiple 
disorders, including type 2 diabetes and cardiovascular disease1,2. 
Although lifestyle changes have driven its prevalence to epidemic 
proportions, heritability studies provide evidence for a substantial 
genetic contribution (with heritability estimates (h2) of ~40%–70%) 
to obesity risk3,4. BMI is an inexpensive, non-invasive measure of 
obesity that predicts the risk of related complications5. Identifying 
genetic determinants of BMI could lead to a better understanding of 
the biological basis of obesity.
Genome-wide association studies (GWAS) of BMI have previously 
identified ten loci with genome-wide significant (P < 5 × 10−8) asso-
ciations6–10 in or near FTO, MC4R, TMEM18, GNPDA2, BDNF, 
NEGR1, SH2B1, ETV5, MTCH2 and KCTD15. Many of these genes 
are expressed or known to act in the central nervous system, high-
lighting a likely neuronal component in the predisposition to obesity9. 
This pattern is consistent with results in animal models and studies 
of monogenic human obesity in which neuronal genes, particularly 
those expressed in the hypothalamus and involved in regulation of 
appetite or energy balance, are known to play a major role in suscep-
tibility to obesity11–13.
The ten previously identified loci account for only a small fraction 
of the variation in BMI. Furthermore, power calculations based on the 
effect sizes of established variants have suggested that increasing the 
sample size would likely lead to the discovery of additional variants9. 
To identify additional loci associated with BMI, we expanded the 
Genetic Investigation of Anthropometric Traits (GIANT) Consortium 
genome-wide association meta-analysis to include a total of 249,796 
individuals of European ancestry.
RESULTS
Stage 1 GWAS identifies new loci associated with BMI
We first conducted a meta-analysis of GWAS of BMI and ~2.8 million 
imputed or genotyped SNPs using data from 46 studies including 
up to 123,865 individuals (Online Methods, Supplementary 
Fig. 1 and Supplementary Note). This stage 1 analysis revealed 
A full list of authors and affiliations appear at the end of the paper.
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with body weight10 or waist circumference14,15, whereas 18 new loci 
had not previously associated with any obesity-related trait in the gen-
eral population. Although we confirmed all loci previously established 
by large-scale GWAS for BMI6–10 and waist circumference14,15, four 
loci previously identified in GWAS for early-onset or adult morbid 
 obesity16,17 (at NPC1, rs1805081, P = 0.0025; MAF, rs1424233, P = 0.25; 
PTER, rs10508503, P = 0.64; and TNKS-MSRA, rs473034, P = 0.23) 
showed limited or no evidence of association with BMI in our study.
Table 1 Stage 1 and stage 2 results of the 32 SNPs that were associated with BMI at genome-wide significant (P < 5 × 10−8) levels
SNP
Nearest  
gene
Other  
nearby  
genesa Chr.
Positionb  
(bp)
Allelesb
Frequency 
effect  
allele
Per allele  
change  
in BMI
Explained 
variance  
(%) Stage 1 P Stage 2 P
Stage 1 + 2
Effect Other B (s.e.m.)c n P
Previously identiﬁed BMI loci
rs1558902 FTO 16 52,361,075 A T 0.42 0.39 (0.02) 0.34% 2.05 × 10−62 1.01 × 10−60 192,344 4.8 × 10−120
rs2867125 TMEM18 2 612,827 C T 0.83 0.31 (0.03) 0.15% 2.42 × 10−22 4.42 × 10−30 197,806 2.77 × 10−49
rs571312 MC4R (B) 18 55,990,749 A C 0.24 0.23 (0.03) 0.10% 1.82 × 10−22 3.19 × 10−21 203,600 6.43 × 10−42
rs10938397 GNPDA2 4 44,877,284 G A 0.43 0.18 (0.02) 0.08% 4.35 × 10−17 1.45 × 10−15 197,008 3.78 × 10−31
rs10767664 BDNF (B,M) 11 27,682,562 A T 0.78 0.19 (0.03) 0.07% 5.53 × 10−13 1.17 × 10−14 204,158 4.69 × 10−26
rs2815752 NEGR1 
(C,Q)
1 72,585,028 A G 0.61 0.13 (0.02) 0.04% 1.17 × 10−14 2.29 × 10−9 198,380 1.61 × 10−22
rs7359397 SH2B1 
(Q,B,M)
APOB48R 
(Q,M),  
SULT1A2 
(Q,M), 
AC138894.2 
(M), ATXN2L 
(M), TUFM (Q)
16 28,793,160 T C 0.40 0.15 (0.02) 0.05% 1.75 × 10−10 7.89 × 10−12 204,309 1.88 × 10−20
rs9816226 ETV5 3 187,317,193 T A 0.82 0.14 (0.03) 0.03% 7.61 × 10−14 1.15 × 10−6 196,221 1.69 × 10−18
rs3817334 MTCH2 
(Q,M)
NDUFS3 (Q), 
CUGBP1 (Q)
11 47,607,569 T C 0.41 0.06 (0.02) 0.01% 4.79 × 10−11 1.10 × 10−3 191,943 1.59 × 10−12
rs29941 KCTD15 19 39,001,372 G A 0.67 0.06 (0.02) 0.00% 1.31 × 10−9 2.40 × 10−2 192,872 3.01 × 10−9
Previously identiﬁed waist and weight loci
rs543874 SEC16B 1 176,156,103 G A 0.19 0.22 (0.03) 0.07% 1.66 × 10−13 2.41 × 10−11 179,414 3.56 × 10−23
rs987237 TFAP2B 6 50,911,009 G A 0.18 0.13 (0.03) 0.03% 5.97 × 10−16 2.40 × 10−6 195,776 2.90 × 10−20
rs7138803 FAIM2 12 48,533,735 A G 0.38 0.12 (0.02) 0.04% 3.96 × 10−11 7.82 × 10−8 200,064 1.82 × 10−17
rs10150332 NRXN3 14 79,006,717 C T 0.21 0.13 (0.03) 0.02% 2.03 × 10−7 2.86 × 10−5 183,022 2.75 × 10−11
Newly identiﬁed BMI loci
rs713586 RBJ ADCY3 (Q, M), 
POMC (Q,B)
2 25,011,512 C T 0.47 0.14 (0.02) 0.06% 1.80 × 10−7 1.44 × 10−16 230,748 6.17 × 10−22
rs12444979 GPRC5B 
(C,Q)
IQCK (Q) 16 19,841,101 C T 0.87 0.17 (0.03) 0.04% 4.20 × 10−11 8.13 × 10−12 239,715 2.91 × 10−21
rs2241423 MAP2K5 LBXCOR1 (M) 15 65,873,892 G A 0.78 0.13 (0.02) 0.03% 1.15 × 10−10 1.59 × 10−9 227,950 1.19 × 10−18
rs2287019 QPCTL GIPR (B,M) 19 50,894,012 C T 0.80 0.15 (0.03) 0.04% 3.18 × 10−7 1.40 × 10−10 194,564 1.88 × 10−16
rs1514175 TNNI3K 1 74,764,232 A G 0.43 0.07 (0.02) 0.02% 1.36 × 10–9 7.04 × 10−6 227,900 8.16 × 10−14
rs13107325 SLC39A8 
(Q,M)
4 103,407,732 T C 0.07 0.19 (0.04) 0.03% 1.37 × 10−7 1.93 × 10−7 245,378 1.50 × 10−13
rs2112347 FLJ35779 
(M)
HMGCR (B) 5 75,050,998 T G 0.63 0.10 (0.02) 0.02% 4.76 × 10−8 8.29 × 10−7 231,729 2.17 × 10−13
rs10968576 LRRN6C 9 28,404,339 G A 0.31 0.11 (0.02) 0.02% 1.88 × 10−8 3.19 × 10−6 216,916 2.65 × 10−13
rs3810291 TMEM160 
(Q)
ZC3H4 (Q) 19 52,260,843 A G 0.67 0.09 (0.02) 0.02% 1.04 × 10−7 1.59 × 10−6 233,512 1.64 × 10−12
rs887912 FANCL 2 59,156,381 T C 0.29 0.10 (0.02) 0.03% 2.69 × 10−6 1.72 × 10−7 242,807 1.79 × 10−12
rs13078807 CADM2 3 85,966,840 G A 0.20 0.10 (0.02) 0.02% 9.81 × 10−8 5.32 × 10−5 237,404 3.94 × 10−11
rs11847697 PRKD1 14 29,584,863 T C 0.04 0.17 (0.05) 0.01% 1.11 × 10−8 2.25 × 10−4 241,667 5.76 × 10−11
rs2890652 LRP1B 2 142,676,401 C T 0.18 0.09 (0.03) 0.02% 2.38 × 10−7 9.47 × 10−5 209,068 1.35 × 10−10
rs1555543 PTBP2 1 96,717,385 C A 0.59 0.06 (0.02) 0.01% 7.65 × 10−7 4.48 × 10−5 243,013 3.68 × 10−10
rs4771122 MTIF3 GTF3A (Q) 13 26,918,180 G A 0.24 0.09 (0.03) 0.02% 1.20 × 10−7 8.24 × 10−4 198,577 9.48 × 10−10
rs4836133 ZNF608 5 124,360,002 A C 0.48 0.07 (0.02) 0.01% 7.04 × 10−7 1.88 × 10−4 241,999 1.97 × 10−9
rs4929949 RPL27A TUB (B) 11 8,561,169 C T 0.52 0.06 (0.02) 0.01% 7.57 × 10−8 1.00 × 10−3 249,791 2.80 × 10−9
rs206936 NUDT3 HMGA1 (B) 6 34,410,847 G A 0.21 0.06 (0.02) 0.01% 2.81 × 10−6 7.39 × 10−4 249,777 3.02 × 10−8
Chr., chromosome; Q, association and eQTL data converge to affect gene expression; B, biological candidate; M, BMI-associated variant is in strong LD (r2 q 0.75) with a missense 
variant in the indicated gene; C, CNV.
aGenes within o 500 kb of the lead SNP. bPositions according to Build 36 and allele coding based on the positive strand. cEffect sizes in kg/m2 obtained from stage 2 cohorts only. 
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As could be expected, the effect sizes of the 18 newly discovered loci 
are slightly smaller, for a given minor allele frequency, than those of 
the previously identified variants (Table 1 and Fig. 1c). The increased 
sample size used here also brought out more signals with low minor 
allele frequency. The BMI-increasing allele frequencies for the 18 
newly identified variants ranged from 4% to 87%, covering more of 
the allele frequency spectrum than previous, smaller GWAS of BMI 
(24%–83%)9,10 (Table 1 and Fig. 1c).
We tested for evidence of non-additive (dominant or recessive) 
effects, SNP × SNP interaction effects and heterogeneity by sex or 
study among the 32 BMI-associated SNPs (Online Methods). We 
found no evidence for any such effects (all P > 0.001 and no significant 
results were seen after correcting for multiple testing) (Supplementary 
Table 1 and Supplementary Note).
Impact of the 32 confirmed loci on BMI, obesity, body size 
and other metabolic traits
Together, the 32 confirmed BMI loci explained 1.45% of the inter-
individual variation in BMI in the stage 2 samples, with the FTO 
SNP accounting for the largest proportion of the variance (0.34%) 
(Table 1). To estimate the cumulative effect of the 32 variants on BMI, 
we constructed a genetic susceptibility score that summed the number 
of BMI-increasing alleles weighted by the overall stage 2 effect sizes in 
the Atherosclerosis Risk in Communities (ARIC) study (n = 8,120), 
one of our largest population-based studies (Online Methods). For 
each unit increase in the genetic-susceptibility score, which is approxi-
mately equivalent to having one additional risk allele, BMI increased 
by 0.17 kg/m2, the equivalent of a 435–551 g gain in body weight in 
adults of 160–180 cm in height. The difference in average BMI between 
individuals with a high genetic-susceptibility score (defined as having 
q38 BMI-increasing alleles, comprising 1.5% (n = 124) of the ARIC 
sample) and those with a low genetic-susceptibility score (defined 
as having a21 BMI-increasing alleles, comprising 2.2% (n = 175) of 
the ARIC sample) was 2.73 kg/m2, equivalent to a 6.99–8.85 kg body 
weight difference in adults of 160–180 cm in height (Fig. 2a). Still, 
we note that the predictive value for obesity risk and BMI of the 32 
variants combined was modest, although it was statistically significant 
(Fig. 2b and Supplementary Fig. 4). The area under the receiver-
operating characteristic (ROC) curve for prediction of risk of obesity 
(BMI q 30 kg/m2) using a model including age, age2 and sex only was 
0.515 (P = 0.023 compared to the area under the curve (AUC) of 0.50), 
which increased to 0.575 (P < 10−5) when the 32 confirmed SNPs were 
also included in the model (Fig. 2b). The area under the ROC curve 
for the model including the 32 SNPs only was 0.574 (P < 10−5).
All 32 confirmed BMI-increasing alleles showed directionally 
consistent effects on the risk of being overweight (BMI q 25 kg/m2) 
or obese (BMI q 30 kg/m2) in the stage 2 samples, with 30 of 32 
variants achieving at least nominally significant associations. The 
BMI-increasing alleles increased the odds of being overweight by 
1.013- to 1.138-fold and the odds of being obese by 1.016- to 1.203-
fold (Supplementary Table 2). In addition, 30 of the 32 loci also 
showed directionally consistent effects on the risk of extreme and 
early-onset obesity in a meta-analysis of seven case-control studies of 
adults and children (binomial sign test P = 1.3 × 10−7) (Supplementary 
Table 3). The BMI-increasing allele observed in adults also increased 
the BMI in children and adolescents with directionally consistent 
effects observed for 23 of the 32 SNPs (binomial sign test P = 0.01). 
Furthermore, in family-based studies, the BMI-increasing allele was 
over-transmitted to the obese offspring for 24 of the 32 SNPs (bino-
mial sign test P = 0.004) (Supplementary Table 3). As these studies 
in extreme obesity cases, children and families were relatively small 
(with n ranging from 354 to 15,251 individuals) compared to the 
overall meta-analyses, their power was likely insufficient to confirm 
association for all 32 loci. Nevertheless, these results show that the 
effects are unlikely to reflect population stratification and that they 
extend to BMI differences throughout the life course.
Figure 1 Genome-wide association results for 
the BMI meta-analysis. (a) Manhattan plot 
showing the significance of association between 
all SNPs and BMI in the stage 1 meta-analysis, 
highlighting SNPs previously reported to show 
genome-wide significant association with BMI 
(blue), weight or waist circumference (green) 
and the 18 new regions described here (red). 
The 19 SNPs that reached genome-wide 
significance in stage 1 (13 previously reported 
and 6 new SNPs) are listed in Table 1.  
(b) Quantile-quantile plot of SNPs in the stage 1 
meta-analysis (black) and after removing any 
SNPs within 1 Mb of the ten previously reported 
genome-wide significant hits for BMI (blue), 
after additionally excluding SNPs from the 
four loci for waist or weight (green), and after 
excluding SNPs from all 32 confirmed  
loci (red). The plot is abridged at the y axis 
(at P < 10−20) to better visualize the excess of 
small P values after excluding the 32 confirmed 
loci (Supplementary Fig. 3 shows the full-scale 
quantile-quantile plot). The shaded region is the 
95% concentration band. (c) Plot of effect size 
(in inverse-normally transformed units (invBMI)) 
versus effect-allele frequency of newly identified 
and previously identified BMI variants after 
stage 1 and stage 2 meta-analysis, including the 
10 previously identified BMI loci (blue), the 4 previously identified waist and weight loci (green) and the 18 newly identified BMI loci (blue). The dotted 
lines represent the minimum effect sizes that could be identified for a given effect-allele frequency with 80% (upper line), 50% (middle line) and 10% 
(lower line) power, assuming a sample size of 123,000 individuals and an A level of 5 × 10−8.
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All BMI-increasing alleles were associated with increased body 
weight, as could be expected from the correlation between BMI and 
body weight (Supplementary Table 2). To confirm an effect of the loci 
on adiposity rather than general body size, we tested for association 
with body fat percentage, for which data was available in a subset of the 
stage 2 replication samples (n = 5,359 to n = 28,425) (Supplementary 
Table 2). The BMI-increasing allele showed directionally consistent 
effects on body fat percentage at 31 of the 32 confirmed loci (binomial 
sign test P = 1.54 × 10−8) (Supplementary Table 2).
We also examined the association of the BMI loci with metabolic 
traits (type 2 diabetes18, fasting glucose, fasting insulin, indices of 
B-cell function (HOMA-B) and insulin resistance (HOMA-IR)19, and 
blood lipid levels20) and with height (Supplementary Tables 2 and 4). 
Although many nominal associations were expected because of known 
correlations between BMI and most of these traits, and because of 
overlap in samples, several associations stood out as possible examples 
of pleiotropic effects of the BMI-associated variants. Particularly 
interesting is the variant in the GIPR locus, where the BMI-increasing 
allele is also associated with increased fasting glucose levels and lower 
2-h glucose levels (Supplementary Table 4)19,21. The direction of 
the effect is opposite to what would be expected due to the correla-
tion between obesity and glucose intolerance but is consistent with 
the suggested roles of GIPR in glucose and energy metabolism (see 
below)22. Three loci showed strong associations (P < 10−4) with height 
(at MC4R, RBJ-ADCY3-POMC and MTCH2-NDUFS3). Because BMI 
is weakly correlated with height (and indeed, the BMI-associated vari-
ants as a group show no consistent effect on height), these associations 
are also suggestive of pleiotropy. Notably, analogous to the effects of 
severe mutations in POMC and MC4R on height and weight23,24, the 
BMI-increasing alleles of the variants near these genes were associated 
with decreased (POMC) and increased (MC4R) height, respectively 
(Supplementary Table 2).
Potential functional roles and pathway analyses
Although associated variants typically implicate genomic regions 
rather than individual genes, we note that some of the 32 loci include 
candidate genes with established connections to obesity. Several of 
the ten previously identified loci are located in or near genes that 
encode neuronal regulators of appetite or energy balance, includ-
ing MC4R12,25, BDNF26 and SH2B111,27. Each of these genes has 
been tied to obesity, not only in animal models, but also by rare 
human variants that disrupt each of these genes and lead to severe 
 obesity24,28,29. Using the automated literature search program Snipper 
(Online Methods), we identified various genes within the newly dis-
covered loci with potential biological links to obesity susceptibility 
(Supplementary Note). Among the new loci, the location of rs713586 
near POMC provides further support for a role of neuroendocrine 
circuits that regulate energy balance in susceptibility to obesity. 
POMC encodes several polypeptides, including A-MSH, a ligand of 
the MC4R gene product30, and rare mutations in POMC also cause 
obesity in humans23,29,31.
In contrast, the locus near GIPR, which encodes a receptor of gastric 
inhibitory polypeptide (GIP), suggests a role for peripheral biology 
in obesity. GIP, which is expressed in the K cell of the duodenum and 
intestine, is an incretin hormone that mediates incremental insulin 
secretion in response to oral intake of glucose. The variant associated 
with BMI is in strong LD (r2 = 0.83) with a missense SNP in GIPR 
(rs1800437, p.Glu354Gln) that has recently been shown to influence 
glucose and insulin response to an oral glucose challenge21. Although 
no human phenotype is known to be caused by mutations in GIPR, 
mice with disruption of Gipr are resistant to diet-induced obesity32. 
The association of a variant in GIPR with BMI suggests that there 
may be a link between incretins, insulin secretion and body weight 
regulation in humans as well.
To systematically identify biological connections among the genes 
located near the 32 confirmed SNPs and to potentially identify new 
pathways associated with BMI, we performed pathway-based ana-
lyses using MAGENTA33. Specifically, we tested for enrichment of 
genetic associations to BMI in biological processes or molecular func-
tions that contain at least one gene from the 32 confirmed BMI loci 
(Online Methods). Using annotations from the Kyoto Encyclopedia 
of Genes and Genomes (KEGG), Ingenuity, Protein Analysis Through 
Evolutionary Relationships (PANTHER) and Gene Ontology data-
bases, we found evidence of enrichment for pathways involved in 
platelet-derived growth factor (PDGF) signaling (PANTHER, 
P = 0.0008, false discovery rate (FDR) = 0.0061), translation elongation 
(PANTHER, P = 0.0008, FDR = 0.0066), hormone or nuclear-hormone 
receptor binding (Gene Ontology, P < 0.0005, FDR < 0.0085), homeo-
box transcription (PANTHER, P = 0.0001, FDR = 0.011), regulation of 
cellular metabolism (Gene Ontology, P = 0.0002, FDR = 0.031), neuro-
genesis and neuron differentiation (Gene Ontology, P < 0.0002, FDR < 
0.034), protein phosphorylation (PANTHER, P = 0.0001, FDR = 0.045) 
Figure 2 Combined impact of risk alleles on 
BMI and obesity. (a) Combined effect of risk 
alleles on average BMI in the population-
based ARIC study (n = 8,120 individuals of 
European descent). For each individual, the 
number of ‘best guess’ replicated (n = 32) 
risk alleles from imputed data (0, 1 or 2) per 
SNP was weighted for its relative effect size 
estimated from the stage 2 data. Weighted risk 
alleles were summed for each individual, and 
the overall individual sum was rounded to the 
nearest integer to represent the individual’s risk 
allele score (ranging from 16 to 44). Along the 
x axis, individuals in each risk allele category 
are shown (grouped as having a21 risk alleles 
and q38 risk alleles at the extremes), and the mean BMI (o s.e.m.) is plotted (y axis on right), with the line representing the regression of the mean BMI 
values across the risk-allele scores. The histogram (y axis on left) represents the number of individuals in each risk-score category. (b) The area under 
the ROC curve (AUC) of two different models predicting the risk of obesity (BMI q 30 kg/m2) in the 8,120 genotyped individuals of European descent in 
the ARIC study. Model 1, represented by the solid line, includes age, age2 and sex (AUC = 0.515, P = 0.023 for difference from the null AUC = 0.50). 
Model 2, represented by the dashed line, includes age, age2, sex and the 32 confirmed BMI SNPs (AUC = 0.575, P < 10−5 for difference from the null 
AUC = 0.50). The difference between both AUCs is significant (P < 10−4).
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and numerous other pathways related to 
growth, metabolism, immune and neuronal 
processes (Gene Ontology, P < 0.002, FDR < 
0.046) (Supplementary Table 5).
Identifying possible functional variants
We used data from the 1000 Genomes Project 
and the HapMap Consortium to explore 
whether the 32 confirmed BMI SNPs were in 
LD (r2 q 0.75) with common missense SNPs or copy number variants 
(CNVs) (Online Methods). Non-synonymous variants in LD with 
our signals were present in BDNF, SLC39A8, FLJ35779-HMGCR, 
QPCTL-GIPR, MTCH2, ADCY3 and LBXCOR1. In addition, the 
rs7359397 signal was in LD with coding variants in several genes 
including SH2B1, ATNX2L, APOB48R, SULT1A2 and AC138894.2 
(Table 1, Fig. 3, Supplementary Table 6 and Supplementary Fig. 2). 
Furthermore, two SNPs tagged common CNVs. The first CNV has 
been previously identified9 and is a 45-kb deletion near NEGR1. The 
second CNV is a 21-kb deletion that lies 50 kb upstream of GPRC5B; 
the deletion allele is tagged by the T allele of rs12444979 (r2 = 1) 
(Fig. 3). Although the correlations with potentially functional vari-
ants do not prove that these variants are indeed causal, they pro-
vide first clues as to which genes and variants at these loci might be 
 prioritized for fine mapping and functional follow up.
Because many of the 32 BMI loci harbor multiple genes, we exam-
ined whether gene expression quantitative trait loci (eQTL) analyses 
could also direct us to positional candidates. Gene expression data 
were available for human brain, lymphocyte, blood, subcutaneous 
and visceral adipose tissue, and liver34–36 (Online Methods, Table 1 
and Supplementary Table 7). Significant cis associations, defined at 
the tissue-specific level, were observed between 14 BMI-associated 
alleles and expression levels (Table 1 and Supplementary Table 7). 
In several instances, the BMI-associated SNP was the most significant 
SNP or explained a substantial proportion of the association with the 
most significant SNP for the gene transcript in conditional analyses 
(adjusted P > 0.05). These significant associations included NEGR1, 
ZC3H4, TMEM160, MTCH2, NDUFS3, GTF3A, ADCY3, APOB48R, 
SH2B1, TUFM, GPRC5B, IQCK, SLC39A8, SULT1A1 and SULT1A2 
(Table 1 and Supplementary Table 7), making these genes higher 
priority candidates within the associated loci. However, we note that 
some BMI-associated variants were correlated with the expression 
of multiple nearby genes, making it difficult to determine the most 
relevant gene.
Evidence for the existence of additional associated variants
Because the variants identified by this large study explain only 1.45% 
of the variance in BMI (2%–4% of genetic variance based on an 
estimated heritability of 40%–70%), we considered how much the 
explained phenotypic variance could be increased by including more 
SNPs at various degrees of significance in a polygene model using 
an independent validation set (Online Methods)37. We found that 
including SNPs associated with BMI at lower significance levels (up 
to P > 0.05) increased the explained phenotypic variance in BMI to 
2.5%, or 4%–6% of the genetic variance (Fig. 4a). In a separate ana-
lysis, we estimated the total number of independent BMI-associated 
variants that are likely to exist with similar effect sizes as the 32 con-
firmed here (Online Methods)38. Based on the effect size and allele 
frequencies of the 32 replicated loci observed in stage 2 and the power 
to detect association in stage 1 and stage 2 combined, we estimated 
that there are 284 (95% CI 132–510) loci with similar effect sizes as 
those currently observed, which together would account for 4.5% 
(95% CI 3.1%–6.8%) of the phenotypic variation or 6%–11% of the 
genetic variation in BMI (based on an estimated heritability of 40%–
70%) (Supplementary Table 8). In order to detect 95% of these loci, 
a sample size of approximately 730,000 subjects would be needed 
(Fig. 4b). This method does not account for the potential of loci of 
smaller effect than those identified here to explain even more of the 
variance and thus provides an estimated lower bound of explained 
variance. These two analyses strongly suggest that larger GWAS will 
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Figure 3 Regional plots of selected replicating 
BMI loci with missense and CNV variants. SNPs 
are plotted by position on the chromosome 
against association with BMI (–log10 P). The 
SNP name shown on the plot was the most 
significant SNP after the stage 1 meta-analysis. 
Estimated recombination rates (from HapMap) 
are plotted in cyan to reflect the local LD 
structure. The SNPs surrounding the most 
significant SNP are color coded to reflect 
their LD with this SNP (taken from pairwise r2 
values from the HapMap CEU data). Genes, 
the position of exons and the direction of 
transcription from the UCSC genome browser 
are noted. Hashmarks represent SNP positions 
available in the meta-analysis. (a–c) Missense 
variants noted with their amino acid change for 
the gene listed above the plot. (d) Structural 
haplotypes and the BMI association signal in the 
GPRC5B region. A 21-kb deletion polymorphism 
was associated with four SNPs (r2 = 1.0) that 
comprise the best haplogroup associating with 
BMI. Plots were generated using LocusZoom 
(see URLs).
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continue to identify additional new associated loci but also indicate 
that even extremely large studies focusing on variants with allele fre-
quencies above 5% will not account for a large fraction of the genetic 
contribution to BMI.
We examined whether selecting only a single variant from each 
locus for follow up led us to underestimate the fraction of phenotypic 
variation explained by the associated loci. To search for additional 
independent loci at each of the 32 associated BMI loci, we repeated 
our genome-wide association meta-analysis conditioning on the 32 
confirmed SNPs. Using a significance threshold of P = 5 × 10−6 for 
SNPs at known loci, we identified one apparently independent signal 
at the MC4R locus; rs7227255 was associated with BMI (P = 6.56 × 
10−7) even after conditioning for the most strongly associated variant 
near MC4R (rs571312) (Fig. 5). Notably, rs7227255 is in perfect LD 
(r2 = 1) with a relatively rare MC4R missense variant (rs2229616, 
p.Val103Ile, minor allele frequency = 1.7%) that has been associ-
ated with BMI in two independent meta-analyses39,40. Furthermore, 
 mutations at the MC4R locus are known to influence early-onset 
obesity24,41, supporting the notion that allelic heterogeneity may be 
a frequent phenomenon in the genetic architecture of obesity.
DISCUSSION
Using a two-stage genome-wide association meta-analysis of up 
to 249,796 individuals of European descent, we identified 18 addi-
tional loci that are associated with BMI at genome-wide significance, 
bringing the total number of such loci to 32. We estimate that more 
than 250 common variant loci (that is, 284 predicted loci minus 32 
confirmed loci) with effects on BMI similar to those described here 
remain to be discovered and that even larger numbers of loci with 
smaller effects remain to be identified. A substantial proportion of 
these loci should be identifiable through larger GWAS and/or by 
 targeted follow up of the top signals selected from our stage 1 analysis. 
The latter approach is already being implemented through large-scale 
genotyping of samples informative for BMI using a custom array (the 
Metabochip) designed to support follow up of 
thousands of promising variants in hundreds 
of thousands of individuals.
The combined effect on BMI of the associ-
ated variants at the 32 loci is modest, and even 
when we try to account for as yet undiscovered 
variants with similar properties, we estimate 
that these common variant signals account 
for only 6%–11% of the genetic variation in 
BMI. There is a strong expectation that addi-
tional variance and biology will be explained 
using complementary approaches that capture 
variants not examined in the current study, 
such as lower frequency variants and short 
insertion-deletion polymorphisms. There is 
good reason to believe (based on our find-
ings at MC4R and other loci, such as those at 
POMC, BDNF and SH2B1, which feature both 
common and rare variant associations) that 
a proportion of such low-frequency and rare 
causal variation will map to the loci already 
identified by GWAS.
A primary goal of human genetic discovery 
is to improve understanding of the biology 
Figure 4 Phenotypic variance explained by 
common variants. (a) The variance explained is 
higher when SNPs not reaching genome-wide 
significance are included in the prediction 
model. The y axis represents the proportion 
of variance explained at different P value 
thresholds from the stage 1 meta-analysis. 
Results are given for three studies (Rotterdam 
Study II (RSII), Rotterdam Study III (RSIII), 
Queens Institute of Medical Research (QIMR)) 
which were not included in the meta-analysis, 
after exclusion of all samples from The 
Netherlands (for RSII and RSIII) and the United 
Kingdom (for QIMR) from the discovery analysis 
for this sub-analysis. The dotted line represents 
the weighted average of the explained variance 
of three validation sets. (b) Cumulative number of susceptibility loci expected to be discovered, including those we have already identified and others 
that have yet to be detected, by the expected percentage of phenotypic variation explained and the sample size required for a one-stage GWAS assuming 
a genomic control correction is used. The projections are based on loci that achieved a significance level of P < 5 × 10−8 in the joint analysis of stage 1  
and stage 2 and the distribution of their effect sizes in stage 2. The dotted red line corresponds to the expected phenotypic variance explained by the 
22 loci that are expected to be discovered in a one-stage GWAS using the sample size of stage 1 of this study.
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Figure 5 A second signal at the MC4R locus contributing to BMI. SNPs are plotted by position in 
a 1-Mb window of chromosome 18 against association with BMI (–log10 P). (a) Plot highlighting 
the most significant SNP in the stage 1 meta-analysis. (b) Plot highlighting the most significant 
SNP after conditional analysis, where the model included the most strongly associated SNP as a 
covariate. Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD 
structure. The SNPs surrounding the most significant SNP are color coded to reflect their LD with 
this SNP (taken from pairwise r2 values from the HapMap CEU database). Genes, exons and the 
direction of transcription from the UCSC genome browser are noted. Hashmarks at the top of the 
figure represent the positions of SNPs in the meta-analysis. Regional plots were generated using 
LocusZoom.
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of conditions such as obesity42. One particularly noteworthy finding 
in this regard is the association between BMI and common variants 
near GIPR, which may indicate a causal contribution of variation 
in postprandial insulin secretion in the development of obesity. In 
most instances, the loci identified by the present study harbor few, if 
any, annotated genes with clear connections to the biology of weight 
regulation. This reflects our still limited understanding of the biology 
of BMI and obesity-related traits and is in striking contrast with the 
results from equivalent studies of certain other traits (such as autoim-
mune diseases or lipid levels). Thus, these results suggest that much 
of the biology that underlies obesity remains to be uncovered and 
that GWAS may provide an important entry point for investigation. 
In particular, further examination of the associated loci through a 
combination of resequencing and fine mapping to find causal variants 
and genomic and experimental studies designed to assign function 
could uncover new insights into the biology of obesity.
In conclusion, we performed GWAS in large samples to identify 
numerous genetic loci associated with variation in BMI, a common 
measure of obesity. Because current lifestyle interventions are largely 
ineffective in addressing the challenges of growing obesity43,44, new 
insights into the biology of obesity are critically needed to guide the 
development and application of future therapies and interventions.
URLs. LocusZoom, http://csg.sph.umich.edu/locuszoom; METAL, 
http://www.sph.umich.edu/csg/abecasis/Metal/.
METHODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Study design. We designed a multistage study (Supplementary Fig. 1) com-
prising a genome-wide association meta-analysis (stage 1) of data on up to 
123,865 genotyped individuals from 46 studies and selected 42 SNPs with P < 
5 × 10−6 for follow up in stage 2. Stage 2 comprised up to 125,931 additional 
genotyped individuals from 42 studies. Meta-analysis of stage 1 and stage 2 
summary statistics identified 32 SNPs that reached genome-wide significance 
(P < 5 × 10−8).
Stage 1 genome-wide association meta-analysis. Samples and genotyping.  
The GIANT consortium currently encompasses 46 studies with up to 
123,865 genotyped adult individuals of European ancestry with data on BMI 
(Supplementary Note). The samples from 46 studies, including between 276 
and 26,799 individuals each, were genotyped using Affymetrix and Illumina 
whole genome genotyping arrays (Supplementary Note). To allow for meta-
analysis across different marker sets, imputation of polymorphic HapMap 
European CEU SNPs (Supplementary Note) was performed using MACH45, 
IMPUTE46 or BimBam47.
Association analysis with BMI. Each study performed single marker asso-
ciation analyses with BMI using an additive genetic model implemented 
in MACH2QTL (Y. Li, C.J.W., P.S. Ding and G.R.A., unpublished data), 
Merlin48, SNPTEST46, ProbAbel49, GenABEL50, LME in R or PLINK51. BMI 
was adjusted for age, age2 and other appropriate covariates (for example, prin-
cipal components) and inverse normally transformed to a mean of 0 and a 
standard deviation of 1. Analyses were stratified by sex and case status (for 
samples ascertained for other diseases) (Supplementary Note). To allow for 
relatedness in the SardiNIA, Framingham Heart, Amish HAPI Heart and 
Family Heart studies, regression coefficients were estimated in the context 
of a variance component model that modeled relatedness in men and women 
combined with sex as a covariate. Before meta-analyzing the genome-wide 
association data for the 46 studies, SNPs with poor imputation quality scores 
(r 2.hat < 0.3 in MACH, observed/expected dosage variance < 0.3 in BimBam 
or proper_info < 0.4 in IMPUTE) and those with a minor allele count (MAC = 
2 × N × minor allele frequency) of < 6 in each sex- and case-specific stratum 
were excluded for each study. All individual GWAS were genomic control cor-
rected before meta-analysis. Individual study-specific genomic control values 
ranged from 0.983 to 1.104 (Supplementary Note).
Meta-analysis of stage 1 association results. Next, we performed the stage 1 
meta-analysis using the inverse variance method, which is based on B values 
and standard errors from each individual GWAS. To ensure consistency of 
results, we also performed the stage 1 meta-analysis using the weighted z-score 
method, which is based on the direction of association and P values of each of 
the individual studies. Both meta-analyses were performed using METAL (see 
URLs), and the correlation between the resulting –log10 P values was high (r > 
0.99). For the discovery of replicating variants, the results of the inverse vari-
ance meta-analysis were used followed by a final genomic control correction 
of the meta-analyzed results. The genomic control value for the meta-analyzed 
results before genomic control correction was 1.318.
Selection of SNPs for follow up. Forty-two lead SNPs, representing the forty-two 
most significant (P < 5 × 10−6) independent loci, were selected for replication 
analyses (stage 2) (Supplementary Table 1). Loci were considered independ-
ent when separated by at least 1 Mb. For some loci, the SNP with the strongest 
association could not be genotyped for technical reasons and was substituted 
by a proxy SNP that was in high LD with it (r2 > 0.8) according to the HapMap 
CEU data (Supplementary Table 1). We tested the association of these 42 
SNPs in 16 de novo and 18 in silico replication studies in stage 2.
Stage 2 follow up. Samples and genotyping. Directly genotyped data for the 
42 SNPs was available from a total of 79,561 adults of European ancestry from 
16 studies using Sequenom iPLEX or TaqMan assays (Supplementary Note). 
Samples and SNPs that did not meet the quality control criteria defined by 
each individual study were excluded. Minimum genotyping quality control 
criteria were defined as Hardy-Weinberg Equilibrium P > 10−6, call rate > 90% 
and concordance > 99% in duplicate samples in each of the follow-up studies. 
Association results were also obtained for the 42 most significant SNPs from 
46,370 individuals of European ancestry from 18 GWAS that had not been 
included in the stage 1 analyses (Supplementary Note). Studies included 
between 345 and 22,888 individuals and were genotyped using Affymetrix 
and Illumina genome-wide genotyping arrays. Autosomal HapMap SNPs were 
imputed using either MACH45 or IMPUTE46. SNPs with poor imputation 
quality scores from the in silico studies (r 2.hat < 0.3 in MACH or proper_info 
< 0.4 in IMPUTE), and SNPs with a MAC < 6 in each sex- and case-specific 
stratum were excluded.
Association analyses and meta-analysis. We tested the association between 
the 42 SNPs and BMI in each in silico and de novo stage 2 study separately as 
described for the stage 1 studies. We subsequently meta-analyzed B values and 
standard errors from the stage 2 studies using the inverse-variance method. 
The meta-analysis using a weighted z-score method was similar (the r between 
P values was >0.99) and included up to 249,796 individuals. Data was available 
for at least 179,000 individuals for 41 of the 42 SNPs. For one SNP (rs6955651 
in KIAA1505), data was only available for 125,672 individuals due to technical 
challenges relating to the genotyping and imputation of this SNP. Next, we 
meta-analyzed the summary statistics of the stage 1 and stage 2 meta-analyses 
using the inverse-variance method in METAL.
Assessment of population stratification. To assess for possible inflation of test 
statistics by population stratification, we performed a family-based analysis, 
which is immune to stratification, in 5,507 individuals with pedigree informa-
tion from the Framingham Heart Study using that the QFAM–within proce-
dure in PLINK. Effect sizes and directions in the Framingham Heart Study 
data are the B statistics reported by PLINK from the within-family analysis, 
and the P values are empirical and are based on permutation testing. For 
imputed SNPs, only those with r2.hat > 0.3 in MACH were analyzed using 
the best-guess genotypes from dosages reported by MACH. For the 32 loci in 
general and the 18 new loci in particular, the estimated effect sizes on BMI 
were essentially identical in the overall meta-analysis and in the Framingham 
Heart Study sample (Supplementary Note), and, as expected in the absence 
of substantial stratification, about half of the loci (18 out of 32 loci total and 10 
out of 18 new loci) had a larger effect size in the family-based sample. These 
results indicate that the genome-wide significant associations in our meta-
analysis are not substantially confounded by stratification.
In addition, we estimated the fixation index (Fst) for all SNPs to test whether 
the 32 confirmed BMI SNPs might be false-positive results due to population 
stratification. We selected five diverse European populations with relatively 
large sample sizes (Northern Finland Birth Cohort (NFBC), British 1958 Birth 
Cohort, SardiNIA, CoLaus and DeCODE) for this analysis. The mean Fst value 
for the 32 confirmed BMI SNPs was not significantly different from the mean 
Fst for 2.1 million non-BMI associated SNPs (t test P = 0.28), suggesting that 
the SNPs that are associated with BMI do not appear to have strong allele 
frequency differences across the European samples examined.
Follow-up analyses. Subsequently, we performed an extensive series of fol-
low-up analyses to estimate the impact of the 32 confirmed BMI loci in adults 
and children and to explore their potential functional roles. These follow-up 
analyses are described in detail in the Supplementary Note.
In brief, we estimated the cumulative effect of the 32 loci combined 
on BMI and assessed their predictive ability in obesity and BMI in the 
ARIC study. Association between the 32 confirmed BMI variants and over-
weight or obese status was assessed in stage 2 samples, and association with 
BMI in children and adolescents was examined in four population-based 
studies. Furthermore, we tested for association between the 32 SNPs and 
extreme or early-onset obesity in seven case-control studies of extremely 
obese adults and extremely obese children or adolescents. Data on the 
association between the 32 SNPs and height and weight were obtained from 
the stage 2 replication samples, and data on the association with related 
traits were extracted from previously reported genome-wide association 
meta-analyses for type 2 diabetes (Diabetes Genetics Replication and 
Meta-analysis (DIAGRAM) Consortium18), lipid levels (the Global Lipids 
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Genetics Consortium20) and glycemic traits (Meta-Analyses of Glucose 
and Insulin-related traits Consortium (MAGIC)19,21).
To discover potentially new pathways associated with BMI, we tested 
whether predefined biological processes or molecular functions that contain 
at least one gene within 300 kb of the 32 confirmed BMI SNPs were enriched 
for multiple modest BMI associations using MAGENTA33. We identified SNPs 
having r2 q 0.75 with the lead SNP that were likely non-synonymous, nonsense 
or which occurred within 5 bp of the exon-intron boundary and also evalu-
ated whether any of the 32 confirmed BMI SNPs tagged common CNVs. We 
examined the cis associations between each of the 32 confirmed BMI SNPs 
and expression of nearby genes in adipose tissue34,52, whole blood34, lym-
phocytes36,52 and brain35.
We evaluated the amount of phenotypic variance explained by the 32 BMI 
loci using a method proposed by the International Schizophrenia Consortium37 
and estimated the number of susceptibility loci that are likely to exist using a 
new method38 based on the distribution of effect sizes and minor allele fre-
quencies observed for the established BMI loci and the power to detect those 
effects in the combined stage 1 and stage 2 analysis.
We performed a conditional genome-wide association analysis to examine 
whether any of the 32 confirmed BMI loci harbored additional independent 
signals, and we also examined gene-by-gene and gene-by-sex interactions among 
the BMI loci. Dominant and recessive analyses were performed for the 32 con-
firmed BMI SNPs to test for non-additive effects.
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